mrk gaap otherassetsus gaap otherassetsus gaap otherliabilitiescurrentus gaap otherliabilitiescurrentus gaap otherliabilitiesnoncurrentus gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap retainedearningsmembersrt gaap accumulatedothercomprehensiveincomemembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap pharmaceuticalsegmentmembercountry ussrt animalhealthsegmentmembercountry ussrt maximummembercountry gaap nonusmembersrt maximummemberus gaap gaap buildingmembersrt gaap buildingmembersrt gaap machineryandequipmentmembersrt maximummemberus gaap gaap softwareandsoftwaredevelopmentcostsmembersrt maximummemberus gaap oncoimmunemembermrk oncoimmunemembersrt maximummembermrk gaap developmentmilestonesmembermrk salesbasedmilestonesmembermrk tukysamembermrk tukysamembermrk regulatorymilestonesmembermrk tukysamembersrt minimummembermrk tukysamembersrt maximummembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk themismembermrk themismembermrk themismembermrk themismembermrk gaap measurementinputdiscountratemembermrk pelotonmembermrk pelotonmembermrk pelotonmembermrk antelliqmembersrt antelliqmembersrt antelliqmemberus gaap astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamemberus gaap astrazenecamembermrk alliancerevenuelynparzamemberus gaap salesmemberus gaap astrazenecamembermrk alliancerevenuelynparzamemberus gaap salesmemberus gaap astrazenecamembermrk alliancerevenuelynparzamemberus gaap salesmemberus gaap astrazenecamembermrk alliancerevenuekoselugomemberus gaap salesmemberus gaap astrazenecamembermrk alliancerevenuekoselugomemberus gaap salesmemberus gaap astrazenecamembermrk alliancerevenuekoselugomemberus gaap salesmemberus gaap astrazenecamemberus gaap salesmemberus gaap astrazenecamemberus gaap salesmemberus gaap astrazenecamemberus gaap salesmemberus gaap astrazenecamemberus gaap collaborativearrangementmemberus gaap astrazenecamemberus gaap collaborativearrangementmemberus gaap astrazenecamemberus gaap collaborativearrangementmemberus gaap astrazenecamemberus gaap sellinggeneralandadministrativeexpensesmemberus gaap astrazenecamemberus gaap sellinggeneralandadministrativeexpensesmemberus gaap astrazenecamemberus gaap sellinggeneralandadministrativeexpensesmemberus gaap astrazenecamemberus gaap researchanddevelopmentexpensememberus gaap astrazenecamemberus gaap researchanddevelopmentexpensememberus gaap astrazenecamemberus gaap researchanddevelopmentexpensememberus gaap astrazenecamemberus gaap othercurrentassetsmemberus gaap astrazenecamemberus gaap othercurrentassetsmemberus gaap astrazenecamemberus gaap accountspayableandaccruedliabilitiesmemberus gaap astrazenecamemberus gaap accountspayableandaccruedliabilitiesmemberus gaap eisaimembersrt eisaimembersrt salesbasedmilestonesmembermrk lenvimamembermrk salesbasedmilestonesmembermrk lenvimamembermrk salesbasedmilestonesmembermrk lenvimamembermrk salesbasedmilestonesmembermrk regulatorymilestonesmembermrk lenvimamembermrk regulatorymilestonesmembermrk lenvimamembermrk regulatorymilestonesmembermrk lenvimamemberus gaap gaap salesmembermrk eisaimemberus gaap gaap salesmembermrk eisaimemberus gaap gaap salesmembermrk eisaimemberus gaap eisaimemberus gaap collaborativearrangementmemberus gaap eisaimemberus gaap collaborativearrangementmemberus gaap eisaimemberus gaap collaborativearrangementmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk eisaimemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk eisaimemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk eisaimemberus gaap gaap researchanddevelopmentexpensemembermrk eisaimemberus gaap gaap researchanddevelopmentexpensemembermrk eisaimemberus gaap gaap researchanddevelopmentexpensemembermrk eisaimemberus gaap gaap othercurrentassetsmembermrk eisaimemberus gaap gaap othercurrentassetsmembermrk eisaimemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk eisaimemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk eisaimemberus gaap gaap othernoncurrentliabilitiesmembermrk eisaimemberus gaap gaap othernoncurrentliabilitiesmembermrk eisaimemberus gaap salesbasedmilestonesmembermrk bayeragmembermrk salesbasedmilestonesmembermrk bayeragmembermrk salesbasedmilestonesmembermrk bayeragmembermrk gaap subsequenteventmembermrk salesbasedmilestonesmembermrk gaap subsequenteventmembermrk salesbasedmilestonesmembermrk adempasmemberus gaap bayeragmemberus gaap salesmemberus gaap bayeragmemberus gaap salesmemberus gaap bayeragmemberus gaap salesmemberus gaap bayeragmemberus gaap collaborativearrangementmemberus gaap bayeragmemberus gaap collaborativearrangementmemberus gaap bayeragmemberus gaap collaborativearrangementmemberus gaap bayeragmemberus gaap sellinggeneralandadministrativeexpensesmemberus gaap bayeragmemberus gaap sellinggeneralandadministrativeexpensesmemberus gaap bayeragmemberus gaap sellinggeneralandadministrativeexpensesmemberus gaap gaap researchanddevelopmentexpensemembermrk bayeragmemberus gaap gaap researchanddevelopmentexpensemembermrk bayeragmemberus gaap gaap researchanddevelopmentexpensemembermrk bayeragmemberus gaap gaap othercurrentassetsmembermrk bayeragmemberus gaap gaap othercurrentassetsmembermrk bayeragmemberus gaap gaap othernoncurrentliabilitiesmembermrk bayeragmemberus gaap gaap othernoncurrentliabilitiesmembermrk bayeragmemberus gaap gaap onetimeterminationbenefitsmemberus gaap accelerateddepreciationmemberus gaap gaap otherrestructuringmemberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk gaap otherrestructuringmemberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap researchanddevelopmentexpensemembermrk gaap researchanddevelopmentexpensememberus gaap gaap onetimeterminationbenefitsmemberus gaap gaap restructuringchargesmembermrk gaap otherrestructuringmemberus gaap gaap gaap gaap gaap onetimeterminationbenefitsmemberus gaap accelerateddepreciationmemberus gaap gaap otherrestructuringmemberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk gaap otherrestructuringmemberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap researchanddevelopmentexpensemembermrk gaap researchanddevelopmentexpensememberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap restructuringchargesmembermrk gaap otherrestructuringmemberus gaap gaap gaap gaap gaap onetimeterminationbenefitsmemberus gaap accelerateddepreciationmemberus gaap gaap otherrestructuringmemberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk gaap otherrestructuringmemberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap researchanddevelopmentexpensemembermrk gaap researchanddevelopmentexpensememberus gaap gaap gaap onetimeterminationbenefitsmemberus gaap gaap restructuringchargesmembermrk gaap otherrestructuringmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap designatedashedginginstrumentmembersrt maximummemberus gaap gaap gaap gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensemembermrk gaap othernonoperatingincomeexpensemembermrk gaap othernonoperatingincomeexpensemembermrk gaap gaap gaap interestrateswapmembermrk gaap gaap designatedashedginginstrumentmemberus gaap othercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap gaap gaap othercurrentassetsmemberus gaap foreignexchangecontractmemberus gaap gaap othercurrentassetsmemberus gaap foreignexchangecontractmemberus gaap gaap othercurrentliabilitiesmemberus gaap foreignexchangecontractmemberus gaap gaap othercurrentliabilitiesmemberus gaap foreignexchangecontractmemberus gaap gaap gaap gaap interestrateswapmemberus gaap gaap interestrateswapmemberus gaap gaap interestrateswapmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap foreignexchangecontractmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap foreignexchangecontractmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap foreignexchangecontractmemberus gaap gaap gaap gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensememberus gaap gaap forwardcontractsmemberus gaap gaap forwardcontractsmemberus gaap gaap forwardcontractsmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap commercialpapermemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap commercialpapermemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap commercialpapermemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap commercialpapermemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap gaap assetbackedsecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap assetbackedsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap sanofipasteurmemberus gaap mckessoncorporationamerisourcebergencorporationandcardinalhealthinc memberus gaap accountsreceivablememberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk gaap developedtechnologyrightsmembermrk antelliqmemberus gaap gaap gaap gaap gaap federalmembermrk federalmembermrk federalmembermrk newjerseystatecourtmembermrk californiastatecourtmembermrk otherstatecourtmembermrk januviamembermrk casescompanyagreedtotollstatuteoflimitationsmembermrk gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry usus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmembercountry gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmembercountry gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usmrk gaap pensionplansdefinedbenefitmembercountry usmrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usmrk gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharemembercountry gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmembercountry usus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmembercountry usus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmembermrk realestateinvestmentfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap otherinvestmentsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap foreignplanmemberus gaap gaap cashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap gaap cashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap cashandcashequivalentsmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap cashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap gaap cashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap cashandcashequivalentsmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap gaap emergingmarketsequitiesinvestmentfundsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap gaap emergingmarketsequitiesinvestmentfundsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap developedmarketsequitysecuritiesmemberus gaap gaap developedmarketsequitysecuritiesmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap developedmarketsequitysecuritiesmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap developedmarketsequitysecuritiesmemberus gaap developedmarketsequitysecuritiesmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap developedmarketsequitysecuritiesmemberus gaap gaap developedmarketsequitysecuritiesmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap developedmarketsequitysecuritiesmemberus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap developedmarketsequitysecuritiesmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap definedbenefitplanequitysecuritiesusmembercountry ussrt gaap definedbenefitplanequitysecuritiesusmembersrt maximummembercountry gaap definedbenefitplanequitysecuritiesnonusmembercountry ussrt gaap definedbenefitplanequitysecuritiesnonusmembersrt maximummembercountry gaap fixedincomeinvestmentsmembercountry ussrt gaap fixedincomeinvestmentsmembersrt maximummembercountry definedbenefitplancashandotherinvestmentsmembersrt maximummembercountry ussrt minimummembersrt maximummembercountry ussrt ussrt maximummembercountry gaap gaap gaap gaap gaap internalrevenueserviceirsmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap accumulatedgainlossnetcashflowhedgeparentmembersrt gaap accumulatednetunrealizedinvestmentgainlossmemberus gaap gaap accumulateddefinedbenefitplansadjustmentmemberus gaap gaap accumulatedtranslationadjustmentmemberus gaap gaap accumulatedothercomprehensiveincomememberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap keytrudamembermrk pharmaceuticalsegmentmembercountry usus gaap keytrudamembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap keytrudamembermrk pharmaceuticalsegmentmemberus gaap keytrudamembermrk pharmaceuticalsegmentmembercountry usus gaap keytrudamembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap keytrudamembermrk pharmaceuticalsegmentmemberus gaap keytrudamembermrk pharmaceuticalsegmentmembercountry usus gaap keytrudamembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap keytrudamembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembermrk alliancerevenuelynparzamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk alliancerevenuelynparzamemberus gaap pharmaceuticalsegmentmembermrk alliancerevenuelynparzamemberus gaap pharmaceuticalsegmentmembermrk alliancerevenuelynparzamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk alliancerevenuelynparzamemberus gaap pharmaceuticalsegmentmembermrk alliancerevenuelynparzamemberus gaap pharmaceuticalsegmentmembermrk alliancerevenuelynparzamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk alliancerevenuelynparzamemberus gaap pharmaceuticalsegmentmembermrk alliancerevenuelynparzamemberus gaap pharmaceuticalsegmentmembermrk lenvimamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk lenvimamemberus gaap pharmaceuticalsegmentmembermrk lenvimamemberus gaap pharmaceuticalsegmentmembermrk lenvimamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk lenvimamemberus gaap pharmaceuticalsegmentmembermrk lenvimamemberus gaap pharmaceuticalsegmentmembermrk lenvimamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk lenvimamemberus gaap pharmaceuticalsegmentmembermrk lenvimamemberus gaap pharmaceuticalsegmentmembermrk emendmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk emendmemberus gaap pharmaceuticalsegmentmembermrk emendmemberus gaap pharmaceuticalsegmentmembermrk emendmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk emendmemberus gaap pharmaceuticalsegmentmembermrk emendmemberus gaap pharmaceuticalsegmentmembermrk emendmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk emendmemberus gaap pharmaceuticalsegmentmembermrk emendmemberus gaap pharmaceuticalsegmentmembermrk usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk gaap pharmaceuticalsegmentmembermrk gaap pharmaceuticalsegmentmembermrk usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk gaap pharmaceuticalsegmentmembermrk gaap pharmaceuticalsegmentmembermrk usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk gaap pharmaceuticalsegmentmembermrk gaap pharmaceuticalsegmentmembermrk proquadmmriivarivaxmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk proquadmmriivarivaxmemberus gaap pharmaceuticalsegmentmembermrk proquadmmriivarivaxmemberus gaap pharmaceuticalsegmentmembermrk proquadmmriivarivaxmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk proquadmmriivarivaxmemberus gaap pharmaceuticalsegmentmembermrk proquadmmriivarivaxmemberus gaap pharmaceuticalsegmentmembermrk proquadmmriivarivaxmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk proquadmmriivarivaxmemberus gaap pharmaceuticalsegmentmembermrk proquadmmriivarivaxmemberus gaap pharmaceuticalsegmentmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmemberus gaap pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmemberus gaap pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmemberus gaap pharmaceuticalsegmentmemberus gaap rotateqmembermrk pharmaceuticalsegmentmembercountry usus gaap rotateqmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap rotateqmembermrk pharmaceuticalsegmentmemberus gaap rotateqmembermrk pharmaceuticalsegmentmembercountry usus gaap rotateqmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap rotateqmembermrk pharmaceuticalsegmentmemberus gaap rotateqmembermrk pharmaceuticalsegmentmembercountry usus gaap rotateqmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap rotateqmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembermrk vaqtamembercountry usus gaap pharmaceuticalsegmentmembermrk vaqtamembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk vaqtamemberus gaap pharmaceuticalsegmentmembermrk vaqtamembercountry usus gaap pharmaceuticalsegmentmembermrk vaqtamembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk vaqtamemberus gaap pharmaceuticalsegmentmembermrk vaqtamembercountry usus gaap pharmaceuticalsegmentmembermrk vaqtamembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk vaqtamemberus gaap pharmaceuticalsegmentmembermrk bridionmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk bridionmemberus gaap pharmaceuticalsegmentmembermrk bridionmemberus gaap pharmaceuticalsegmentmembermrk bridionmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk bridionmemberus gaap pharmaceuticalsegmentmembermrk bridionmemberus gaap pharmaceuticalsegmentmembermrk bridionmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk bridionmemberus gaap pharmaceuticalsegmentmembermrk bridionmemberus gaap pharmaceuticalsegmentmembercountry usmrk noxafilmemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk noxafilmemberus gaap pharmaceuticalsegmentmembermrk noxafilmemberus gaap pharmaceuticalsegmentmembercountry usmrk noxafilmemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk noxafilmemberus gaap pharmaceuticalsegmentmembermrk noxafilmemberus gaap pharmaceuticalsegmentmembercountry usmrk noxafilmemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk noxafilmemberus gaap pharmaceuticalsegmentmembermrk noxafilmemberus gaap pharmaceuticalsegmentmembercountry usmrk prevymismemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk prevymismemberus gaap pharmaceuticalsegmentmembermrk prevymismemberus gaap pharmaceuticalsegmentmembercountry usmrk prevymismemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk prevymismemberus gaap pharmaceuticalsegmentmembermrk prevymismemberus gaap pharmaceuticalsegmentmembercountry usmrk prevymismemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk prevymismemberus gaap pharmaceuticalsegmentmembermrk prevymismemberus gaap primaxinmembermrk pharmaceuticalsegmentmembercountry usus gaap primaxinmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap primaxinmembermrk pharmaceuticalsegmentmemberus gaap primaxinmembermrk pharmaceuticalsegmentmembercountry usus gaap primaxinmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap primaxinmembermrk pharmaceuticalsegmentmemberus gaap primaxinmembermrk pharmaceuticalsegmentmembercountry usus gaap primaxinmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap primaxinmembermrk pharmaceuticalsegmentmemberus gaap cancidasmembermrk pharmaceuticalsegmentmembercountry usus gaap cancidasmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap cancidasmembermrk pharmaceuticalsegmentmemberus gaap cancidasmembermrk pharmaceuticalsegmentmembercountry usus gaap cancidasmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap cancidasmembermrk pharmaceuticalsegmentmemberus gaap cancidasmembermrk pharmaceuticalsegmentmembercountry usus gaap cancidasmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap cancidasmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembermrk invanzmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk invanzmemberus gaap pharmaceuticalsegmentmembermrk invanzmemberus gaap pharmaceuticalsegmentmembermrk invanzmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk invanzmemberus gaap pharmaceuticalsegmentmembermrk invanzmemberus gaap pharmaceuticalsegmentmembermrk invanzmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk invanzmemberus gaap pharmaceuticalsegmentmembermrk invanzmemberus gaap pharmaceuticalsegmentmembermrk cubicinmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk cubicinmemberus gaap pharmaceuticalsegmentmembermrk cubicinmemberus gaap pharmaceuticalsegmentmembermrk cubicinmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk cubicinmemberus gaap pharmaceuticalsegmentmembermrk cubicinmemberus gaap pharmaceuticalsegmentmembermrk cubicinmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk cubicinmemberus gaap pharmaceuticalsegmentmembermrk cubicinmemberus gaap pharmaceuticalsegmentmembermrk zerbaxamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk zerbaxamemberus gaap pharmaceuticalsegmentmembermrk zerbaxamemberus gaap pharmaceuticalsegmentmembermrk zerbaxamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk zerbaxamemberus gaap pharmaceuticalsegmentmembermrk zerbaxamemberus gaap pharmaceuticalsegmentmembermrk zerbaxamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk zerbaxamemberus gaap pharmaceuticalsegmentmembermrk zerbaxamemberus gaap pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk remicademembercountry usus gaap pharmaceuticalsegmentmembermrk remicademembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk remicadememberus gaap pharmaceuticalsegmentmembermrk remicademembercountry usus gaap pharmaceuticalsegmentmembermrk remicademembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk remicadememberus gaap pharmaceuticalsegmentmembermrk remicademembercountry usus gaap pharmaceuticalsegmentmembermrk remicademembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk remicadememberus gaap pharmaceuticalsegmentmembermrk belsomramembercountry usus gaap pharmaceuticalsegmentmembermrk belsomramembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk belsomramemberus gaap pharmaceuticalsegmentmembermrk belsomramembercountry usus gaap pharmaceuticalsegmentmembermrk belsomramembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk belsomramemberus gaap pharmaceuticalsegmentmembermrk belsomramembercountry usus gaap pharmaceuticalsegmentmembermrk belsomramembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk belsomramemberus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmembercountry usus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmemberus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmembercountry usus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmemberus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmembercountry usus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap isentressisentresshdmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembermrk zepatiermembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk zepatiermemberus gaap pharmaceuticalsegmentmembermrk zepatiermemberus gaap pharmaceuticalsegmentmembermrk zepatiermembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk zepatiermemberus gaap pharmaceuticalsegmentmembermrk zepatiermemberus gaap pharmaceuticalsegmentmembermrk zepatiermembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk zepatiermemberus gaap pharmaceuticalsegmentmembermrk zepatiermemberus gaap pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk vytorinmembermrk pharmaceuticalsegmentmembercountry usus gaap vytorinmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap vytorinmembermrk pharmaceuticalsegmentmemberus gaap vytorinmembermrk pharmaceuticalsegmentmembercountry usus gaap vytorinmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap vytorinmembermrk pharmaceuticalsegmentmemberus gaap vytorinmembermrk pharmaceuticalsegmentmembercountry usus gaap vytorinmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap vytorinmembermrk pharmaceuticalsegmentmemberus gaap atozetmembermrk pharmaceuticalsegmentmembercountry usus gaap atozetmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap atozetmembermrk pharmaceuticalsegmentmemberus gaap atozetmembermrk pharmaceuticalsegmentmembercountry usus gaap atozetmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap atozetmembermrk pharmaceuticalsegmentmemberus gaap atozetmembermrk pharmaceuticalsegmentmembercountry usus gaap atozetmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap atozetmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk adempasmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk adempasmemberus gaap pharmaceuticalsegmentmembermrk adempasmemberus gaap pharmaceuticalsegmentmembermrk adempasmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk adempasmemberus gaap pharmaceuticalsegmentmembermrk adempasmemberus gaap pharmaceuticalsegmentmembermrk adempasmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk adempasmemberus gaap pharmaceuticalsegmentmembermrk adempasmemberus gaap pharmaceuticalsegmentmembermrk januviamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk januviamemberus gaap pharmaceuticalsegmentmembermrk januviamemberus gaap pharmaceuticalsegmentmembermrk januviamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk januviamemberus gaap pharmaceuticalsegmentmembermrk januviamemberus gaap pharmaceuticalsegmentmembermrk januviamembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk januviamemberus gaap pharmaceuticalsegmentmembermrk januviamemberus gaap janumetmembermrk pharmaceuticalsegmentmembercountry usus gaap janumetmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap janumetmembermrk pharmaceuticalsegmentmemberus gaap janumetmembermrk pharmaceuticalsegmentmembercountry usus gaap janumetmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap janumetmembermrk pharmaceuticalsegmentmemberus gaap janumetmembermrk pharmaceuticalsegmentmembercountry usus gaap janumetmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap janumetmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembermrk implanonnexplanonmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk implanonnexplanonmemberus gaap pharmaceuticalsegmentmembermrk implanonnexplanonmemberus gaap pharmaceuticalsegmentmembermrk implanonnexplanonmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk implanonnexplanonmemberus gaap pharmaceuticalsegmentmembermrk implanonnexplanonmemberus gaap pharmaceuticalsegmentmembermrk implanonnexplanonmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk implanonnexplanonmemberus gaap pharmaceuticalsegmentmembermrk implanonnexplanonmemberus gaap pharmaceuticalsegmentmembermrk nuvaringmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk nuvaringmemberus gaap pharmaceuticalsegmentmembermrk nuvaringmemberus gaap pharmaceuticalsegmentmembermrk nuvaringmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk nuvaringmemberus gaap pharmaceuticalsegmentmembermrk nuvaringmemberus gaap pharmaceuticalsegmentmembermrk nuvaringmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk nuvaringmemberus gaap pharmaceuticalsegmentmembermrk nuvaringmemberus gaap pharmaceuticalsegmentmembermrk singulairmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk singulairmemberus gaap pharmaceuticalsegmentmembermrk singulairmemberus gaap pharmaceuticalsegmentmembermrk singulairmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk singulairmemberus gaap pharmaceuticalsegmentmembermrk singulairmemberus gaap pharmaceuticalsegmentmembermrk singulairmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmembermrk singulairmemberus gaap pharmaceuticalsegmentmembermrk singulairmemberus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmembercountry usus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmemberus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmembercountry usus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmemberus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmembercountry usus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap cozaarhyzaarmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembermrk arcoxiamembercountry usus gaap pharmaceuticalsegmentmembermrk arcoxiamembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk arcoxiamemberus gaap pharmaceuticalsegmentmembermrk arcoxiamembercountry usus gaap pharmaceuticalsegmentmembermrk arcoxiamembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk arcoxiamemberus gaap pharmaceuticalsegmentmembermrk arcoxiamembercountry usus gaap pharmaceuticalsegmentmembermrk arcoxiamembermrk internationalmemberus gaap pharmaceuticalsegmentmembermrk arcoxiamemberus gaap nasonexmembermrk pharmaceuticalsegmentmembercountry usus gaap nasonexmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap nasonexmembermrk pharmaceuticalsegmentmemberus gaap nasonexmembermrk pharmaceuticalsegmentmembercountry usus gaap nasonexmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap nasonexmembermrk pharmaceuticalsegmentmemberus gaap nasonexmembermrk pharmaceuticalsegmentmembercountry usus gaap nasonexmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap nasonexmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usmrk follistimaqmemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk follistimaqmemberus gaap pharmaceuticalsegmentmembermrk follistimaqmemberus gaap pharmaceuticalsegmentmembercountry usmrk follistimaqmemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk follistimaqmemberus gaap pharmaceuticalsegmentmembermrk follistimaqmemberus gaap pharmaceuticalsegmentmembercountry usmrk follistimaqmemberus gaap pharmaceuticalsegmentmembermrk internationalmembermrk follistimaqmemberus gaap pharmaceuticalsegmentmembermrk follistimaqmemberus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmembercountry usus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmemberus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmembercountry usus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmemberus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmembercountry usus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmembermrk internationalmemberus gaap otherpharmaceuticalmembermrk pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmemberus gaap pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmemberus gaap pharmaceuticalsegmentmemberus gaap pharmaceuticalsegmentmembercountry usus gaap pharmaceuticalsegmentmembermrk internationalmemberus gaap pharmaceuticalsegmentmemberus gaap livestockmembermrk animalhealthsegmentmembercountry usus gaap livestockmembermrk animalhealthsegmentmembermrk internationalmemberus gaap livestockmembermrk animalhealthsegmentmemberus gaap livestockmembermrk animalhealthsegmentmembercountry usus gaap livestockmembermrk animalhealthsegmentmembermrk internationalmemberus gaap livestockmembermrk animalhealthsegmentmemberus gaap livestockmembermrk animalhealthsegmentmembercountry usus gaap livestockmembermrk animalhealthsegmentmembermrk internationalmemberus gaap livestockmembermrk animalhealthsegmentmemberus gaap companionanimalsmembermrk animalhealthsegmentmembercountry usus gaap companionanimalsmembermrk animalhealthsegmentmembermrk internationalmemberus gaap companionanimalsmembermrk animalhealthsegmentmemberus gaap companionanimalsmembermrk animalhealthsegmentmembercountry usus gaap companionanimalsmembermrk animalhealthsegmentmembermrk internationalmemberus gaap companionanimalsmembermrk animalhealthsegmentmemberus gaap companionanimalsmembermrk animalhealthsegmentmembercountry usus gaap companionanimalsmembermrk animalhealthsegmentmembermrk internationalmemberus gaap companionanimalsmembermrk animalhealthsegmentmemberus gaap animalhealthsegmentmembercountry usus gaap animalhealthsegmentmembermrk internationalmemberus gaap animalhealthsegmentmemberus gaap animalhealthsegmentmembercountry usus gaap animalhealthsegmentmembermrk internationalmemberus gaap animalhealthsegmentmemberus gaap animalhealthsegmentmembercountry usus gaap animalhealthsegmentmembermrk internationalmemberus gaap animalhealthsegmentmemberus gaap usus gaap operatingsegmentsmemberus gaap internationalmemberus gaap operatingsegmentsmemberus gaap gaap operatingsegmentsmemberus gaap usus gaap operatingsegmentsmemberus gaap internationalmemberus gaap operatingsegmentsmemberus gaap gaap operatingsegmentsmemberus gaap usus gaap operatingsegmentsmemberus gaap internationalmemberus gaap operatingsegmentsmemberus gaap gaap operatingsegmentsmemberus gaap usus gaap internationalmemberus gaap gaap usus gaap internationalmemberus gaap gaap usus gaap internationalmemberus gaap gaap gaap corporatenonsegmentmembercountry internationalmemberus gaap gaap gaap corporatenonsegmentmembercountry internationalmemberus gaap gaap gaap corporatenonsegmentmembercountry internationalmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap filed security exchange commission february united statessecurities and exchange commissionwashington mark one annual report pursuant section the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of the transition period to commission file _________________________________merck co inc galloping hill roadkenilworthnew new state or jurisdiction of incorporation employer identification no security registered pursuant to section of the act title of classtrading symbol name of each exchange on registeredcommon stock par value mrknew york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangenumber of share of common stock par value outstanding of january aggregate market value of common stock par value held non affiliate on june based on closing price on june indicate by check mark the registrant well known seasoned issuer defined rule of the security act yes no indicate by check mark if the registrant is required to file report pursuant to section or section of the act yes no indicate by check mark whether the registrant filed report required to filed by section or of the security exchange act of the preceding month or shorter period the registrant required to file such report and ha subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act check one large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to management assessment of the effectiveness of it internal control financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no document incorporated by reference document part of form kproxy statement for the annual meeting of shareholder to be held may to be filed with the security and exchange commission within day the close of the fiscal year covered by this report part iiitable of contentstable of content pagepart iitem risk factor that may affect future unresolved staff legal mine safety officer of the iiitem market for registrant common equity related stockholder matter and issuer purchase of equity management discussion and analysis of financial condition and result of quantitative and qualitative disclosure market financial statement and supplementary financial to consolidated financial of independent registered public accounting change in and disagreement with accountant on accounting and financial control and other iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and relatedstockholder certain relationship and related transaction and director principal accountant fee and ivitem exhibit and financial statement form of contentspart item business merck co inc merck or the company is global health care company that delivers innovative health solution it prescription medicine vaccine biologic therapy and animal health product the company operation principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment in the first quarter of the company previously had an alliance segment that primarily included activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in all product or service mark appearing in type form different from that of the surrounding text are trademark or service mark owned licensed to promoted or distributed by merck it subsidiary or affiliate except noted all other trademark or service mark are of respective owner planned spin of woman health biosimilars and established brand new company in february merck announced it intention to spin off the spin off product from it woman health biosimilars and established brand business into new independent publicly traded company named organon co organon through distribution of organon publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the established brand included in the transaction consist of dermatology non opioid pain management respiratory and select cardiovascular product including zetia ezetimibe and vytorin ezetimibe simvastatin well the rest of merck diversified brand franchise merck existing research pipeline program continue to be owned and developed within merck planned organon will development capability initially focused on late stage development and life cycle management and is expected over time to develop research capability in selected therapeutic area the spin off is expected to be completed late in the second quarter of subject to market and certain other condition see risk factor risk related to the proposed spin off of organon of contentsproduct salestotal company sale including sale of the company top pharmaceutical product well sale of animal health product follows in million sale januvia gardasil gardasil proquad ii pneumovax isentress isentress alliance revenue lynparza implanon zetia alliance revenue lenvima animal companion other revenue alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost other revenue are primarily comprised of third party manufacturing sale and miscellaneous corporate revenue including revenue hedging activity pharmaceuticalthe pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office certain of the product within the company franchise are follows oncologykeytruda pembrolizumab the company anti pd programmed death receptor therapy monotherapy for the treatment of certain patient with cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal cancer gastric or gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc non small cell lung cancer nsclc small cell lung cancer sclc melanoma merkel cell carcinoma microsatellite instability high msi or mismatch repair deficient dmmr cancer including msi dmmr colorectal cancer primary mediastinal large cell lymphoma pmbcl tumor mutational burden high tmb cancer and urothelial carcinoma including non muscle invasive bladder cancer keytruda is also approved for the treatment of certain patient in combination with chemotherapy for metastatic squamous and non squamous nsclc in combination with chemotherapy for hnscc in combination with chemotherapy for triple negative breast cancer in combination with axitinib for renal cell carcinoma and in combination with lenvatinib for endometrial carcinoma and emend aprepitant for the prevention of certain chemotherapy induced nausea and vomiting in addition the company recognizes alliance revenue related to sale of lynparza olaparib an oral poly adp ribose polymerase parp inhibitor for certain type of advanced ovarian breast pancreatic and prostate cancer and lenvima lenvatinib for certain type of thyroid cancer hepatocellular carcinoma in combination with everolimus for certain patient with renal cell carcinoma and in combination with keytruda for certain patient with endometrial carcinoma vaccinesgardasil human papillomavirus quadrivalent type and vaccine recombinant gardasil human papillomavirus valent vaccine recombinant vaccine to help prevent certain disease of contentscaused by certain type of human papillomavirus hpv proquad measles mumps rubella and varicella virus vaccine live pediatric combination vaccine to help protect measles mumps rubella and varicella ii measles mumps and rubella virus vaccine live vaccine to help prevent measles mumps and rubella varivax varicella virus vaccine live vaccine to help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine to help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine to help protect against rotavirus gastroenteritis in infant and child and vaqta hepatitis vaccine inactivated indicated for the prevention of disease caused by hepatitis virus in person month of age and older hospital acute carebridion sugammadex injection medication for the reversal of two type of neuromuscular blocking agent used during surgery noxafil posaconazole an antifungal agent for the prevention of certain invasive fungal infection prevymis letermovir for the prophylaxis of cytomegalovirus cmv reactivation and disease in adult cmv seropositive recipient of an allogeneic hematopoietic stem cell transplant primaxin imipenem and cilastatin for injection an antibiotic for the treatment of certain bacterial infection cancidas caspofungin acetate for injection an anti fungal agent for the treatment of certain fungal infection invanz ertapenem for injection an antibiotic for the treatment of certain bacterial infection cubicin daptomycin for injection an antibiotic for the treatment of certain bacterial infection and zerbaxa ceftolozane and tazobactam for injection combination antibacterial and beta lactamase inhibitor for the treatment of certain bacterial infection immunologysimponi golimumab monthly subcutaneous treatment for certain inflammatory disease and remicade infliximab treatment for inflammatory disease both of which the company market in europe russia and turkey neurosciencebelsomra suvorexant an orexin receptor antagonist indicated for the treatment of insomnia characterized by difficulty with sleep onset and or sleep maintenance virologyisentress isentress hd raltegravir an hiv integrase inhibitor for use in combination with other antiretroviral agent for the treatment of hiv infection and zepatier elbasvir and grazoprevir for the treatment of adult patient with chronic hepatitis virus hcv genotype gt or infection with ribavirin in certain patient population cardiovascularzetia ezetimibe marketed ezetrol in country outside the united state vytorin ezetimibe simvastatin marketed inegy outside the united state atozet ezetimibe and atorvastatin marketed outside of the united state and rosuzet ezetimibe and rosuvastatin marketed outside of the united state cholesterol modifying medicine and adempas riociguat cardiovascular drug for the treatment of pulmonary arterial hypertension diabetesjanuvia sitagliptin and janumet sitagliptin metformin hcl for the treatment of type diabetes woman healthimplanon etonogestrel implant single rod subdermal contraceptive implant nexplanon etonogestrel implant single radiopaque rod shaped subdermal contraceptive implant and nuvaring etonogestrel ethinyl estradiol vaginal ring vaginal contraceptive product animal healththe animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical vaccine and health management solution and service well an extensive suite of digitally connected identification traceability and monitoring product principal product in this segment include livestock productsnuflor florfenicol antibiotic range for use in cattle and swine bovilis vista vaccine line for infectious disease in cattle banamine flunixin meglumine bovine and swine anti inflammatory estrumate cloprostenol sodium for the treatment of fertility disorder in cattle matrix altrenogest fertility management for swine resflor florfenicol and flunixin meglumine combination broad spectrum antibiotic and non steroidal anti inflammatory of contentsdrug for bovine respiratory disease zuprevo tildipirosin for bovine respiratory disease zilmax zilpaterol hydrochloride and revalor trenbolone acetate and estradiol to improve production efficiency in beef cattle safe guard fenbendazole de wormer for cattle pac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin and circumvent porcine circovirus vaccine type killed baculovirus vector vaccine line for infectious disease in swine nobilis innovax live marek disease vector vaccine line for poultry paracox and coccivac coccidiosis vaccine exzolt systemic treatment for poultry red mite infestation slice emamectin benzoate parasiticide for sea louse in salmon aquavac avirulent live culture norvax vaccine against bacterial and viral disease in fish compact pd vaccine for salmon aquaflor florfenicol antibiotic for farm raised fish and allflex livestock intelligence solution for animal identification monitoring and traceability companion animal productsbravecto line of oral and topical parasitic control product including the original bravecto fluralaner product for dog and cat that last to week bravecto fluralaner one month monthly product for dog and bravecto plus fluralaner moxidectin two month product for cat sentinel line of oral parasitic product for dog including sentinel spectrum milbemycin oxime lufenuron and praziquantel and sentinel flavor tab milbemycin oxime lufenuron optimmune cyclosporine an ophthalmic ointment nobivac vaccine line for flexible dog and cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp and clotrimazole usp ointment mometamax gentamicin sulfate usp mometasone furoate monohydrate and clotrimazole usp otic suspension posatex orbifloxacin mometasone furoate monohydrate and posaconazole suspension ear ointment for acute and chronic otitis caninsulin vetsulin porcine insulin zinc suspension diabetes mellitus treatment for dog and cat panacur fenbendazole safeguard fenbendazole broad spectrum anthelmintic de wormer for use in many animal regumate altrenogest fertility management for horse prestige vaccine line for horse scalibor deltamethrin exspot for protecting against bite from flea tick mosquito and sandfly and sure petcare product for companion animal identification and well including the microchip and pet recovery system home for discussion of sale of the company product see item management discussion and analysis of financial condition and result of operation product approvalsset forth below is summary of significant product approval received by the company in productdateapprovaldificid january food and drug administration fda approved dificid an oral suspension and dificid tablet for the treatment of clostridioides formerly clostridium difficile associated diarrhea in child aged six month and older gardasilnovember national medical product administration nmpa granted expanded approval for gardasil for use in girl and woman from to year of age gardasil ministry of health labour and welfare mhlw approved additional indication dosage and administration of gardasil marketed silgard for the prevention of anal cancer squamous cell cancer and precursor lesion anal intraepithelial neoplasia grade caused by hpv type and for individual year and older and for genital wart condyloma acuminate for men year and older july pharmaceutical and medical device agency pmda approved gardasil for use in girl and woman year and older for the prevention of cervical cancer certain cervical vaginal and vulvar precancers and genital wart caused by the hpv type covered by the vaccine june granted accelerated approval for an expanded indication for gardasil for the prevention of oropharyngeal and other head and neck cancer caused by hpv type and of contentskeytrudadecember approved keytruda monotherapy for the first line treatment of patient with metastatic or with unresectable recurrent hnscc whose tumor express pd combined positive score cps determined by fully validated test november granted accelerated approval for keytruda in combination with chemotherapy for patient with locally recurrent unresectable or metastatic triple negative breast cancer whose tumor express pd cps october approved an expanded label for keytruda monotherapy for the treatment of adult patient with relapsed or refractory chl august approved keytruda for use at an additional recommended dosage of mg every six week administered an intravenous infusion over minute across all adult indication including keytruda monotherapy and combination therapy august approved keytruda for the treatment of patient whose tumor are pd positive and have radically unresectable advanced or recurrent esophageal squamous cell carcinoma escc have progressed after chemotherapy june approved keytruda monotherapy for the first line treatment of patient with unresectable or metastatic msi or dmmr colorectal cancer june approved keytruda monotherapy for the treatment of patient with recurrent or metastatic cscc that is not curable by surgery or radiation june approved keytruda monotherapy for the treatment of patient with locally advanced or metastatic escc whose tumor express pd cps determined by fully validated test following failure of one prior line of systemic therapy june granted accelerated approval for keytruda monotherapy for the treatment of adult and pediatric patient with unresectable or metastatic tmb mutation megabase mut mb solid tumor determined by an fda approved test that have progressed following prior treatment and who have no satisfactory alternative treatment option april granted accelerated approval for keytruda for use at an additional recommended dose of mg every six week for all approved adult indication january approved keytruda for patient with bacillus calmette guerin bcg unresponsive high risk non muscle invasive bladder cancer with carcinoma in situ with or without papillary tumor who are ineligible for or have elected not to undergo cystectomy koselugo april approved the kinase inhibitor koselugo for the treatment of pediatric patient two year of age and older with neurofibromatosis type who have symptomatic inoperable plexiform neurofibroma pn lenvimanovember approved lenvima monotherapy for the treatment of differentiated thyroid cancer of contentslynparza december approved lynparza for the treatment of patient with brca gene mutated brcam castration resistant prostate cancer with distant metastasis december approved lynparza maintenance treatment after platinum based chemotherapy for patient with brcam curatively unresectable pancreas cancer december approved lynparza maintenance treatment after first line chemotherapy containing bevacizumab genetical recombination in patient with homologous recombination repair deficient hrd ovarian cancer november european commission ec approved lynparza for the maintenance treatment of adult patient with advanced figo stage iii and iv high grade epithelial ovarian fallopian tube or primary peritoneal cancer who are in response complete or partial following completion of first line platinum based chemotherapy in combination with bevacizumab and whose cancer is associated with hrd positive status defined by either breast cancer susceptibility gene mutation and or genomic instability november approved lynparza monotherapy for the treatment of adult patient with metastatic castration resistant prostate cancer mcrpc and mutation germline and or somatic who have progressed following prior therapy that included new hormonal agent july approved lynparza monotherapy for the maintenance treatment of adult patient with germline mutation who have metastatic adenocarcinoma of the pancreas and have not progressed after minimum of week of platinum treatment within first line chemotherapy regimen may approved lynparza for the treatment of adult patient with deleterious or suspected deleterious germline or somatic homologous recombination repair hrr gene mutated mcrpc determined by an fda approved test who have progressed following prior treatment with enzalutamide or abiraterone may approved lynparza in combination with bevacizumab first line maintenance treatment of adult patient with advanced epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to first line platinum based chemotherapy and whose cancer is associated with hrd positive status defined by either deleterious or suspected deleterious brca mutation and or genomic instability determined by an fda approved test recarbriojune approved recarbrio for the treatment of patient year of age and older with hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia habp vabp steglatro july approved steglatro mg tablet for the treatment of type diabetes dificid in the and canada is trademark of cubist pharmaceutical llc an indirect wholly owned subsidiary of merck sharp dohme corp in july merck and astrazeneca entered into global strategic oncology collaboration to co develop and co commercialize astrazeneca lynparza and koselugo being commercialized and promoted in worldwide except japan collaboration with pfizer inc of contentscompetition and the health care environmentcompetitionthe market in which the company conduct it business and the pharmaceutical industry in general are highly competitive and highly regulated the company competitor include other worldwide research based pharmaceutical company smaller research company with limited therapeutic focus generic drug manufacturer and animal health care company the company operation may be adversely affected by generic and biosimilar competition the company product mature well technological advance of competitor industry consolidation patent granted to competitor competitive combination product new product of competitor the generic availability of competitor branded product and new information from clinical trial of marketed product or post marketing surveillance in addition patent right are increasingly being challenged by competitor and the outcome be highly uncertain an adverse result in patent dispute can preclude commercialization of product or negatively affect sale of existing product and could result in the payment of royalty or in the recognition of an impairment charge with respect to intangible asset associated with certain product pharmaceutical competition involves rigorous search for technological innovation and the ability to market these innovation effectively with it long standing emphasis on research and development the company is well positioned to compete in the search for technological innovation the company is active in acquiring and marketing product through external alliance such licensing arrangement and collaboration and ha been refining it sale and marketing effort to address changing industry condition however the introduction of new product and process by competitor may result in price reduction and product displacement even for product protected by patent for example the number of compound available to treat particular disease typically increase over time and can result in slowed sale growth or reduced sale for the company product in that therapeutic category the highly competitive animal health business is affected by several factor including regulatory and legislative issue scientific and technological advance product innovation the quality and price of the company product well competitor product effective promotional effort and the frequent introduction of generic product by competitor health care environment and government regulationglobal effort toward health care cost containment continue to exert pressure on product pricing and market access united statesin the united state federal and state government for many year have pursued method to reduce the cost of drug and vaccine for which pay for example federal and state law require the company to pay specified rebate for medicine reimbursed by medicaid and to provide discount for medicine purchased by certain state and federal entity such the department of defense veteran affair public health service entity and hospital serving disproportionate share of low income or uninsured patient health care programsthe united state enacted major health care reform legislation in the aca various insurance market reform have since advanced and state and federal insurance exchange were launched in with respect to the effect of the law on the pharmaceutical industry the law increased the mandated medicaid rebate from to expanded the rebate to medicaid managed care utilization and increased the type of entity eligible for the federal drug discount program the law also requires pharmaceutical manufacturer to pay of the cost of the medicine including biosimilar product medicare part beneficiary are in the medicare part coverage gap the called donut hole which increased from beginning in result of the balanced budget act of merck recorded approximately million million and million reduction to revenue in and respectively related to the donut hole provision also pharmaceutical manufacturer are required to pay an annual non tax deductible health care reform fee the total annual industry fee ha been set at billion the fee is assessed on each company in proportion to it share of prior year branded pharmaceutical sale to certain government program such medicare and medicaid the company recorded approximately million million and million of cost within selling general and administrative of contentsexpenses in and respectively for the annual health care reform fee in february the center for medicare medicaid service cm issued the medicaid rebate final rule that implemented provision of the aca effective april the rule provides comprehensive guidance on the calculation of average manufacturer price and best price two metric utilized to determine the rebate drug manufacturer are required to pay to state medicaid program more recently although cm previously declined to define constitutes product line extension beyond the statutory definition cm issued new rule on december that will significantly expand the definition of the term line extension of january to include broad range of product including product reflecting new strength dosage form release mechanism and route of administration this expanded definition will increase the number of drug subject to higher medicaid rebate effective january this final rule also change the way that manufacturer must calculate best price in relation to certain patient support program including coupon which also may result in an increase in the company medicaid rebate the impact of these and other provision in this final rule could adversely impact the company business cash flow result of operation financial condition and prospect the patient protection and affordable care actthere is significant uncertainty about the future of the aca in particular and health care law in general in the united state in december texas federal district court struck the aca on the ground that the individual health insurance mandate is unconstitutional the united state supreme court heard argument in this case on november the company is participating in the health care debate and monitoring any proposed change could affect it business the company is unable to predict the likelihood of change to the aca depending on the nature of any change to the aca such action could have material adverse effect on the company business cash flow result of operation financial condition and prospect other legislative changesin addition other legislative change have been proposed and adopted in the united state since the aca wa enacted number of state have passed pharmaceutical price and cost transparency law these law typically require manufacturer to report certain product price information or other financial data to the state law also require manufacturer to provide advance notification of price increase the company expects that state will continue their focus on pharmaceutical price transparency and that this focus will continue to exert pressure on product pricing drug pricingthe company also face increasing pricing pressure globally from managed care organization government agency and program that could negatively affect the company sale and profit margin including in the united state practice of managed care organization federal and state exchange and institutional and governmental purchaser and ii federal law and regulation related to medicare and medicaid including the medicare prescription drug improvement and modernization act of and the aca in november the department of health and human service office of inspector general oig issued final rule that would effective january eliminate the anti kickback statute safe harbor for rebate paid to medicare part plan or to pharmacy benefit manager pbms on behalf of such plan the company can not anticipate the effect of this change to the way currently contract this new framework could significantly alter the way it business with part plan sponsor and pbms on behalf of such plan this rulemaking also established effective january new safe harbor for point of sale discount at the pharmacy counter and new safe harbor for certain service arrangement pharmaceutical manufacturer and pbms cm also recently issued an interim final rule the mfn rule that alters how physician will be reimbursed under the medicare program for physician administered drug pursuant to the mfn rule which wa intended to be effective january rather use the current average sale price asp based payment framework for certain physician administered drug the mfn rule would institute new pricing system for certain prescription drug and biologic product covered by medicare part in which medicare would reimburse no more than the most favored nation price meaning the lowest price after adjusting for volume and difference in gross domestic product for the top part reimbursed product which includes keytruda sold in member country of the organisation for economic co operation and development oecd several organization including two of contentstrade group of which merck is member have filed suit challenging this regulation those lawsuit remain pending with preliminary injunction been entered in one of the case at this time the company can not predict with any certainty if or when the mfn rule will go into effect implementation of the mfn rule could have material adverse effect on the company business cash flow result of operation financial condition and prospect the fda also recently issued rulemaking allowing the commercial importation of certain prescription drug from canada through fda authorized time limited program sponsored by state or native american tribe recognized under the rule and in certain future circumstance pharmacist and wholesaler the fda also recently released final guidance for industry detailing procedure for drug manufacturer to import fda approved prescription drug biological and combination product that were manufactured abroad and authorized and intended for sale in foreign country trade organization in which merck is member brought suit which remains pending in federal district court challenging the commercial importation rule these proposed change could have material adverse effect on the company business cash flow result of operation financial condition and prospect change to the health care system enacted part of health care reform in the united state well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary could result in further pricing pressure an example health care reform ha contributed to an increase in the number of patient in the medicaid program under which sale of pharmaceutical product are subject to substantial rebate the pharmaceutical industry also could be considered potential source of saving via other legislative and administrative proposal that have been debated not enacted these type of revenue generating or cost saving proposal include additional direct price control wa active consideration of drug pricing related legislation in the last congress and it remains uncertain to what proposal if any may be included part of future federal legislative proposal that would directly or indirectly affect the company in the private sector consolidation and integration among health care provider is major factor in the competitive marketplace for pharmaceutical product health plan and pbms have been consolidating into fewer larger entity thus enhancing their purchasing strength and importance private third party insurer well government employ formulary to control cost by negotiating discounted price in exchange for formulary inclusion failure to obtain timely or adequate pricing or formulary placement for merck product or obtaining such placement at unfavorable pricing could adversely affect revenue in addition to formulary tier co pay differential private health insurance company and self insured employer have been raising co payment required from beneficiary particularly for branded pharmaceutical and biotechnology product private health insurance company also are increasingly imposing utilization management tool such clinical protocol requiring prior authorization for branded product if generic product is available or requiring the patient to first fail on one or more generic product permitting access to branded medicine these management tool are also used in treatment area in which the payor ha taken the position that multiple branded product are therapeutically comparable the payor market concentrate further and more drug become available in generic form pharmaceutical company may face greater pricing pressure from private third party payors in order to provide information about the company pricing practice the company annually post on it website it pricing transparency report for the united state the report provides the company average annual list price net price increase and average discount across the company portfolio dating back to in the company gross sale were reduced by result of rebate discount and return european unionefforts toward health care cost containment remain intense in the european union eu the company face competitive pricing pressure resulting from generic and biosimilar drug in addition majority of country in the eu attempt to contain drug cost by engaging in reference pricing in which authority examine pre determined market for published price of drug reference pricing may either compare product price in other market external reference pricing or compare product price with those of other product in national class internal reference pricing the authority use the price data to set new local price for brand name drug including the company drug guideline for examining reference pricing are usually set in local market and can be changed of contentspursuant to local regulation some eu member state have established free pricing system but regulate the pricing for drug through profit control plan others seek to negotiate or set price based on the cost effectiveness of product or an assessment of whether it offer therapeutic benefit over other product in the relevant class the downward pressure on health care cost in general particularly prescription drug ha become intense result increasingly high barrier are being erected to the entry of new product in some eu member state cross border import from low priced market also exert competitive pressure that may reduce pricing within an eu member state additionally eu member state have the power to restrict the range of pharmaceutical product for which their national health insurance system provide reimbursement in the eu pricing and reimbursement plan vary widely from member state to member state some eu member state provide that drug product may be marketed after reimbursement price ha been agreed some eu member state may require the completion of additional study that compare the cost effectiveness of particular product candidate to already available therapy or so called health technology assessment hta in order to obtain reimbursement or pricing approval the hta of pharmaceutical product is becoming an increasingly common part of the pricing and reimbursement procedure in most eu member state the hta process which is governed by the national law of these country involves the assessment of the cost effectiveness public health impact therapeutic impact and or the economic and social impact of use of given pharmaceutical product in the national health care system of the individual country is conducted ultimately hta measure the added value of new health technology compared to existing one the outcome of htas regarding specific pharmaceutical product will often influence the pricing and reimbursement status granted to these pharmaceutical product by the regulatory authority of individual eu member state negative hta of one of the company product may mean that the product is not reimbursable or may force the company to reduce it reimbursement price or offer discount or rebate negative hta by leading and recognized hta body could also undermine the company ability to obtain reimbursement for the relevant product outside jurisdiction for example eu member state that have not yet developed hta mechanism may rely to some extent on the hta performed in other country with developed hta framework to inform their pricing and reimbursement decision hta procedure require additional data review and administrative process all of which increase the complexity timing and cost of obtaining product reimbursement and exert downward pressure on available reimbursement to obtain reimbursement or pricing approval in some eu member state the company may be required to conduct study that compare the cost effectiveness of the company product candidate to other therapy that are considered the local standard of care there can be no assurance that any eu member state will allow favorable pricing reimbursement and market access condition for any of the company product or that it will be feasible to conduct additional cost effectiveness study if required brexitin the united kingdom uk held referendum in which voter approved an exit from the eu commonly referred to brexit result of that referendum and subsequent negotiation the uk left the eu on january transitional period applied from january december and during this period the eu and uk operated if the uk wa an eu member state and the uk continued to participate in the eu custom union allowing for the freedom of movement for people and good it wa announced on december that the eu and the uk agreed to trade and cooperation agreement tca the tca set the new arrangement for trade of good including medicine and vaccine which allows good to continue to flow between the eu and the uk on december the council of the eu adopted the decision to sign the tca and for the tca to be provisionally applied from january the uk and eu signed the tca on december in order for the tca to be ratified and formally come into effect the council of the eu must unanimously approve the tca and the european parliament must consent to it which the company belief will occur result of the tca the company belief that it operation will not be materially adversely affected by brexit of contentsjapanin japan the pharmaceutical industry is subject to government mandated biennial price reduction of pharmaceutical product and certain vaccine furthermore the government can order pricing for specific product if it determines that use of such product will exceed certain threshold defined under applicable re pricing rule the next government mandated price reduction will occur in april and is expected to impact many company product chinathe company business in china ha grown rapidly in the past year and the importance of china to the company overall pharmaceutical and vaccine business ha increased accordingly continued growth of the company business in china is dependent upon ongoing development of favorable environment for innovative pharmaceutical product and vaccine sustained access for the company current in line product and the absence of trade impediment or adverse pricing control in recent year the chinese government ha introduced and implemented number of structural reform to accelerate the shift to innovative product and reduce cost since there have been multiple new policy introduced by the government to improve access to new innovation reduce the complexity of regulatory filing and accelerate the review and approval process this ha led to significant increase in the number of new product being approved each year additionally in the chinese government updated the national reimbursement drug list nrdl for the first time in eight year while the mechanism for drug being added to the list evolves inclusion may require price negotiation which could impact the outlook in the market for selected brand in drug were added to the nrdl through double digit price reduction while pricing pressure ha always existed in china health care reform ha increased this pressure in part due to the acceleration of generic substitution through volume based procurement vbp in the government implemented the vbp program through tendering process for mature product which have generic substitute with generic quality consistency evaluation approval mature product that have entered into the first three round of vbp have had on average price reduction of the company expects vbp to be semi annual process that will have significant impact on mature product moving forward emerging marketsthe company focus on emerging market in addition to china ha continued government in many emerging market are also focused on constraining health care cost and have enacted price control and measure impacting intellectual property including in exceptional case threat of compulsory license that aim to put pressure on the price of innovative pharmaceutical or result in constrained market access to innovative medicine the company anticipates that pricing pressure and market access challenge will continue in the future to varying degree in the emerging market beyond pricing and market access challenge other condition in emerging market country can affect the company effort to continue to grow in these market including potential political instability change in trade sanction and embargo significant currency fluctuation and control financial crisis limited or changing availability of funding for health care credit worthiness of health care partner such hospital due to covid and other development that may adversely impact the business environment for the company further the company may engage third party agent to assist in operating in emerging market country which may affect it ability to realize continued growth and may also increase the company risk exposure in addressing cost containment pressure the company engages in public policy advocacy with policymakers and continues to work to demonstrate that it medicine provide value to patient and to those who pay for health care the company advocate with government policymakers to encourage long term approach to sustainable health care financing that ensures access to innovative medicine and doe not disproportionately target pharmaceutical source of budget saving in market with historically low rate of health care spending the company encourages those government to increase their investment and adopt market reform in order to improve their citizen access to appropriate health care including medicine operating condition have become more challenging under the global pressure of competition industry regulation and cost containment effort although no one can predict the effect of these and other factor on the company business the company continually take measure to evaluate adapt and improve the organization and of contentsits business practice to better meet customer need and belief that it is well positioned to respond to the evolving health care environment and market force regulationthe pharmaceutical industry is also subject to regulation by regional country state and local agency around the world focused on standard and process for determining drug safety and effectiveness well condition for sale or reimbursement of particular importance is the fda in the united state which administers requirement covering the testing approval safety effectiveness manufacturing labeling and marketing of prescription pharmaceutical in some case the fda requirement and practice have increased the amount of time and resource necessary to develop new product and bring to market in the united state at the same time the fda ha committed to expediting the development and review of product bearing the breakthrough therapy designation which ha accelerated the regulatory review process for medicine with this designation the fda ha also undertaken effort to bring generic competition to market more efficiently and in more timely manner the eu ha adopted directive and other legislation concerning the classification approval for marketing labeling advertising manufacturing wholesale distribution integrity of the supply chain pharmacovigilance and safety monitoring of medicinal product for human use these provide mandatory standard throughout the eu which may be supplemented or implemented with additional regulation by the eu member state in particular eu regulator may approve product subject to number of post authorization condition example of typical post authorization commitment include additional pharmacovigilance the conduct of clinical trial the establishment of patient registry physician or patient education and controlled distribution and prescribing arrangement non compliance with post authorization condition pharmacovigilance and other obligation can lead to regulatory action including the variation suspension or withdrawal of the marketing authorization or other enforcement or regulatory action including the imposition of financial penalty the company policy and procedure are already consistent with the substance of these directive consequently it is believed that they will not have any material effect on the company business the company belief that it will continue to be able to conduct it operation including launching new drug in this regulatory environment see research and development below for discussion of the regulatory approval process access to medicinesas global health care company merck primary role is to discover and develop innovative medicine and vaccine the company also recognizes that it ha an important role to play in helping to improve access to it medicine vaccine and to quality health care around the world the company effort in this regard are wide ranging and include set of principle that the company strives to embed into it operation and business strategy to guide the company worldwide approach to expanding access to health care in addition through innovative social investment including philanthropic program and impact investing merck is also helping to strengthen health system and build capacity particularly in under resourced community the merck patient assistance program provides medicine and adult vaccine for free to people in the united state who not have prescription drug or health insurance coverage and who without the company assistance can not afford their merck medicine and vaccine merck ha funded merck for mother long term effort with global health partner to end preventable death from complication of pregnancy and childbirth merck ha also provided fund to the merck foundation an independent grantmaking organization which ha partnered with variety of organization dedicated to improving global health privacy and data protectionthe company is subject to significant number of privacy and data protection law and regulation globally many of which place restriction on the company ability to transfer access and use personal data across it business the legislative and regulatory landscape for privacy and data protection continues to evolve there ha been increased attention to privacy and data protection issue in both developed and emerging market with the potential to affect directly the company business including the eu general data protection regulation gdpr which went into effect in may and imposes penalty of up to of global revenue of contentsthe gdpr and related implementing law in individual eu member state govern the collection and use of personal health data and other personal data in the eu the gdpr increased responsibility and liability in relation to personal data that the company process it also imposes number of strict obligation and restriction on the ability to process which includes collection analysis and transfer of personal data including health data from clinical trial and adverse event reporting the gdpr also includes requirement relating to the consent of the individual to the personal data relates the information provided to the individual prior to processing their personal data or personal health data notification of data processing obligation to the national data protection authority and the security and confidentiality of the personal data further the gdpr prohibits the transfer of personal data to country outside of the eu that are not considered by the ec to provide an adequate level of data protection including to the united state except if the data controller meet very specific requirement following the schrems ii decision of the court of justice of the european union on july there is considerable uncertainty to the permissibility of international data transfer under the gdpr in light of the implication of this decision the company may face difficulty regarding the transfer of personal data from the eu to third country failure to comply with the requirement of the gdpr and the related national data protection law of the eu member state may result in significant monetary fine and other administrative penalty well civil liability claim from individual whose personal data wa processed data protection authority from the different eu member state may still implement certain variation enforce the gdpr and national data protection law differently and introduce additional national regulation and guideline which add to the complexity of processing personal data in the eu guidance developed at both eu level and at the national level in individual eu member state concerning implementation and compliance practice is often updated or otherwise revised there is moreover growing trend towards required public disclosure of clinical trial data in the eu which add to the complexity of obligation relating to processing health data from clinical trial failing to comply with these obligation could lead to government enforcement action and significant penalty against the company harm to it reputation and adversely impact it business and operating result the uncertainty regarding the interplay between different regulatory framework further add to the complexity that the company face with regard to data protection regulation additional law and regulation enacted in the united state such the california consumer privacy act europe asia and latin america have increased enforcement and litigation activity in the united state and other developed market well increased regulatory cooperation among privacy authority globally the company ha adopted comprehensive global privacy program to manage these evolving risk and facilitate the transfer of personal information across international border distributionthe company sell it human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pbms and other institution human health vaccine are sold primarily to physician wholesaler physician distributor and government entity the company professional representative communicate the effectiveness safety and value of the company pharmaceutical and vaccine product to health care professional in private practice group practice hospital and managed care organization the company sell it animal health product to veterinarian distributor and animal producer patent trademark and licensespatent protection is considered in the aggregate to be of material importance to the company marketing of it product in the united state and in most major foreign market patent may cover product per se pharmaceutical formulation process for or intermediate useful in the manufacture of product or the us of product protection for individual product extends for varying period in accordance with the legal life of patent in the various country the protection afforded which may also vary from country to country depends upon the type of patent and it scope of coverage the food and drug administration modernization act includes pediatric exclusivity provision that may provide an additional six month of market exclusivity in the united state for indication of new or currently marketed drug if certain agreed upon pediatric study are completed by the applicant current patent law of contentsprovides additional patent term for period when the patented product wa under regulatory review by the fda the eu also provides an additional six month of pediatric market exclusivity attached to product supplementary protection certificate spc japan provides the additional term for pediatric study attached to market exclusivity unrelated to patent term patent portfolio developed for product introduced by the company normally provide market exclusivity the company ha the following key patent protection in the united state the eu japan and china including the potential for patent term extension pte and spcs indicated for the following marketed product productyear of expiration year of expiration eu year of expiration japan year of expiration china an lenvima with pending pte patent spcs with pending pte device device with pending pte patent spcs expiredn agardasil patent spcs patent spcs with pending pte patent spcs patent spcs with pending pte patent spcs with pending pte patent spcs asegluromet with pending pte patent spcs asteglatro with pending pte patent spcs with pending pte patent spcs averquvo with pending pte with pending pte patent spcs an with pending pte patent spcs with pending pte an an anote compound patent unless otherwise noted certain of the product listed may be the subject of patent litigation see item financial statement and supplementary data note contingency and environmental liability below currently no marketing approval of content the eu date represents the expiration date for the following five country france germany italy spain and the united kingdom major eu market if spc application have been filed but have not been granted in all major eu market both the patent expiry date and the spc expiry date are listed the pte system in japan allows for patent to be extended more than once provided the later approval is directed to different indication from that of the previous approval this may result in multiple pte approval for given patent each with it expiration date eligible for month pediatric exclusivity the company ha no marketing right in the japan or china expiration of the distribution agreement with janssen pharmaceutical inc part of global strategic oncology collaboration with eisai being commercialized in worldwide collaboration with bayer ag part of global strategic oncology collaboration with astrazeneca being commercialized and promoted in worldwide except japan collaboration with pfizer inc the company ha no marketing right in japan the company ha no marketing right in the eu japan or china the company also ha the following key patent protection for drug candidate under review or in phase development phase drug candidatecurrently anticipatedyear of expiration in the mk gefapixant pneumoconjugate vaccine vaccine composition mk islatravir doravirine belzutifan otherwise noted the patent in the chart are compound patent each patent may be subject to future patent term restoration of up to five year and six month pediatric market exclusivity either or both of which may be available in addition depending on the circumstance surrounding any final regulatory approval of the compound there may be other listed patent or patent application pending that could have relevance to the product finally approved the relevance of any such application would depend upon the claim that ultimately may be granted and the nature of the final regulatory approval of the product also regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and in some case may provide more effective or longer lasting marketing exclusivity than compound patent estate in the united state the data protection generally run five year from first marketing approval of new chemical entity extended to seven year for an orphan drug indication and year from first marketing approval of biological product while the expiration of product patent normally result in loss of market exclusivity for the covered pharmaceutical product commercial benefit may continue to be derived from later granted patent on process and intermediate related to the most economical method of manufacture of the active ingredient of such product ii patent relating to the use of such product iii patent relating to novel composition and formulation and iv in the united state and certain other country market exclusivity that may be available under relevant law the effect of product patent expiration on pharmaceutical product also depends upon many other factor such the nature of the market and the position of the product in it the growth of the market the complexity and economics of the process for manufacture of the active ingredient of the product and the requirement of new drug provision of the federal food drug and cosmetic act or similar law and regulation in other country addition to market exclusivity are sought in the united state and other country through all relevant law including law increasing patent life some of the benefit of increase in patent life have been partially offset by an increase in the number of incentive for and use of generic product additionally improvement in intellectual property law are sought in the united state and other country through reform of patent and other relevant law and implementation of international treaty for further information with respect to the company patent see item risk factor and item financial statement and supplementary data note contingency and environmental liability below of contentsworldwide all of the company important product are sold under trademark that are considered in the aggregate to be of material importance trademark protection continues in some country long used in other country long registered registration is for fixed term and can be renewed indefinitely royalty income in on patent and know how license and other right amounted to million merck also incurred royalty expense amounting to billion in under patent and know how license it hold research and developmentthe company business is characterized by the introduction of new product or new us for existing product through strong research and development program at december approximately people were employed in the company research activity the company prioritizes it research and development effort and focus on candidate that it belief represent breakthrough science that will make difference for patient and payer the company maintains number of long term exploratory and fundamental research program in biology and chemistry well research program directed toward product development the company research and development model is designed to increase productivity and improve the probability of success by prioritizing the company research and development resource on candidate the company belief are capable of providing unambiguous promotable advantage to patient and payer and delivering the maximum value of it approved medicine and vaccine through new indication and new formulation merck is pursuing emerging product opportunity independent of therapeutic area or modality small molecule biologics and vaccine and is building it biologics capability the company is committed to ensuring that externally sourced program remain an important component of it pipeline strategy with focus on supplementing it internal research with licensing and external alliance strategy focused on the entire spectrum of collaboration from early research to late stage compound well access to new technology the company clinical pipeline includes candidate in multiple disease area including cancer cardiovascular disease metabolic disease infectious disease neuroscience respiratory disease and vaccine in the development of human health product industry practice and government regulation in the united state and most foreign country provide for the determination of effectiveness and safety of new chemical compound through pre clinical test and controlled clinical evaluation before new drug or vaccine may be marketed in the united state recorded data on pre clinical and clinical experience are included in the new drug application nda for drug or the biologics license application bla for vaccine or biologic submitted to the fda for the required approval once the company scientist discover new small molecule compound or biologic that they believe ha promise to treat medical condition the company commences pre clinical testing with that compound pre clinical testing includes laboratory testing and animal safety study to gather data on chemistry pharmacology immunogenicity and toxicology pending acceptable pre clinical data the company will initiate clinical testing in accordance with established regulatory requirement the clinical testing begin with phase study which are designed to ass safety tolerability pharmacokinetics and preliminary pharmacodynamic activity of the compound in human if favorable additional larger phase study are initiated to determine the efficacy of the compound in the affected population define appropriate dosing for the compound well identify any adverse effect that could limit the compound usefulness in some situation the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspect of the ongoing clinical study it continues without undermining the validity and integrity of the trial one type of adaptive clinical trial is an adaptive phase trial design two stage trial design consisting of phase proof of concept stage and phase dose optimization finding stage if data from the phase trial are satisfactory the company commences large scale phase trial to confirm the compound efficacy and safety another type of adaptive clinical trial is an adaptive phase trial design study that includes an interim analysis and an adaptation that change the trial from having feature common in phase study multiple dose group to design similar to phase trial an adaptive phase trial design reduces timeline by eliminating activity which would be required to start separate study upon completion of phase trial if satisfactory the company submits regulatory filing with the appropriate regulatory agency around the world to have the product candidate approved for marketing there can of contentsbe no assurance that compound that is the result of any particular program will obtain the regulatory approval necessary for it to be marketed vaccine development follows the same general pathway for drug pre clinical testing focus on the vaccine safety and ability to elicit protective immune response immunogenicity pre marketing vaccine clinical trial are typically done in three phase initial phase clinical study are conducted in normal subject to evaluate the safety tolerability and immunogenicity of the vaccine candidate phase study are dose ranging study finally phase trial provide the necessary data on effectiveness and safety if successful the company submits regulatory filing with the appropriate regulatory agency in the united state the fda review process begin once complete nda or bla is submitted received and accepted for review by the agency within day after receipt the fda determines if the application is sufficiently complete to permit substantive review the fda also ass at that time whether the application will be granted priority review or standard review pursuant to the prescription drug user fee act pdufa the fda review period target for ndas or original blas is either six month for priority review or ten month for standard review from the time the application is deemed sufficiently complete once the review timeline are determined the fda will generally act upon the application within those timeline unless major amendment ha been submitted either at the company own initiative or the fda request to the pending application if this occurs the fda may extend the review period to allow for review of the new information but by no more than three month extension to the review period are communicated to the company the fda can act on an application either by issuing an approval letter or by issuing complete response letter crl stating that the application will not be approved in it present form and describing all deficiency that the fda ha identified the company wish to pursue an application after receiving crl it can resubmit the application with information that address the question or issue identified by the fda in order to support approval resubmissions are subject to review period target which vary depending on the underlying submission type and the content of the resubmission the fda ha four program designation fast track breakthrough therapy accelerated approval and priority review to facilitate and expedite development and review of new drug to address unmet medical need in the treatment of serious or life threatening condition the fast track designation provides pharmaceutical manufacturer with opportunity for frequent interaction with fda reviewer during the product development and the ability for the manufacturer to do rolling submission of the nda bla rolling submission allows completed portion of the application to be submitted and reviewed by the fda on an ongoing basis the breakthrough therapy designation provides manufacturer with all of the feature of the fast track designation well intensive guidance on implementing an efficient development program for the product and commitment by the fda to involve senior manager and experienced staff in the review the accelerated approval designation allows the fda to approve product based on an effect on surrogate or intermediate endpoint that is reasonably likely to predict product clinical benefit and generally requires the manufacturer to conduct required post approval confirmatory trial to verify the clinical benefit the priority review designation mean that the fda goal is to take action on the nda bla within six month compared to ten month under standard review more than one of these special designation can be granted for given application product designated breakthrough therapy may also be eligible for priority review due to the covid public health crisis the united state secretary of health and human service ha exercised statutory authority to determine that public health emergency exists and declare these circumstance justify the emergency use of drug and biological product authorized by the fda while in effect this declaration enables the fda to issue emergency use authorization euas permitting distribution and use of specific medical product absent nda bla submission or approval including product to treat or prevent disease or condition caused by the sars cov virus subject to the term of any such euas the fda must make certain finding to grant an eua including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective and that known or potential benefit when used under the term of the eua outweigh known or potential risk additionally the fda must find that there is no adequate approved and available alternative to the emergency use the primary method the company us to obtain marketing authorization of pharmaceutical product in the eu is through the centralized procedure this procedure is compulsory for certain pharmaceutical product in of contentsparticular those using biotechnological process and is also available for certain new chemical compound and product company seeking to market an innovative pharmaceutical product through the centralized procedure must file complete set of safety data and efficacy data part of marketing authorization application maa with the european medicine agency ema after the ema evaluates the maa it provides recommendation to the ec and the ec then approves or denies the maa it is also possible for new chemical product to obtain marketing authorization in the eu through mutual recognition procedure in which an application is made to single member state and if the member state approves the pharmaceutical product under national procedure the applicant may submit that approval to the mutual recognition procedure of some or all other eu member state outside of the united state and the eu the company submits marketing application to national regulatory authority example of such are the ministry of health labour and welfare in japan the national medical product administration in china health canada agncia nacional de vigilncia sanatria in brazil korea food and drug administration in south korea and the therapeutic good administration in australia each country ha separate and independent review process and timeline in many market approval time can be longer the regulatory authority requires approval in major market such the united state or the eu and issuance of certificate of pharmaceutical product from that market before initiating their local review process research and development updatethe company currently ha several candidate under regulatory review in the united state and internationally or in late stage clinical development mk is combination of relebactum beta lactamase inhibitor and imipenem cilastatin carbapenem antibiotic under review in japan for the treatment of bacterial infection mk wa approved by the fda in and is marketed in the united state recarbrio mk vericiguat is an orally administered soluble guanylate cyclase sgc stimulator under review in the eu and in japan to reduce the risk of cardiovascular death and heart failure hospitalization following worsening heart failure event in patient with symptomatic chronic heart failure with reduced ejection fraction in combination with other heart failure therapy the application are based on result from the phase victoria trial vericiguat wa approved by the fda in january and will be marketed in the united state verquvo vericiguat is being jointly developed with bayer bayer will commercialize vericiguat in territory outside the united state if approved mk selumetinib is under review in the eu for the treatment of pediatric patient two year of age and older with neurofibromatosis type who have symptomatic inoperable plexiform neurofibroma pn based on positive result from the national cancer institute cancer therapy evaluation program sponsored phase sprint stratum trial selumetinib wa approved by the fda in april and is marketed in the united state koselugo selumetinib is being jointly developed and commercialized with astrazeneca globally is an investigational valent pneumococcal conjugate vaccine under priority review by the fda for the prevention of invasive pneumococcal disease in adult year of age and older the fda set pdufa date of july the ema is also reviewing an application for licensure of in adult additionally the company ha several ongoing phase trial evaluating in pediatric patient previously received breakthrough therapy designation from the fda for the prevention of invasive pneumococcal disease in pediatric patient week to year of age and adult year of age and older the company is involved in litigation challenging the validity of several pfizer inc patent that relate to pneumococcal vaccine technology in the united state and several foreign jurisdiction keytruda is an anti pd therapy approved for the treatment of many cancer that is in clinical development for expanded indication these approval were the result of broad clinical development program that currently consists of more than clinical trial including more than trial that combine keytruda with other cancer treatment these study encompass more than cancer type including biliary tract cervical colorectal cutaneous squamous cell endometrial esophageal estrogen receptor positive breast cancer gastric glioblastoma head and neck hepatocellular hodgkin lymphoma non hodgkin lymphoma non small cell lung small cell lung melanoma mesothelioma ovarian prostate renal triple negative breast and urothelial many of which are currently in phase clinical development further trial are being planned for other cancer of contentskeytruda in combination with chemotherapy is under review in the eu for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer tnbc in adult whose tumor express pd with cps and who have not received prior chemotherapy for metastatic disease based on the result of the keynote trial keytruda wa approved for this indication under accelerated approval based on progression free survival pfs by the fda in november keytruda in combination with chemotherapy is also under review in japan for the treatment of patient with locally recurrent unresectable or metastatic tnbc based on data from the keynote trial in july the fda accepted for standard review supplemental bla for keytruda for the treatment of patient with high risk early stage tnbc in combination with chemotherapy neoadjuvant pre operative treatment and then single agent adjuvant post operative treatment after surgery the application wa based on data from the first and second interim analysis of the keynote trial in february the fda oncologic drug advisory committee odac which discussed the company supplemental bla for keytruda voted that regulatory decision should be deferred until further data are available from the phase keynote trial the study met one of the dual primary endpoint of pathological complete response and is continuing to evaluate event free survival the odac provides the fda with independent expert advice and recommendation on marketed and investigational medicine for use in the treatment of cancer the fda is not bound by the committee guidance but take it advice into consideration the pdufa date for this application is march the next interim analysis is calendar driven and data is expected in the third quarter of in february merck announced that the committee for medicinal product for human use chmp of the ema adopted positive opinion recommending approval of an expanded label for keytruda monotherapy for the treatment of adult and pediatric patient aged year and older with relapsed or refractory chl who have failed an earlier line of therapy this recommendation is based on result from the pivotal phase keynote trial in which keytruda monotherapy demonstrated significant improvement in pfs compared with brentuximab vedotin commonly used treatment the recommendation is also based on supportive data from an updated analysis of the keynote trial which supported ec approval of keytruda for the treatment of adult patient with relapsed or refractory chl the chmp recommendation will be reviewed by the ec for marketing authorization in the eu keytruda wa approved for this indication by the fda in october keytruda is also under review monotherapy for the first line treatment of adult patient with metastatic msi or dmmr colorectal cancer in japan based on the result of the keynote trial keytruda wa approved for this indication by the fda in june and by the eu in january in january the fda accepted supplemental bla seeking use of keytruda for the treatment of patient with locally advanced cscc that is not curable by surgery or radiation based on the result of the keynote trial the fda set pdufa date of september in december the fda accepted and granted priority review for supplemental bla for keytruda in combination with chemotherapy for the first line treatment of patient with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction this supplemental bla is based on data from the pivotal phase keynote trial in which keytruda plus chemotherapy demonstrated significant improvement in the primary endpoint of overall survival and pfs versus chemotherapy in these patient regardless of pd expression status and tumor histology these data were presented at the european society of medical oncology esmo virtual congress the fda set pdufa date of april in december the chmp of the ema announced the start of procedure to extend the indication to include in combination with chemotherapy first line treatment of locally advanced unresectable or metastatic carcinoma of the esophagus or negative gastroesophageal junction adenocarcinoma in adult for keytruda based on the result from keynote keytruda is also under review for this indication in japan keytruda also received breakthrough therapy designation from the fda in february for the combination of keytruda with padcev enfortumab vedotin ejfv in the first line setting for the treatment of patient with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin containing chemotherapy the fda breakthrough therapy designation is intended to expedite the development and review of candidate that is planned for use alone or in combination to treat serious or life threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapy on one or more clinically significant endpoint of contentsin january merck announced first time data from the phase keynote study evaluating keytruda in combination with ipilimumab yervoy compared with keytruda monotherapy first line treatment for patient with metastatic nsclc without egfr or alk genomic tumor aberration and whose tumor express pd tumor proportion score result of the study showed that the addition of ipilimumab to keytruda not improve or pfs but added toxicity compared with keytruda monotherapy in these patient these result were presented in the presidential symposium at the iaslc world conference on lung cancer hosted by the international association for the study of lung cancer in january and published in the journal of clinical oncology previously announced in november the study wa discontinued due to futility based on the recommendation of an independent data monitoring committee dmc which determined the benefit risk profile of keytruda in combination with ipilimumab did not support continuing the trial the dmc also advised that patient in the study discontinue treatment with ipilimumab placebo in february merck announced that the phase keynote trial evaluating keytruda versus standard of care treatment capecitabine gemcitabine or docetaxel for the treatment of recurrent or metastatic nasopharyngeal cancer did not meet it primary endpoint of full result will be presented at future medical meeting in may merck and eisai presented data from analysis of two phase trial evaluating keytruda plus lenvima at the american society of clinical oncology asco annual meeting in which the keytruda plus lenvima combination demonstrated clinically meaningful objective response rate orr the keynote study trial in patient with unresectable hcc with no prior systemic therapy and the keynote study trial in patient with metastatic clear cell renal cell carcinoma ccrcc who progressed following immune checkpoint inhibitor therapy in july merck and eisai announced that the fda issued crl regarding merck and eisai application seeking accelerated approval for the first line treatment of patient with unresectable hcc based on this trial which showed clinically meaningful efficacy in the single arm setting these data supported breakthrough therapy designation granted by the fda in july ahead of the pdufa action date of merck and eisai application another combination therapy wa approved based on randomized controlled trial that demonstrated improvement in versus standard of care treatment consequently the crl stated that merck and eisai application do not provide evidence that keytruda in combination with lenvima represents meaningful advantage over available therapy for the treatment of unresectable or metastatic hcc with no prior systemic therapy for advanced disease since the application for keynote study no longer meet the criterion for accelerated approval both company plan to work with the fda to take appropriate next step which include conducting well controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination such leap the phase trial evaluating the keytruda plus lenvima combination first line treatment for advanced hcc is currently underway and fully enrolled the crl doe not impact the current approved indication for keytruda or for lenvima in february merck and eisai announced the first presentation of new investigational data from the pivotal phase clear study keynote study at the genitourinary cancer symposium asco gu and published simultaneously in the new england journal of medicine the trial evaluated the combination of keytruda plus lenvima and lenvima plus everolimus versus sunitinib for the first line treatment of patient with advanced rcc keytruda plus lenvima demonstrated statistically significant and clinically meaningful improvement in pfs and orr versus sunitinib lenvima plus everolimus also showed significant improvement in pfs and orr versus sunitinib merck and eisai will discus these data with regulatory authority worldwide with the intent to submit marketing authorization application based on these result in december merck and eisai announced that the pivotal phase keynote study trial evaluating the investigational use of keytruda plus lenvima met it dual primary endpoint of and pfs and it secondary efficacy endpoint of orr in patient with advanced endometrial cancer following at least one prior platinum based regimen these positive result were observed in the mismatch repair proficient pmmr subgroup and the itt study population which includes both patient with endometrial carcinoma that is pmmr well patient whose disease is msi dmmr based on an analysis conducted by an independent dmc keytruda plus lenvima demonstrated statistically significant and clinically meaningful improvement in pfs and orr versus chemotherapy merck and eisai will discus these data with regulatory authority worldwide with the intent to of contentssubmit marketing authorization application based on these result and plan to present these result at an upcoming medical meeting keynote study is the confirmatory trial for keynote study which supported accelerated approval by the fda in of the keytruda plus lenvima combination for the treatment of patient with advanced endometrial carcinoma that is not msi or dmmr who have disease progression following prior systemic therapy and are not candidate for curative surgery or radiation merck and eisai are continuing to study the keytruda plus lenvima combination through the leap lenvatinib and pembrolizumab clinical program across trial in different tumor type endometrial carcinoma hcc melanoma nsclc rcc squamous cell carcinoma of the head and neck urothelial cancer biliary tract cancer colorectal cancer gastric cancer glioblastoma ovarian cancer and tnbc mk belzutifan is an investigational hypoxia inducible factor hif inhibitor being evaluated for the treatment of patient with von hippel lindau vhl disease associated rcc with nonmetastatic rcc tumor le than three centimeter in size unless immediate surgery is required in july the fda granted breakthrough therapy designation to belzutifan and ha also granted orphan drug designation to belzutifan for vhl disease these designation are based on data from phase trial evaluating belzutifan in patient with vhl associated ccrcc which were presented at the asco annual meeting additionally phase data showing anti tumor response in vhl disease patient with ccrcc and other tumor were presented at the esmo virtual congress in february merck and eisai began phase trial examining lenvima in combination with belzutifan in previously treated patient with metastatic rcc mk tukysa is small molecule tyrosine kinase inhibitor for the treatment of positive cancer in september seagen granted merck an exclusive license and entered into co development agreement with merck to accelerate the global reach of tukysa merck and seagen also announced collaboration to globally develop and commercialize seagen ladiratuzumab vedotin mk an investigational antibody drug conjugate targeting liv which is currently in phase clinical trial for breast cancer and other solid tumor the collaboration will pursue broad joint development program evaluating ladiratuzumab vedotin monotherapy and in combination with keytruda in tnbc hormone receptor positive breast cancer and other liv expressing solid tumor mk lynparza is an oral parp inhibitor currently approved for certain type of advanced ovarian breast pancreatic and prostate cancer being co developed for multiple cancer type part of collaboration with astrazeneca mk gefapixant is an investigational orally administered selective receptor antagonist for the treatment of refractory or unexplained chronic cough in september merck announced the result from two ongoing pivotal phase trial cough and cough evaluating the efficacy and safety of gefapixant in these study adult patient treated with gefapixant mg twice daily demonstrated statistically significant reduction in hour cough frequency versus placebo at week cough and week cough the gefapixant mg twice daily treatment arm did not meet the primary efficacy endpoint in either phase study these result were presented at the virtual european respiratory society international congress merck plan to share data from cough and cough with regulatory authority worldwide mk also known is an investigational treatment for patient hospitalized with covid merck obtained mk through the acquisition of oncoimmune in september oncoimmune reported topline finding from an interim efficacy analysis of phase study evaluating mk an interim analysis of data from participant of the planned enrollment indicated that selected hospitalized patient with covid treated with single dose of mk showed higher probability of improvement in clinical status compared to placebo defined by the protocol the risk of death or respiratory failure wa reduced by more than full result from this phase study which were consistent with the topline result were received in february and will be submitted for publication in the future mk is also being studied in phase trial for the treatment of graft versus host disease molnupiravir also known mk is an orally available antiviral candidate for the treatment of covid being developed in collaboration with ridgeback biotherapeutics lp it is currently being evaluated in of contentsphase clinical trial in both the hospital and outpatient setting the primary completion date for the phase study is june the company anticipates interim efficacy data in the first quarter of mk is combination of islatravir the company investigational oral nucleoside reverse transcriptase translocation inhibitor nrtti and doravirine pifeltro being evaluated for the treatment of hiv infection in october merck announced week data from the phase trial evaluating the efficacy and safety of mk in treatment nave adult with hiv infection week finding demonstrated that the combination of islatravir and doravirine maintained virologic suppression similar to delstrigo doravirine lamivudine tenofovir disoproxil fumarate and the finding were consistent with week result additional week data from the study show low rate of participant meeting the definition of protocol defined virologic failure in both the islatravir plus doravirine and the delstrigo treatment arm and no participant in either arm met the criterion for resistance testing these data were presented at the virtual international congress on drug therapy in hiv infection hiv glasgow in november merck announced collaboration with the bill melinda gate foundation the foundation where the foundation is committing to provide funding to support pivotal phase study investigating once monthly oral pre exposure prophylaxis prep option in woman and adolescent girl at high risk for acquiring hiv infection in sub saharan africa the study impower will evaluate the efficacy and safety of once monthly islatravir and is anticipated to begin in early merck will be funding the impower clinical trial in the united state merck also plan to conduct additional study in hiv prevention with islatravir in once monthly oral prep these study will include impower global phase clinical trial to evaluate islatravir once monthly oral agent for prep at site across the world and among other key population impacted by the epidemic including men who have sex with men and transgender woman in january the fda accepted for standard review supplemental nda for steglatro ertugliflozin to incorporate the result of the phase vertis cardiovascular cv outcome trial in the product labeling the vertis cv trial evaluated steglatro an oral sodium glucose cotransporter inhibitor versus placebo added to background standard of care treatment in patient with type diabetes and atherosclerotic cv disease the study met the primary endpoint of non inferiority on major adverse cv event mace which is composite of cv death nonfatal myocardial infarction or nonfatal stroke compared to placebo the key secondary endpoint of superiority for steglatro versus placebo for time to the first occurrence of the composite of cv death or hospitalization for heart failure time to cv death alone and time to the first occurrence of the composite of renal death dialysis transplant or doubling of serum creatinine from baseline were not met while not pre specified hypothesis for statistical testing reduction in hospitalization for heart failure wa observed with steglatro supplemental application wa also submitted to the ema and is currently under review in january the company announced the discontinuation of the clinical development program for it covid vaccine candidate and following merck review of finding from phase clinical study for the vaccine in these study both and were generally well tolerated but the immune response were inferior to those seen following natural infection and those reported for other sars cov covid vaccine the chart below reflects the company research pipeline of february candidate shown in phase include specific product and the date such candidate entered into phase development candidate shown in phase include the most advanced compound with specific mechanism or if listed compound have the same mechanism they are each currently intended for commercialization in given therapeutic area small molecule and biologics are given mk number designation and vaccine candidate are given number designation except otherwise noted candidate in phase additional indication in the same therapeutic area other than with respect to cancer and additional claim line extension or formulation for in line product are not shown of contentsphase phase entry date under reviewantiviral covid molnupiravir cancermk hematological malignanciesmk quavonlimab melanomanon small cell lungsolid tumor mk head and neckmk solid tumorsmk keytrudaadvanced solid tumorsmk hematological malignancy non small cell lungmk small cell lungmk non small cell lungmk ladiratuzumab vedotin advanced solid tumorsbreastmk tukysa advanced solid tumorscolorectalgastricmk lynparza advanced solid tumorsmk vibostolimab melanoma non small cell lung mk lenvima advanced solid tumorsbiliary squamous cellhead and neckmelanomasolid tumorschikungunya preventionmk islatravir nonalcoholic steatohepatitis nashmk syndromemk miransertib pneumococcal vaccine syncytial virusmk keytruda biliary tract september cervical october eu cutaneous squamous cell august eu endometrial august eu gastric may eu hepatocellular may eu mesothelioma may ovarian december prostate may small cell lung may eu mk belzutifan renal cell february mk tukysa breast october mk lynparza colorectal august non small cell lung june small cell lung december mk lenvima bladder may endometrial june eu gastric december head and neck february melanoma march non small cell lung march coughmk gefapixant march covid december hiv infection mk doravirine islatravir february new molecular entity vaccinesbacterial infectionmk relebactam imipenem cilastatin jpn heart failuremk vericiguat eu jpn pediatric neurofibromatosis type selumetinib eu pneumococcal infection adultv eu certain supplemental filing cancermk keytruda metastatic triple negative breast cancer keynote eu jpn early stage triple negative breast cancer keynote refractory classical hodgkin lymphoma keynote eu unresectable or metastatic msi or dmmr colorectal cancer keynote jpn cutaneous squamous cell cancer keynote advanced unresectable metastatic esophageal cancer keynote eu jpn first line metastatic gastric cancer keynote mk lenvima first line metastatic hepatocellular carcinoma keynote thymic carcinoma remora jpn footnote being developed in collaboration being developed in combination with keytruda being developed monotherapy and in combination with keytruda in july the fda issued crl for merck and eisai application merck and eisai intend to submit additional data when available to the fda human capitalas of december the company had approximately employee worldwide with approximately employed in the united state including puerto rico and approximately third party contractor globally approximately of the company employee are full time employee woman and individual with ethnically diverse background comprise approximately and of it workforce in the united state respectively woman comprise of the member of the board of director additionally the company executive team which includes individual up to two structural level below the chief executive of contentsofficer is made up of woman approximately of the company employee are represented by various collective bargaining group the company recognizes that it employee are critical to meet the need of it patient and customer and that it ability to excel depends on the integrity skill and diversity of it employee talent acquisition the company us comprehensive approach to ensure recruiting retention and leadership development goal are systematically executed throughout the company and that it hire talented leader to achieve improved gender parity and representation across all dimension of diversity the company provides training to it manager and external recruiting organization on strategy to mitigate unconscious bias in the candidate selection and hiring process in addition the company utilizes comprehensive communication strategy marketing outreach social medium and strategic alliance partnership to reach broad pool of talent in it critical business area in the company hired approximately employee across the globe through various channel including the company external career site diversity partnership employee referral university and other external source global diversity and inclusion diversity and inclusion are fundamental to the company success and core to future innovation the company foster globally diverse and inclusive workforce for it employee by creating an environment of belonging engagement equity and empowerment the company is proactive and intentional about diversity hiring and development program to advance talent the company creates competitive advantage by leveraging diversity and inclusion to accelerate business performance this includes fostering global supplier diversity integrating diversity and inclusion into the company commercialization strategy and leveraging employee insight to improve performance in addition to these effort the company ha ten employee business resource group that provide opportunity for employee to take an active part in contributing to the company inclusive culture through their work in talent acquisition and development business and customer insight and social and community outreach gender and ethnicity performance data in the woman in the workforce in the nrwomen on the board of woman in executive role woman in management role member of underrepresented ethnic group on the board of member of underrepresented ethnic group in executive role member of underrepresented ethnic group in the workforce member of underrepresented ethnic group in management role new hire that were new hire that were member of underrepresented ethnic group nr not reported of executive is defined the chief executive officer and two structural level below management role is defined all manager with direct report other than executive defined in note compensation and benefitsthe company provides valuable total reward package reflecting it commitment to attract retain and motivate it talent and to supporting it employee and their family in every stage of life the company continuously monitor and adjusts it compensation and benefit program to ensure they are competitive contemporary helpful and engaging and that they support strategic imperative such diversity and inclusion equity flexibility quality security and affordability for example in the company added personal health care concierge service to assist employee participating in the company medical plan with their health care of contentsneeds aligned with it business and in support of it cancer care strategy the company also improved cancer screening benefit added resource and provided immediate access to leading cancer center of excellence for employee globally the company implemented minimum standard of week of paid parental leave which inclusively applies to all parent in the united state the company benefit rank in the top quartile of fortune company under the aon hewitt benefit index the company ha been included in the working mother best company ranking for consecutive year and wa named working mother best company for dad in employee wellbeingthe company is committed to helping it employee and their family improve their own health and wellbeing the company culture of wellbeing is referred to live it which includes program to support preventive health emotional and financial wellbeing physical fitness and nutrition it is designed to inspire all employee to pursue enjoy and share healthy lifestyle live it wa launched in the united state in and today is available in every country in which the company ha employee in addition many of the company larger site offer onsite health clinic that provide an array of service to help it employee stay or get well including vaccination cancer and biometric screening travel medicine and advice diagnosis and treatment of non occupational illness or injury health counseling and referral the company overall employee wellbeing program wa recognized for excellence in health and wellbeing by receiving the highest level award from the business group on health and and the american heart association covid responsethe company recognizes that it ha unique responsibility to help in response to the covid pandemic and is committed to supporting and protecting it employee and their family ensuring that it supply of medicine and vaccine reach it patient contributing it scientific expertise to the development of antiviral approach and supporting it health care provider and the community in which they serve the company continues to provide employee with easy and regular access to information including detail regarding the company tracking process guidance around hygiene measure and travel and best practice for working from home example of pandemic support resource and program available to the company employee include pay continuation for worker who have been sick or exposed volunteer policy adjustment to enable employee with medical background to volunteer in sars cov related activity resource to prioritize physical and mental wellness adjustment to medical plan to cover of covid related diagnosis testing and treatment backup childcare and more engaging employeesthe company strives to foster employee engagement by promoting safe positive diverse and inclusive work environment that provides numerous opportunity for two way communication with employee some of the company key program and initiative include promoting global employee engagement survey ongoing pulse check to the organization for interim feedback on specific topic fostering professional networking and collaboration identifying and providing opportunity for volunteering and establishing positive cooperative business relation with designated employee representative talent management and developmentas the company pursues it goal of becoming the world premier research based biopharmaceutical company it need to continuously develop it diverse and talented people the company current talent management system support company wide performance management development talent review and succession planning annual performance review help further the professional development of the company employee and ensure that the company workforce is aligned with the company objective the company seek to continuously build the skill and capability of it workforce to accelerate talent improve performance and mitigate risk through relevant continuous learning experience this includes but is not limited to building leadership and management skill well providing technical and functional training to all employee environmental mattersthe company belief that there are no compliance issue associated with applicable environmental law and regulation that would have material adverse effect on the company the company is also remediating environmental contamination resulting from past industrial activity at certain of it site expenditure for of contentsremediation and environmental liability were million in and are estimated at million in the aggregate for the year through these amount do not consider potential recovery from other party the company ha taken an active role in identifying and accruing for these cost and in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million at both december and although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed approximately million in the aggregate management also doe not believe that these expenditure should have material adverse effect on the company financial condition result of operation liquidity or capital resource for any year merck belief that climate change could present risk to it business some of the potential impact of climate change to it business include increased operating cost due to additional regulatory requirement physical risk to the company facility water limitation and disruption to it supply chain these potential risk are integrated into the company business planning including investment in reducing energy usage water use and greenhouse gas emission the company doe not believe these risk are material to it business at this time geographic area informationthe company operation outside the united state are conducted primarily through subsidiary sale worldwide by subsidiary outside the united state percentage of total company sale were in both and and were in the company worldwide business is subject to risk of currency fluctuation governmental action and other governmental proceeding abroad the company doe not regard these risk deterrent to further expansion of it operation abroad however the company closely review it method of operation and adopts strategy responsive to changing economic and political condition merck ha operation in country located in latin america the middle east africa eastern europe and asia pacific business in these developing area while sometimes le stable offer important opportunity for growth over time available informationthe company internet website address is www merck com the company will make available free of charge at the investor portion of it website it annual report on form quarterly report on form current report on form and all amendment to those report filed or furnished pursuant to section or of the security exchange act of amended soon reasonably practicable after such report are electronically filed with or furnished to the security and exchange commission sec the address of that website is www sec gov in addition the company will provide without charge copy of it annual report on form including financial statement and schedule upon the written request of any shareholder to the office of the secretary merck co inc galloping hill road kenilworth nj the company corporate governance guideline and the charter of the board of director four standing committee are available on the company website at www merck com company overview leadership and all such information is available in print to any shareholder who request it from the company item risk factor summary risk factorsthe company is subject to number of risk that if realized could materially adversely affect it business result of operation cash flow financial condition or prospect the following is summary of the principal risk factor facing the company the company is dependent on it patent right and if it patent right are invalidated or circumvented it business could be materially adversely affected the company product lose market exclusivity the company generally experience significant and rapid loss of sale from those product of content key product generate significant amount of the company profit and cash flow and any event that adversely affect the market for it leading product could have material adverse effect on the company result of operation and financial condition the company research and development effort may not succeed in developing commercially successful product and the company may not be able to acquire commercially successful product in other way in consequence the company may not be able to replace sale of successful product that lose patent protection the company success is dependent on the successful development and marketing of new product which are subject to substantial risk the company face continued pricing pressure with respect to it product the uncertainty in global economic condition together with cost reduction measure being taken by certain government could negatively affect the company operating result the company face intense competition from lower cost generic product the company face intense competition from competitor product the global covid pandemic is having an adverse impact on the company business operation and financial performance the company is unable to predict the full extent to which the covid pandemic or any future pandemic epidemic or similar public health threat will adversely impact it business operation financial performance result of operation and financial condition the company ha significant global operation which expose it to additional risk and any adverse event could have material adverse effect on the company result of operation and financial condition failure to attract and retain highly qualified personnel could affect the company ability to successfully develop and commercialize product in the past the company ha experienced difficulty and delay in manufacturing certain of it product including vaccine the company may not be able to realize the expected benefit of it investment in emerging market the company is exposed to market risk from fluctuation in currency exchange rate and interest rate pharmaceutical product can develop unexpected safety or efficacy concern reliance on third party relationship and outsourcing arrangement could materially adversely affect the company business negative event in the animal health industry could have material adverse effect on future result of operation and financial condition biologics and vaccine carry unique risk and uncertainty which could have material adverse effect on the company future result of operation and financial condition the health care industry in the united state ha been and will continue to be subject to increasing regulation and political action the company product including product in development can not be marketed unless the company obtains and maintains regulatory approval development following regulatory approval may adversely affect sale of the company product the company is subject to variety of and international law and regulation of content the company is subject to evolving and complex tax law which may result in additional liability that may affect result of operation and financial condition product liability insurance for product may be limited cost prohibitive or unavailable the company is increasingly dependent on sophisticated software application computing infrastructure and cloud service provider in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation the company could be target of future cyber attack social medium platform present risk and challenge the proposed spin off of organon may not be completed on the term or timeline currently contemplated if at all and may not achieve the expected result the cost to complete the proposed spin off will be significant in addition the company may be unable to achieve some or all of the strategic and financial benefit that it expects to achieve from the spin off of organon following the spin off the price of share of the company common stock may fluctuate significantly there could be significant income tax liability if the spin off or certain related transaction are determined to be taxable for federal income tax purpose the above list is not exhaustive and the company face additional challenge and risk investor should carefully consider all of the information set forth in this form including the following risk factor before deciding to invest in any of the company security risk factor the risk below are not the only one the company face additional risk not currently known to the company or that the company presently deems immaterial may also impair it business operation the company business financial condition result of operation cash flow or prospect could be materially adversely affected by any of these risk this form also contains forward looking statement that involve risk and uncertainty the company result could materially differ from those anticipated in these forward looking statement result of certain factor including the risk it face described below and elsewhere see cautionary factor that may affect future result below risk related to the company businessthe company is dependent on it patent right and if it patent right are invalidated or circumvented it business could be materially adversely affected patent protection is considered in the aggregate to be of material importance to the company marketing of human health and animal health product in the united state and in most major foreign market patent covering product that it ha introduced normally provide market exclusivity which is important for the successful marketing and sale of it product the company seek patent covering each of it product in each of the market where it intends to sell the product and where meaningful patent protection is available even if the company succeeds in obtaining patent covering it product third party or government authority may challenge or seek to invalidate or circumvent it patent and patent application it is important for the company business to defend successfully the patent right that provide market exclusivity for it product the company is often involved in patent dispute relating to challenge to it patent or claim by third party of infringement against the company the company defends it patent both within and outside the united state including by filing claim of infringement against other party see item financial statement and supplementary data note contingency and environmental liability below in particular manufacturer of generic pharmaceutical product from time to time file abbreviated ndas with the fda seeking to market generic form of the company product prior to the expiration of relevant patent owned or licensed by the company the company normally responds by defending it patent including by filing lawsuit alleging patent of contentsinfringement patent litigation and other challenge to the company patent are costly and unpredictable and may deprive the company of market exclusivity for patented product or in some case third party patent may prevent the company from marketing and selling product in particular geographic area additionally certain foreign government have indicated that compulsory license to patent may be granted in the case of national emergency or in other circumstance which could diminish or eliminate sale and profit from those region and negatively affect the company result of operation further court decision relating to other company patent potential legislation in both the united state and certain foreign market relating to patent well regulatory initiative may result in more general weakening of intellectual property protection if one or more important product lose patent protection in profitable market sale of those product are likely to decline significantly result of generic version of those product becoming available the company result of operation may be adversely affected by the lost sale unless and until the company ha launched commercially successful product that replace the lost sale in addition if product that were measured at fair value and capitalized in connection with acquisition experience difficulty in the market that negatively affect product cash flow the company may recognize material non cash impairment charge with respect to the value of those product chart listing the patent protection for certain of the company marketed product and patent protection for candidate in phase clinical development is set forth above in item business patent trademark and license the company product lose market exclusivity the company generally experience significant and rapid loss of sale from those product the company depends upon patent to provide it with exclusive marketing right for it product for some period of time loss of patent protection for one of the company product typically lead to significant and rapid loss of sale for that product lower priced generic version of that drug become available in the case of product that contribute significantly to the company sale the loss of market exclusivity can have material adverse effect on the company business cash flow result of operation financial condition and prospect for example the patent that provided market exclusivity for nuvaring expired in april and generic competition began in december the company experienced rapid and substantial decline in nuvaring sale in result of this generic competition in addition januvia and janumet will lose market exclusivity in the united state in january januvia will lose market exclusivity in the eu in september finally the spc that provides market exclusivity for janumet in the eu expires in april the company anticipates sale of januvia and janumet in these market will decline substantially after the loss of market exclusivity key product generate significant amount of the company profit and cash flow and any event that adversely affect the market for it leading product could have material adverse effect on the company result of operation and financial condition the company ability to generate profit and operating cash flow depends largely upon the continued profitability of the company key product such keytruda gardasil gardasil januvia janumet and bridion in particular in the company oncology portfolio led by keytruda represented the vast majority of the company revenue growth result of the company dependence on key product any event that adversely affect any of these product or the market for any of these product could have significant adverse impact on result of operation and cash flow these event could include loss of patent protection increased cost associated with manufacturing generic or over the counter availability of the company product or competitive product the discovery of previously unknown side effect result of post approval trial increased competition from the introduction of new more effective treatment and discontinuation or removal from the market of the product for any reason such event could have material adverse effect on the sale of any such product of contentsthe company research and development effort may not succeed in developing commercially successful product and the company may not be able to acquire commercially successful product in other way in consequence the company may not be able to replace sale of successful product that lose patent protection in order to remain competitive the company like other major pharmaceutical company must continue to launch new product expected decline in sale of product after the loss of market exclusivity mean that the company future success is dependent on it pipeline of new product including new product that it may develop through collaboration and joint venture and product that it is able to obtain through license or acquisition to accomplish this the company commits substantial effort fund and other resource to research and development both through it own dedicated resource and through various collaboration with third party there is high rate of failure inherent in the research and development process for new drug and vaccine result there is high risk that fund invested by the company in research program will not generate financial return this risk profile is compounded by the fact that this research ha long investment cycle to bring pharmaceutical compound from the discovery phase to market may take decade or more and failure can occur at any point in the process including later in the process after significant fund have been invested for description of the research and development process see item business research and development above each phase of testing is highly regulated and during each phase there is substantial risk that the company will encounter serious obstacle or will not achieve it goal therefore the company may abandon product in which it ha invested substantial amount of time and resource some of the risk encountered in the research and development process include the following pre clinical testing of new compound may yield disappointing result competing product from other manufacturer may reach the market first clinical trial of new drug may not be successful new drug may not be effective or may have harmful side effect new drug may not be approved by the regulator for it intended use it may not be possible to obtain patent for new drug payer may refuse to cover or reimburse the new product or sale of new product may be disappointing the company can not state with certainty when or whether any of it product now under development will be approved or launched whether it will be able to develop license or otherwise acquire compound product candidate or product or whether any product once launched will be commercially successful the company must maintain continuous flow of successful new product and successful new indication for existing product sufficient both to cover it substantial research and development cost and to replace sale that are lost profitable product lose market exclusivity or are displaced by competing product or therapy failure to do so in the short term or long term would have material adverse effect on the company business result of operation cash flow financial condition and prospect the company success is dependent on the successful development and marketing of new product which are subject to substantial risk product that appear promising in development may fail to reach the market or fail to succeed for numerous reason including the following finding of ineffectiveness superior safety or efficacy of competing product or harmful side effect in clinical or pre clinical testing failure to receive the necessary regulatory approval including delay in the approval of new product and new indication or the anticipated labeling and uncertainty about the time required to obtain regulatory approval and the benefit risk standard applied by regulatory agency in determining whether to grant approval failure in certain market to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product lack of economic feasibility due to manufacturing cost or other factor and preclusion from commercialization by the proprietary right of others of contentsin the future if certain pipeline program are cancelled or if the company belief that their commercial prospect have been reduced the company may recognize material non cash impairment charge for those program that were measured at fair value and capitalized in connection with acquisition or certain collaboration failure to successfully develop and market new product in the short term or long term would have material adverse effect on the company business result of operation cash flow financial condition and prospect the company face continued pricing pressure with respect to it product the company face continued pricing pressure globally and particularly in mature market from managed care organization government agency and program that could negatively affect the company sale and profit margin in the united state these include practice of managed care group and institutional and governmental purchaser ii federal law and regulation related to medicare and medicaid including the medicare prescription drug improvement and modernization act of and the aca and iii state activity aimed at increasing price transparency including new law noted above in item competition and the health care environment change to the health care system enacted part of health care reform in the united state well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary could result in further pricing pressure in addition in the united state larger customer have received higher rebate on drug in certain highly competitive category the company must also compete to be placed on formulary of managed care organization exclusion of product from formulary can lead to reduced usage in the managed care organization in order to provide information about the company pricing practice the company annually post on it website it pricing transparency report for the united state the report provides the company average annual list price and net price increase across the company portfolio dating back to in the company gross sale were reduced by result of rebate discount and return outside the united state numerous major market including the eu japan and china have pervasive government involvement in funding health care and in that regard fix the pricing and reimbursement of pharmaceutical and vaccine product consequently in those market the company is subject to government decision making and budgetary action with respect to it product in japan the pharmaceutical industry is subject to government mandated biennial price reduction of pharmaceutical product and certain vaccine furthermore the government can order re pricing for specific product if it determines that use of such product will exceed certain threshold defined under applicable re pricing rule the next government mandated price reduction will occur in april and is expected to impact many company product the company expects pricing pressure to continue in the future the uncertainty in global economic condition together with cost reduction measure being taken by certain government could negatively affect the company operating result uncertainty in global economic and geopolitical condition may result in slowdown to the global economy that could affect the company business by reducing the price that drug wholesaler and retailer hospital government agency and managed health care provider may be able or willing to pay for the company product or by reducing the demand for the company product which could in turn negatively impact the company sale and result in material adverse effect on the company business cash flow result of operation financial condition and prospect discussed above in competition and the health care environment global effort toward health care cost containment continue to exert pressure on product pricing and market access worldwide change to the health care system part of health care reform well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively affected by other cost reduction measure taken by government and other third party to lower health care cost the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance of contentsif credit and economic condition worsen the resulting economic and currency impact in the affected market and globally could have material adverse effect on the company result the company face intense competition from lower cost generic product in general the company face increasing competition from lower cost generic product the patent right that protect it product are of varying strength and duration in addition in some country patent protection is significantly weaker than in the united state or in the eu in the united state and the eu political pressure to reduce spending on prescription drug ha led to legislation and other measure that encourage the use of generic and biosimilar product although it is the company policy to actively protect it patent right generic challenge to the company product can arise at any time and the company patent may not prevent the emergence of generic competition for it product loss of patent protection for product typically is followed promptly by generic substitute reducing the company sale of that product availability of generic substitute for the company drug may adversely affect it result of operation and cash flow in addition proposal emerge from time to time in the united state and other country for legislation to further encourage the early and rapid approval of generic drug any such proposal that is enacted into law could worsen this substantial negative effect on the company sale and potentially it business cash flow result of operation financial condition and prospect the company face intense competition from competitor product the company product face intense competition from competitor product this competition may increase new product enter the market in such an event the competitor product may be safer or more effective more convenient to use have better insurance coverage or reimbursement level or be more effectively marketed and sold than the company product alternatively in the case of generic competition including the generic availability of competitor branded product they may be equally safe and effective product that are sold at substantially lower price than the company product result if the company fails to maintain it competitive position this could have material adverse effect on it business cash flow result of operation financial condition and prospect in addition if product that were measured at fair value and capitalized in connection with acquisition experience difficulty in the market that negatively impact product cash flow the company may recognize material non cash impairment charge with respect to the value of those product the global covid pandemic is having an adverse impact on the company business operation and financial performance the company is unable to predict the full extent to which the covid pandemic or any future pandemic epidemic or similar public health threat will adversely impact it business operation financial performance result of operation and financial condition the company business and financial result were negatively impacted by the outbreak of covid in the continued duration and severity of the covid pandemic is uncertain rapidly changing and difficult to predict the degree to which covid impact the company result in will depend on future development beyond the company knowledge or control including but not limited to the duration of the outbreak it severity the success of action taken to contain or prevent the virus or treat it impact and how quickly and to what extent normal economic and operating condition can resume in the covid pandemic impacted the company business in numerous way expected within the company human health business revenue wa negatively impacted by reduced access to health care provider given social distancing measure which negatively affected vaccine and oncology sale in particular the estimated overall negative impact of the covid pandemic to merck revenue for the full year wa approximately billion largely attributable to the pharmaceutical segment with approximately million attributable to the animal health segment roughly two third of merck pharmaceutical segment revenue is comprised of physician administered product which despite strong underlying demand have been affected by social distancing measure fewer well visit and delay in elective surgery due to the covid pandemic these impact well the prioritization of covid patient at health care provider have resulted in reduced administration of many of the company human health product in particular for it vaccine including gardasil well for keytruda and implanon of contentsnexplanon in addition decline in elective surgery negatively affected the demand for bridion however sale of pneumovax have increased due to heightened awareness of pneumococcal vaccination merck belief that global health system and patient have largely adapted to the impact of covid but the company assumption is that ongoing residual negative impact will persist particularly during the first half of and most notably with respect to vaccine sale with the impact expected to be more acute in the united state for the full year of merck assumes an unfavorable impact to revenue of approximately due to the covid pandemic all of which relates to pharmaceutical segment sale in addition for the full year of with respect to the covid pandemic merck expects net negative impact to operating expense spending on the development of it covid antiviral program is expected to exceed the favorable impact of lower spending in other area due to the covid pandemic despite the company effort to manage these impact their ultimate impact will also depend on factor beyond the company knowledge or control including the duration of the covid virus well governmental and third party action taken to contain or prevent it spread treat the virus and mitigate it public health and economic effect in addition any future pandemic epidemic or similar public health threat could present similar risk to the company business cash flow result of operation financial condition and prospect the company ha significant global operation which expose it to additional risk and any adverse event could have material adverse effect on the company result of operation and financial condition the extent of the company operation outside the united state is significant risk inherent in conducting global business include change in medical reimbursement policy and program and pricing restriction in key market multiple regulatory requirement that could restrict the company ability to manufacture and sell it product in key market trade protection measure and import or export licensing requirement including the imposition of trade sanction or similar restriction by the united state or other government foreign exchange fluctuation diminished protection of intellectual property in some country and possible nationalization and expropriation in addition there may be change to the company business and political position if there is instability disruption or destruction in significant geographic region regardless of cause including war terrorism riot civil insurrection or social unrest and natural or man made disaster including famine flood fire earthquake storm or disease failure to attract and retain highly qualified personnel could affect the company ability to successfully develop and commercialize product the company success is largely dependent on it continued ability to attract and retain highly qualified scientific technical and management personnel well personnel with expertise in clinical research and development governmental regulation and commercialization competition for qualified personnel in the pharmaceutical industry is intense the company can not be sure that it will be able to attract and retain quality personnel or that the cost of so will not materially increase in the past the company ha experienced difficulty and delay in manufacturing certain of it product including vaccine merck ha in the past experienced difficulty in manufacturing certain of it product including vaccine for example in the company issued product recall for zerbaxa following the identification of product sterility issue the company may in the future experience other difficulty and delay in manufacturing it product such failure of the company or any of it vendor or supplier to comply with current good manufacturing practice and other applicable regulation and quality assurance guideline that could lead to of contentsmanufacturing shutdown product shortage and delay in product manufacturing ii delay related to the construction of new facility or the expansion of existing facility including those intended to support future demand for the company product and iii other manufacturing or distribution problem including change in manufacturing production site and limit to manufacturing capacity due to regulatory requirement change in type of product produced or physical limitation that could impact continuous supply in addition the company could experience difficulty or delay in manufacturing it product caused by natural disaster such hurricane manufacturing difficulty can result in product shortage leading to lost sale and reputational harm to the company the company may not be able to realize the expected benefit of it investment in emerging market the company ha been taking step to increase it sale in emerging market however there is no guarantee that the company effort to expand sale in these market will succeed some country within emerging market may be especially vulnerable to period of global financial instability or may have very limited resource to spend on health care in order for the company to successfully implement it emerging market strategy it must attract and retain qualified personnel the company may also be required to increase it reliance on third party agent within le developed market in addition many of these country have currency that fluctuate substantially and if such currency devalue and the company can not offset the devaluation the company financial performance within such country could be adversely affected the company business in china ha grown rapidly in the past few year and the importance of china to the company overall pharmaceutical and vaccine business outside the united state ha increased accordingly continued growth of the company business in china is dependent upon ongoing development of favorable environment for innovative pharmaceutical product and vaccine sustained access for the company currently marketed product and the absence of trade impediment or adverse pricing control noted above in competition and the health care environment pricing pressure in china ha increased the chinese government ha been taking step to reduce cost including implementing health care reform that ha led to the acceleration of generic substitution where available in the chinese government updated the nrdl for the first time in eight year while the mechanism for drug being added to the list evolves inclusion may require price negotiation which could impact the outlook in the market for selected brand in drug were added to the nrdl through double digit price reduction while pricing pressure ha always existed in china health care reform ha increased this pressure in part due to the acceleration of generic substitution through the government vbp program in the government implemented the vbp program through tendering process for mature product which have generic substitute with generic quality consistency evaluation approval mature product that have entered into the first three round of vbp had on average price reduction of the company expects vbp to be semi annual process that will have significant impact on mature product moving forward in addition the company anticipates that the reported inquiry made by various governmental authority involving multinational pharmaceutical company in china may continue for all these reason sale within emerging market carry significant risk however at the same time macro economic growth of selected emerging market is expected to outpace europe and even the united state leading to significant increased headcount spending in those country and access to innovative medicine for patient failure to maintain the company presence in emerging market could therefore have material adverse effect on the company business cash flow result of operation financial condition and prospect the company is exposed to market risk from fluctuation in currency exchange rate and interest rate the company operates in multiple jurisdiction and virtually all sale are denominated in currency of the local jurisdiction additionally the company ha entered and will enter into business development transaction borrowing or other financial transaction that may give rise to currency and interest rate exposure since the company can not with certainty foresee and mitigate against such adverse fluctuation fluctuation in currency exchange rate interest rate and inflation could negatively affect the company business cash flow result of operation financial condition and prospect of contentsin order to mitigate against the adverse impact of these market fluctuation the company will from time to time enter into hedging agreement while hedging agreement such currency option and forward and interest rate swap may limit some of the exposure to exchange rate and interest rate fluctuation such attempt to mitigate these risk may be costly and not always successful certain of the company interest rate derivative and investment are based on the london interbank offered rate libor and portion of merck indebtedness bear interest at variable interest rate primarily based on libor libor is the subject of recent national international and other regulatory guidance and proposal for reform which will cause libor to cease to exist entirely in the future while the company expects that reasonable alternative to libor will be implemented prior to it termination the company can not predict the consequence and timing of these development which could include an increase in interest expense and may also require the amendment of contract that reference libor pharmaceutical product can develop unexpected safety or efficacy concern unexpected safety or efficacy concern can arise with respect to marketed product whether or not scientifically justified leading to product recall withdrawal or declining sale well product liability consumer fraud and or other claim including potential civil or criminal governmental action reliance on third party relationship and outsourcing arrangement could materially adversely affect the company business the company depends on third party including supplier alliance with other pharmaceutical and biotechnology company and third party service provider for key aspect of it business including development manufacture and commercialization of it product and support for it information technology it system failure of these third party to meet their contractual regulatory and other obligation to the company or the development of factor that materially disrupt the relationship between the company and these third party could have material adverse effect on the company business negative event in the animal health industry could have material adverse effect on future result of operation and financial condition future sale of key animal health product could be adversely affected by number of risk factor including certain risk that are specific to the animal health business for example the outbreak of disease carried by animal such african swine fever could lead to their widespread death and precautionary destruction well the reduced consumption and demand for animal which could adversely affect the company result of operation also the outbreak of any highly contagious disease near the company main production site could require the company to immediately halt the manufacture of it animal health product at such site or force the company to incur substantial expense in procuring raw material or product elsewhere other risk specific to animal health include epidemic and pandemic government procurement and pricing practice weather and global agribusiness economic event the animal health segment of the company business becomes more significant the impact of any such event on future result of operation would also become more significant biologics and vaccine carry unique risk and uncertainty which could have material adverse effect on the company future result of operation and financial condition the successful development testing manufacturing and commercialization of biologics and vaccine particularly human and animal health vaccine is long complex expensive and uncertain process there are unique risk and uncertainty related to biologics and vaccine including there may be limited access to and supply of normal and diseased tissue sample cell line pathogen bacteria viral strain and other biological material in addition government regulation in multiple jurisdiction such the united state and the eu could result in restricted access to or transport or use of such material if the company loses access to sufficient source of such material or if tighter restriction are imposed on the use of such material the company may not be able to conduct research activity planned and may incur additional development cost of content the development manufacturing and marketing of biologics and vaccine are subject to regulation by the fda the ema and other regulatory body these regulation are often more complex and extensive than the regulation applicable to other pharmaceutical product for example in the united state bla including both pre clinical and clinical trial data and extensive data regarding the manufacturing procedure is required for human vaccine candidate and fda approval is generally required for the release of each manufactured commercial lot manufacturing biologics and vaccine especially in large quantity is often complex and may require the use of innovative technology to handle living micro organism each lot of an approved biologic and vaccine must undergo thorough testing for identity strength quality purity and potency manufacturing biologics requires facility specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedure are necessary slight deviation anywhere in the manufacturing process including filling labeling packaging storage and shipping and quality control and testing may result in lot failure product recall or spoilage when change are made to the manufacturing process the company may be required to provide pre clinical and clinical data showing the comparable identity strength quality purity or potency of the product before and after such change biologics and vaccine are frequently costly to manufacture production ingredient are derived from living animal or plant material and most biologics and vaccine can not be made synthetically in particular keeping up with the demand for vaccine may be difficult due to the complexity of producing vaccine the use of biologically derived ingredient can lead to variability in the manufacturing process and could lead to allegation of harm including infection or allergic reaction which allegation would be reviewed through standard investigation process that could lead to closure of product facility due to possible contamination any of these event could result in substantial cost risk relating to government regulation and legal proceedingsthe health care industry in the united state ha been and will continue to be subject to increasing regulation and political action discussed above competition and the health care environment the company belief that the health care industry will continue to be subject to increasing regulation well political and legal action future proposal to reform the health care system are considered by the executive branch congress and state legislature in the united state enacted major health care reform legislation in the form of the aca various insurance market reform have advanced and state and federal insurance exchange were launched in the aca increased the mandated medicaid rebate from to expanded the rebate to medicaid managed care utilization and increased the type of entity eligible for the federal drug discount program the aca also requires pharmaceutical manufacturer to pay of the cost of medicine including biosimilar product when medicare part beneficiary are in the medicare part coverage gap the so called donut hole in the company revenue wa reduced by approximately million due to this requirement also pharmaceutical manufacturer are required to pay an annual non tax deductible health care reform fee in the company recorded million of cost for this annual fee in february the center for medicare medicaid service cm issued the medicaid rebate final rule that implemented provision of the aca effective april the rule provides comprehensive guidance on the calculation of average manufacturer price and best price two metric utilized to determine the rebate drug manufacturer are required to pay to state medicaid program more recently although cm previously declined to define what constitutes product line extension beyond the statutory definition cm issued new rule on december that will significantly expand the definition of the term line extension of january to include broad range of product including product reflecting new strength dosage form release mechanism and route of administration this expanded definition will increase the number of drug subject to higher medicaid rebate effective january this final rule also change the way that manufacturer must calculate best price in relation to certain patient support program including coupon which also may result in an increase in of contentsthe company medicaid rebate the impact of these and other provision in this final rule could adversely impact the company business cash flow result of operation financial condition and prospect discussed above in competition and the health care environment in november the department of health and human service office of inspector general oig issued final rule that would effective january eliminate the anti kickback statute safe harbor for rebate paid to medicare part plan or to pbms on behalf of such plan while the company can not anticipate the effect of this change to the way it currently contract this new framework could significantly alter the way it doe business with part plan sponsor and pbms on behalf of such plan on november cm also issued the mfn rule which wa intended to be effective january to institute new pricing system for certain prescription drug and biologic product covered by medicare part in which medicare would reimburse no more than the most favored nation price meaning the lowest price after adjusting for volume and difference in gross domestic product for the top fifty part reimbursed product which includes keytruda sold in member country of the oecd rather than use the current average sale price asp based payment framework for certain physician administered drug implementation of the mfn rule could have material adverse effect on the company business cash flow result of operation financial condition and prospect the fda also recently issued rulemaking allowing the commercial importation of certain prescription drug from canada through fda authorized time limited program sponsored by state or native american tribe recognized under the rule and in certain future circumstance pharmacist and wholesaler the fda also recently released final guidance for industry detailing procedure for drug manufacturer to import fda approved prescription drug biological and combination product that were manufactured abroad and authorized and intended for sale in foreign country these change if they become effective could have material adverse effect on the company business cash flow result of operation financial condition and prospect several organization including two trade group of which merck is member have filed suit challenging the mfn rule those lawsuit remain pending with preliminary injunction having been entered in one of the case trade organization in which merck is member brought suit which is pending in federal district court challenging the commercial importation rule the company can not predict the likelihood of these regulation becoming effective or what additional future change in the health care industry in general or the pharmaceutical industry in particular will occur however these change could have material adverse effect on the company business cash flow result of operation financial condition and prospect the company product including product in development can not be marketed unless the company obtains and maintains regulatory approval the company activity including research pre clinical testing clinical trial and the manufacturing and marketing of it product are subject to extensive regulation by numerous federal state and local governmental authority in the united state including the fda and by foreign regulatory authority including in the eu japan and china in the united state the fda administers requirement covering the testing approval safety effectiveness manufacturing labeling and marketing of prescription pharmaceutical in many case the fda requirement have increased the amount of time and money necessary to develop new product and bring them to market in the united state regulation outside the united state also is primarily focused on drug safety and effectiveness and in many case reduction in the cost of drug the fda and foreign regulatory authority including in japan and china have substantial discretion to require additional testing to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of product even if the company is successful in developing new product it will not be able to market any of those product unless and until it ha obtained all required regulatory approval in each jurisdiction where it proposes to market the new product once obtained the company must maintain approval long it plan to market it new product in each jurisdiction where approval is required the company failure to obtain approval significant delay in the approval process or it failure to maintain approval in any jurisdiction will prevent it from selling the product in that jurisdiction the company would not be able to realize revenue for those new product in any jurisdiction where it doe not have approval of contentsdevelopments following regulatory approval may adversely affect sale of the company product even after product reach the market certain development following regulatory approval may decrease demand for the company product including the following result in post approval phase trial or other study the re review of product that are already marketed the recall or loss of marketing approval of product that are already marketed changing government standard or public expectation regarding safety efficacy quality or labeling change and scrutiny of advertising and promotion in the past clinical trial and post marketing surveillance of certain marketed drug of the company and of competitor within the industry have raised concern that have led to recall withdrawal or adverse labeling of marketed product clinical trial and post marketing surveillance of certain marketed drug also have raised concern among some prescribers and patient relating to the safety or efficacy of pharmaceutical product in general that have negatively affected the sale of such product in addition increased scrutiny of the outcome of clinical trial ha led to increased volatility in market reaction further these matter often attract litigation and even where the basis for the litigation is groundless considerable resource may be needed to respond in addition following in the wake of product withdrawal and other significant safety issue health authority such the fda the ema japan pmda and china nmpa have increased their focus on safety when assessing the benefit risk balance of drug some health authority appear to have become more cautious when making decision about approvability of new product or indication if previously unknown side effect are discovered or if there is an increase in negative publicity regarding known side effect of any of the company product it could significantly reduce demand for the product or require the company to take action that could negatively affect sale including removing the product from the market restricting it distribution or applying for labeling change further in the current environment in which all pharmaceutical company operate the company is at risk for product liability and consumer protection claim and civil and criminal governmental action related to it product research and or marketing activity in addition dissemination of promotional material through evolving digital channel serf to increase visibility and scrutiny in the marketplace the company is subject to variety of and international law and regulation the company is currently subject to number of government law and regulation and in the future could become subject to new government law and regulation the cost of compliance with such law and regulation or the negative result of non compliance could adversely affect the business cash flow result of operation financial condition and prospect of the company these law and regulation include additional health care reform initiative in the united state or in other country including additional mandatory discount or fee ii the foreign corrupt practice act or other anti bribery and corruption law iii new law regulation and judicial or other governmental decision affecting pricing drug reimbursement and access or marketing within or across jurisdiction iv change in intellectual property law change in accounting standard vi new and increasing data privacy regulation and enforcement particularly in the eu and the united state vii legislative mandate or preference for local manufacturing of pharmaceutical or vaccine product viii emerging and new global regulatory requirement for reporting payment and other value transfer to health care professional ix environmental regulation and the potential impact of importation restriction embargo trade sanction and legislative and or other regulatory change of contentsthe company is subject to evolving and complex tax law which may result in additional liability that may affect result of operation and financial condition the company is subject to evolving and complex tax law in the jurisdiction in which it operates significant judgment is required for determining the company tax liability and the company tax return are periodically examined by various tax authority the company belief that it accrual for tax contingency is adequate for all open year based on past experience interpretation of tax law and judgment about potential action by tax authority however due to the complexity of tax contingency the ultimate resolution of any tax matter may result in payment greater or le than amount accrued in addition the company may be negatively affected by change in tax law or new tax law affecting for example tax rate and or revised tax law interpretation in domestic or foreign jurisdiction product liability insurance for product may be limited cost prohibitive or unavailable result of number of factor product liability insurance ha become le available while the cost of such insurance ha increased significantly the company is subject to substantial number of product liability claim see item financial statement and supplementary data note contingency and environmental liability below for more information on the company current product liability litigation with respect to product liability the company self insures substantially all of it risk the availability of commercial insurance ha become more restrictive the company ha evaluated it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such ha no insurance for most product liability the company will continually ass the most efficient mean to address it risk however there can be no guarantee that insurance coverage will be obtained or if obtained will be sufficient to fully cover product liability that may arise risk related to technologythe company is increasingly dependent on sophisticated software application and computing infrastructure in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation the company could be target of future cyber attack the company is increasingly dependent on sophisticated software application complex information technology system computing infrastructure and cloud service provider collectively it system to conduct critical operation certain of these system are managed hosted provided or used by third party to assist in conducting the company business disruption degradation or manipulation of these it system through intentional or accidental mean by the company employee third party with authorized access or unauthorized third party could adversely affect key business process cyber attack against the company it system or third party provider it system such cloud based system could result in exposure of confidential information the modification of critical data and or the failure of critical operation misuse of any of these it system could result in the disclosure of sensitive personal information or the theft of trade secret intellectual property or other confidential business information the company continues to leverage new and innovative technology across the enterprise to improve the efficacy and efficiency of it business process the use of which can create new risk in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation and resulting loss the company ha implemented variety of measure to further enhance and modernize it system to guard against similar attack in the future and also is pursuing an enterprise wide effort to enhance the company resiliency against future cyber attack including incident similar to the attack the objective of these effort is not only to protect against future cyber attack but also to improve the speed of the company recovery from such attack and enable continued business operation to the greatest extent possible during any recovery period although the aggregate impact of cyber attack and network disruption including the cyber attack on the company operation and financial condition ha not been material to date the company continues to be target of event of this nature and expects them to continue the company monitor it data information technology and personnel usage of company it system to reduce these risk and continues to do so on an ongoing of contentsbasis for any current or potential threat there can be no assurance that the company effort to protect it data and it system or the effort of third party provider to protect their it system will be successful in preventing disruption to the company operation including it manufacturing research and sale operation such disruption have in the past and could in the future result in loss of revenue or the loss of critical or sensitive information from the company or the company third party provider database or it system and have in the past and could in the future also result in financial legal business or reputational harm to the company and substantial remediation cost social medium platform present risk and challenge the inappropriate and or unauthorized use of certain social medium channel could cause brand damage or information leakage or could lead to legal implication including from the improper collection and or dissemination of personally identifiable information in addition negative or inaccurate post or comment about the company or it product on any social networking platform could damage the company reputation brand image and goodwill further the disclosure of non public company sensitive information by the company workforce or others through external medium channel could lead to information loss although there is an internal company social medium policy that guide employee on appropriate personal and professional use of social medium about the company the process in place may not completely secure and protect information identifying new point of entry social medium continues to expand also present new challenge risk related to the proposed spin off of organonthe proposed spin off of organon may not be completed on the term or timeline currently contemplated if at all and may not achieve the expected result in february the company announced it intention to spin off product from it woman health biosimilars and established brand business into new independent publicly traded company which ha been named organon co organon through distribution of organon publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the transaction is expected to be completed late in the second quarter of completion of the spin off will be subject to number of factor and condition and there can be no assurance that the company will be able to complete the spin off on the term or on the timeline that wa announced if at all unanticipated development could delay prevent or otherwise adversely affect the proposed spin off including but not limited to disruption in general or financial market condition or potential problem or delay in obtaining various regulatory and tax approval or clearance in addition consummation of the proposed spin off will require final approval from the company board of director the cost to complete the proposed spin off will be significant in addition the company may be unable to achieve some or all of the strategic and financial benefit that it expects to achieve from the spin off of organon the company will incur significant expense in connection with the spin off in addition the company may not be able to achieve the full strategic and financial benefit that are expected to result from the spin off the anticipated benefit of the spin off are based on number of assumption some of which may prove incorrect following the spin off the price of share of the company common stock may fluctuate significantly the company can not predict the effect of the spin off on the trading price of share of it common stock and the market value of share of it common stock may be le than equal to or greater than the market value of share of it common stock prior to the spin off in addition the price of merck common stock may be more volatile around the time of the spin off there could be significant income tax liability if the spin off or certain related transaction are determined to be taxable for federal income tax purpose the company expects that prior to completion of the spin off it will receive an opinion from it tax counsel that concludes among other thing that the spin off of all of the outstanding organon share to merck of contentsshareholders and certain related transaction will qualify tax free to merck and it shareholder under section and of the internal revenue code except to the extent of any cash received in lieu of fractional share of organon common stock any such opinion is not binding on the internal revenue service irs accordingly while the company belief the risk is low the irs may reach conclusion with respect to the spin off that are different from the conclusion reached in the opinion the opinion will rely on certain fact assumption representation and undertaking from merck and organon regarding the past and future conduct of the company respective business and other matter which if incomplete incorrect or not satisfied could alter the conclusion of the party giving such opinion if the proposed spin off ultimately is determined to be taxable which the company belief is unlikely the spin off could be treated taxable dividend to merck shareholder for federal income tax purpose and merck shareholder could incur significant federal income tax liability in addition merck would recognize taxable gain to the extent that the fair market value of organon common stock exceeds merck tax basis in such stock on the date of the spin off cautionary factor that may affect future result cautionary statement under the private security litigation reform act of this report and other written report and oral statement made from time to time by the company may contain so called forward looking statement all of which are based on management current expectation and are subject to risk and uncertainty which may cause result to differ materially from those set forth in the statement one can identify these forward looking statement by their use of word such anticipates expects plan will estimate forecast project and other word of similar meaning or negative variation of any of the foregoing one can also identify them by the fact that they do not relate strictly to historical or current fact these statement are likely to address the company growth strategy financial result product approval product potential development program and include statement related to the expected impact of the covid pandemic one must carefully consider any such statement and should understand that many factor could cause actual result to differ materially from the company forward looking statement these factor include inaccurate assumption and broad variety of other risk and uncertainty including some that are known and some that are not no forward looking statement can be guaranteed and actual future result may vary materially the company doe not assume the obligation to update any forward looking statement the company caution not to place undue reliance on these forward looking statement although it is not possible to predict or identify all such factor they may include the following competition from generic and or biosimilar product the company product lose patent protection increased brand competition in therapeutic area important to the company long term business performance the difficulty and uncertainty inherent in new product development the outcome of the lengthy and complex process of new product development is inherently uncertain drug candidate can fail at any stage of the process and one or more late stage product candidate could fail to receive regulatory approval new product candidate may appear promising in development but fail to reach the market because of efficacy or safety concern the inability to obtain necessary regulatory approval the difficulty or excessive cost to manufacture and or the infringement of patent or intellectual property right of others furthermore the sale of new product may prove to be disappointing and fail to reach anticipated level pricing pressure both in the united state and abroad including rule and practice of managed care group judicial decision and governmental law and regulation related to medicare medicaid and health care reform pharmaceutical reimbursement and pricing in general the impact of the global covid pandemic and any future pandemic epidemic or similar public health threat on the company business operation and financial performance change in government law and regulation including law governing intellectual property and the enforcement thereof affecting the company business of content efficacy or safety concern with respect to marketed product whether or not scientifically justified leading to product recall withdrawal or declining sale significant change in customer relationship or change in the behavior and spending pattern of purchaser of health care product and service including delaying medical procedure rationing prescription medication reducing the frequency of physician visit and foregoing health care insurance coverage legal factor including product liability claim antitrust litigation and governmental investigation including tax dispute environmental concern and patent dispute with branded and generic competitor any of which could preclude commercialization of product or negatively affect the profitability of existing product cyber attack on the company or third party provider information technology system which could disrupt the company operation lost market opportunity resulting from delay and uncertainty in the approval process of the fda and foreign regulatory authority increased focus on privacy issue in country around the world including the united state and the eu the legislative and regulatory landscape for privacy and data protection continues to evolve and there ha been an increasing amount of focus on privacy and data protection issue with the potential to affect directly the company business including recently enacted law in majority of state in the united state requiring security breach notification change in tax law including change related to the taxation of foreign earnings change in accounting pronouncement promulgated by standard setting or regulatory body including the financial accounting standard board and the sec that are adverse to the company economic factor over which the company ha no control including change in inflation interest rate and foreign currency exchange rate the proposed spin off might be delayed or the cost to complete the spin off might be more significant than expected this list should not be considered an exhaustive statement of all potential risk and uncertainty see risk factor above item unresolved staff comment none item property the company corporate headquarters is currently located in kenilworth new jersey the company ha previously announced that it intends to consolidate it new jersey campus into single corporate headquarters location in rahway new jersey by the end of the company also maintains operational or divisional headquarters in kenilworth new jersey madison new jersey and upper gwynedd pennsylvania principal research facility are located in rahway and kenilworth new jersey west point pennsylvania boston massachusetts south san francisco california and elkhorn nebraska animal health principal research facility outside the united state are located in the united kingdom switzerland and china merck manufacturing operation are currently headquartered in whitehouse station new jersey the company also ha production facility for human health product at nine location in the united state and puerto rico outside the united state through subsidiary the company owns or ha an interest in manufacturing plant or other property in japan singapore south africa and other country in western europe central and south america and asia number of property will be transferred to organon in the spin off capital expenditure were billion in billion in and billion in in the united state these amounted to billion in billion in and billion in abroad such expenditure amounted to billion in billion in and billion in of contentsthe company and it subsidiary own their principal facility and manufacturing plant under title that they consider to be satisfactory the company belief that it property are in good operating condition and that it machinery and equipment have been well maintained the company belief that it plant for the manufacture of product are suitable for their intended purpose and have capacity and projected capacity including previously disclosed capital expansion project that will be adequate for current and projected need for existing company product some capacity of the plant is being converted with any needed modification to the requirement of newly introduced and future product item legal proceeding the information called for by this item is incorporated herein by reference to item financial statement and supplementary data note contingency and environmental liability item mine safety disclosure not applicable of contentsexecutive officer of the registrant age of february all officer listed below serve at the pleasure of the board of director none of these officer wa elected pursuant to any arrangement or understanding between the officer and any other person nameageoffices and business experiencekenneth president and chief executive officer since december sanat vice president and president merck manufacturing division since march frank vice president chief commercial officer since january president global oncology business unit october december robert vice president global service and chief financial officer since april executive vice president and chief financial officer april april richard deluca jr vice president and president merck animal health since september michael vice president chief ethic and compliance officer since march senior vice president international legal and compliance january march vice president international legal and compliance july january julie vice president and chief patient officer strategic communication global public policy and population health since july executive vice president for strategic communication global public policy and population health january july rita vice president finance global controller since march dean merck research laboratory since january senior vice president discovery science and translational medicine merck research laboratory november january vice president translational medicine march november prior to that chief scientific officer and associate vice president university of utah health sciencessteven vice president chief human resource officer since december executive vice president human resource monsanto company august december michael vice president chief marketing officer since january president global vaccine global human health september january managing director united kingdom and ireland global human health january september jennifer vice president general counsel and corporate secretary since january executive vice president and general counsel april january partner covington burling llp january march in february merck announced that kenneth frazier chairman and chief executive officer will retire chief executive officer effective june mr frazier will continue to serve on merck board of director executive chairman for transition period to be determined by the board the merck board of director ha unanimously elected robert davis merck current executive vice president global service and chief financial officer chief executive officer well member of the board effective july mr davis will become president of merck effective april at which time the company operating division human health animal health manufacturing and merck research laboratory will begin reporting to mr davis of contentspart ii item market for registrant common equity related stockholder matter and issuer purchase of equity security the principal market for trading of the company common stock is the new york stock exchange nyse under the symbol mrk of january there were approximately shareholder of record of the company common stock issuer purchase of equity security for the three month ended december were follows issuer purchase of equity security in million periodtotal numberof sharespurchased average pricepaid pershareapproximate dollar value of sharesthat may yet be purchasedunder the plan or program october october november december the company did not purchase any share during the three month ended december under the plan approved by the board of director in october to purchase up to billion in merck share for it treasury of contentsperformance graphthe following graph assumes investment on december and reinvestment of all dividend in each of the company common share the index and composite peer group of major and european based pharmaceutical company which are abbvie inc amgen inc astrazeneca plc bristol myers squibb company johnson johnson eli lilly and company glaxosmithkline plc novartis ag pfizer inc roche holding ag and sanofi sa comparison of five year cumulative total return merck co inc composite peer group and indexend ofperiod merck peer grp grp compound annual growth rate peer group average wa calculated on market cap weighted basis this performance graph will not be deemed to be incorporated by reference into any filing under the security act of or the security exchange act of except to the extent that the company specifically incorporates it by reference in addition the performance graph will not be deemed to be soliciting material or to be filed with the sec or subject to regulation or other than provided in regulation or to the liability of section of the security exchange act of except to the extent that the company specifically request that such information be treated soliciting material or specifically incorporates it by reference into filing under the security act or the exchange act of contentsitem management discussion and analysis of financial condition and result of operation the following section of this form generally discus and result and year to year comparison between and discussion of result and year to year comparison between and that are not included in this form can be found in management discussion and analysis of financial condition and result of operation in part ii item of the company annual report on form for the fiscal year ended december filed on february description of merck businessmerck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously had healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment in the first quarter of the company previously had an alliance segment that primarily included activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in planned spin off of woman health biosimilars and established brand into new company in february merck announced it intention to spin off product from it woman health biosimilars and established brand business into new independent publicly traded company named organon co organon through distribution of organon publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the established brand included in the transaction consist of dermatology non opioid pain management respiratory and select cardiovascular product including zetia and vytorin well the rest of merck diversified brand franchise merck existing research pipeline program will continue to be owned and developed within merck planned organon will have development capability initially focused on late stage development and life cycle management and is expected over time to develop research capability in selected therapeutic area the spin off is expected to be completed late in the second quarter of subject to market and certain other condition of contentsoverviewfinancial highlight in million change change excluding net income attributable to merck co inc non gaap net income attributable to merck co inc earnings per common share assuming dilution attributable to merck co inc common shareholder gaap earnings per common share assuming dilution attributable to merck co inc common shareholder non gaap net income and non gaap earnings per share eps exclude acquisition and divestiture related cost restructuring cost and certain other item for further discussion and reconciliation of gaap to non gaap net income and eps see non gaap income and non gaap eps below executive summaryworldwide sale were billion in an increase of compared with or excluding the unfavorable effect from foreign exchange the sale increase wa driven primarily by oncology certain hospital acute care product and animal health growth in these area wa largely offset by the negative effect of the coronavirus disease covid pandemic discussed below the effect of generic competition particularly in the diversified brand and woman health franchise competitive pressure in the virology franchise and pricing pressure in the diabetes franchise during merck continued executing on it strategic priority reporting year over year sale growth despite the business challenge posed by the covid pandemic roughly two third of merck pharmaceutical segment revenue is comprised of physician administered product sale of which were negatively affected in by patient inability to access health care provider fewer well visit and social distancing measure however in the latter part of the year the company experienced partial recovery in the underlying demand for product across it key growth pillar despite the pandemic merck employee across the organization continued their important work enrolling and maintaining clinical study progressing the pipeline and ensuring the supply of and patient access to the company portfolio of medically important medicine and vaccine the company also executed on merck capital allocation priority by completing business development transaction and investing in it pipeline additionally the company remains on track to complete the spin off of organon late in the second quarter of thereby creating two company each focused on their strength and portfolio allowing them to pursue their respective market opportunity and business strategy in the product that will comprise organon had total sale of billion merck actively monitor the business development landscape for growth opportunity that meet the company strategic criterion to expand it oncology presence merck completed the acquisition of arqule inc arqule biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of cancer and other disease and velosbio inc velosbio clinical stage biopharmaceutical company committed to developing first in class cancer therapy targeting receptor tyrosine kinase like orphan receptor currently being evaluated for the treatment of patient with hematologic malignancy and solid tumor additionally merck entered into strategic collaboration agreement with seagen to gain access to ladiratuzumab vedotin an investigational antibody drug conjugate targeting liv and tukysa tucatinib small molecule tyrosine kinase inhibitor for the treatment of human epidermal growth factor receptor positive cancer to augment merck animal health business the company acquired the right to sentinel flavor tab and sentinel spectrum chew part of industry wide effort to develop solution to the pandemic the company acquired oncoimmune company developing therapeutic candidate for the treatment of patient hospitalized with covid and themis bioscience gmbh themis company focused on vaccine and immune modulation therapy for infectious disease including covid vaccine candidate additionally merck entered into of contentsstrategic collaboration with ridgeback biotherapeutics lp ridgeback bio to develop an orally available antiviral candidate in clinical development for the treatment of patient with covid and with the international aid vaccine initiative inc iavi to develop an investigational vaccine against sars cov being studied for the prevention of covid in january the company announced it wa discontinuing development of the covid vaccine candidate see note to the consolidated financial statement during the company received numerous regulatory approval within oncology keytruda received approval in the united state monotherapy in the therapeutic area of cutaneous squamous cell carcinoma cscc metastatic microsatellite instability high msi or mismatch repair deficient dmmr colorectal cancer non muscle invasive bladder cancer nmibc and tumor mutational burden high tmb solid tumor well in combination with chemotherapy for the treatment of triple negative breast cancer tnbc merck also received approval in the united state for an every six week dosing regimen across all adult indication additionally keytruda received approval in china for the treatment of certain patient with head and neck squamous cell carcinoma hnscc and in both china and japan for the treatment of certain patient with esophageal squamous cell carcinoma escc lynparza which is being developed in collaboration with astrazeneca plc astrazeneca received approval in the united state in combination with bevacizumab first line maintenance treatment of certain adult patient with advanced epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to first line platinum based chemotherapy and for the treatment of certain adult patient with metastatic castration resistant prostate cancer mcrpc following progression on prior treatment additionally lynparza wa approved in the european union eu monotherapy for the treatment of adult patient with mcrpc and mutation who have progressed following prior therapy and for the maintenance treatment of certain adult patient with metastatic adenocarcinoma of the pancreas lynparza wa also approved in japan for the treatment of three type of advanced cancer ovarian prostate and pancreatic cancer lenvima which is being developed in collaboration with eisai co ltd eisai received approval in china monotherapy for the treatment of differentiated thyroid cancer also in gardasil wa approved for use in woman and girl in japan where it is marketed silgard additionally in the food and drug and administration fda granted accelerated approval for an expanded indication for gardasil for the prevention of oropharyngeal and other head and neck cancer caused by certain hpv type in january the company received fda approval for verquvo vericiguat to reduce the risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretic in adult verquvo is being jointly developed with bayer ag bayer in addition to the recent regulatory approval discussed above the company advanced it late stage pipeline with several regulatory submission keytruda is under review in united state and or internationally for the treatment of certain patient with tnbc classical hodgkin lymphoma chl colorectal cancer cscc esophageal and gastric cancer lenvima is under review in japan monotherapy for the treatment of thymic cancer an investigational valent pneumococcal conjugate vaccine is under priority review by the fda for the prevention of invasive pneumococcal disease in adult year of age and older the european medicine agency ema is also reviewing an application for licensure of in adult the company is involved in litigation challenging the validity of several pfizer inc patent that relate to pneumococcal vaccine technology in the united state and several foreign jurisdiction the company phase oncology program include keytruda in the therapeutic area of biliary tract cervical cutaneous squamous cell endometrial gastric hepatocellular mesothelioma ovarian prostate and small cell lung cancer lynparza monotherapy for colorectal cancer and in combination with keytruda for non small cell lung and small cell lung cancer and lenvima in combination with keytruda for bladder endometrial gastric head and neck melanoma and non small cell lung cancer also within oncology mk belzutifan an investigational hypoxia inducible factor alpha hif inhibitor being evaluated for the treatment of patient with von hippel lindau disease associated renal cell carcinoma rcc received breakthrough therapy designation from the fda additionally the company ha candidate in phase clinical development in several other therapeutic area including mk gefapixant selective non narcotic orally administered investigational receptor antagonist being developed for the treatment of refractory chronic cough mk an investigational treatment for patient hospitalized with covid mk islatravir an investigational nucleoside reverse transcriptase translocation inhibitor nrtti in combination with doravirine for the treatment of hiv infection and which is being evaluated for the prevention of pneumococcal disease in pediatric patient of contentsthe company is allocating resource to support it commercial opportunity in the near term while making the necessary investment to support long term growth research and development expense in reflect higher cost related to business development activity higher clinical development spending and increased investment in discovery research and early drug development in november merck board of director approved an increase to the company quarterly dividend raising it to per share from per share on the company outstanding common stock during the company returned billion to shareholder through dividend and share repurchase managementin february merck announced that kenneth frazier chairman and chief executive officer will retire chief executive officer effective june mr frazier will continue to serve on merck board of director executive chairman for transition period to be determined by the board the merck board of director ha unanimously elected robert davis merck current executive vice president global service and chief financial officer chief executive officer well member of the board effective july mr davis will become president of merck effective april at which time the company operating division human health animal health manufacturing and merck research laboratory mrl will begin reporting to mr davis covid in response to the covid pandemic merck remains focused on protecting the safety of it employee ensuring that it supply of medicine and vaccine reach it patient contributing it scientific expertise to the development of antiviral approach and supporting health care provider and merck community although covid related disruption to patient ability to access health care provider negatively affected result in merck remains confident in the fundamental underlying demand for it product and it prospect for long term growth in the estimated negative impact of the covid pandemic to merck sale wa approximately billion largely attributable to the pharmaceutical segment with approximately million attributable to the animal health segment roughly two third of merck pharmaceutical segment revenue is comprised of physician administered product which despite strong underlying demand have been affected by social distancing measure fewer well visit and delay in elective surgery due to the covid pandemic these impact well the prioritization of covid patient at health care provider have resulted in reduced administration of many of the company human health product in particular for it vaccine including gardasil well for keytruda and implanon nexplanon in addition decline in elective surgery negatively affected the demand for bridion however sale of pneumovax increased due to heightened awareness of pneumococcal vaccination operating expense were positively affected in by approximately million primarily due to lower promotional and selling cost well lower research and development expense net of investment in covid related antiviral and vaccine research program merck belief that global health system and patient have largely adapted to the impact of covid but the company assumption is that ongoing residual negative impact will persist particularly during the first half of and most notably with respect to vaccine sale with the impact expected to be more acute in the united state for the full year of merck assumes an unfavorable impact to revenue of approximately due to the covid pandemic all of which relates to pharmaceutical segment sale in addition for the full year of with respect to the covid pandemic merck expects net negative impact to operating expense spending on the development of it covid antiviral program is expected to exceed the favorable impact of lower spending in other area due to the covid pandemic pricingglobal effort toward health care cost containment continue to exert pressure on product pricing and market access worldwide change to the health care system part of health care reform well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively of contentsaffected by other cost reduction measure taken by government and other third party to lower health care cost the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance operating resultssales in million change change excluding change change excluding state total plus international may not equal total due to rounding worldwide sale grew in due to higher sale in the oncology franchise reflecting strong growth of keytruda well increased alliance revenue from lynparza and lenvima also contributing to revenue growth were higher sale of certain vaccine including gardasil gardasil and pneumovax well increased sale of certain hospital acute care product including prevymis and bridion higher sale of animal health product also drove revenue growth in sale growth in wa partially offset by the effect of generic competition for certain product including woman health product nuvaring hospital acute care product noxafil and cubicin oncology product emend emend for injection cardiovascular product zetia and vytorin and product within the diversified brand franchise particularly singulair the diversified brand franchise includes certain product that are approaching the expiration of their marketing exclusivity or that are no longer protected by patent in developed market lower sale of pediatric vaccine including proquad ii and varivax well lower sale of diabetes product januvia and janumet and virology product zepatier and isentress isentress hd also partially offset revenue growth in discussed above the covid pandemic negatively affected sale in sale in the united state grew in primarily driven by higher sale of keytruda increased alliance revenue from lynparza and lenvima and higher sale of animal health product revenue growth wa largely offset by lower sale of nuvaring januvia noxafil emend emend for injection ii janumet varivax and implanon nexplanon international sale grew in the increase in international sale primarily reflects growth in keytruda gardasil gardasil increased alliance revenue from lynparza well higher sale of pneumovax prevymis januvia and animal health product sale growth wa partially offset by lower sale of zepatier vytorin noxafil zetia remicade emend emend for injection and product within the diversified brand franchise particularly singulair and nasonex international sale represented of total sale in both and see note to the consolidated financial statement for detail on sale of the company product discussion of performance for select product in the franchise follows pharmaceutical segmentoncology in million change change excluding change change excluding alliance revenue lynparza alliance revenue lenvima alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost see note to the consolidated financial statement of contentskeytruda is an anti pd programmed death receptor therapy that ha been approved monotherapy for the treatment of certain patient with cervical cancer chl cscc escc gastric or gastroesophageal junction adenocarcinoma hnscc hepatocellular carcinoma hcc non small cell lung cancer nsclc small cell lung cancer sclc melanoma merkel cell carcinoma msi or dmmr cancer including msi dmmr colorectal cancer primary mediastinal large cell lymphoma pmbcl tmb cancer and urothelial carcinoma including nmibc keytruda is also approved for the treatment of certain patient in combination with chemotherapy for metastatic squamous and nonsquamous nsclc in combination with chemotherapy for hnscc in combination with chemotherapy for tnbc in combination with axitinib for rcc and in combination with lenvima for endometrial carcinoma the keytruda clinical development program includes study across broad range of cancer type global sale of keytruda grew in driven by higher demand the company continues to launch keytruda with multiple new indication globally although the covid pandemic had dampening effect on growing demand sale in the united state continue to build across the multiple approved indication in particular for the treatment of advanced nsclc monotherapy and in combination with chemotherapy for both nonsquamous and squamous metastatic nsclc along with uptake in the rcc adjuvant melanoma hnscc bladder cancer and endometrial carcinoma indication uptake of the every six week adult dosing regimen in the united state benefited sale in keytruda sale growth in international market wa driven by continued uptake in approved indication particularly in the eu sale growth wa partially offset by decline in japan due to pricing pursuant to re pricing rule the japanese government reduced the price of keytruda by effective february additionally keytruda wa subject to another price reduction of in april under provision of the japanese pricing rule in january the fda approved keytruda monotherapy for the treatment of certain patient with bacillus calmette guerin bcg unresponsive high risk nmibc based on the result of the keynote trial in april the fda granted accelerated approval for an additional recommended dosage of mg every six week for keytruda across all adult indication including monotherapy and combination therapy this new dosage option is available in addition to the current dose of mg every three week in june the fda granted accelerated approval for keytruda monotherapy for the treatment of adult and pediatric patient with unresectable or metastatic tmb solid tumor determined by an fda approved test that have progressed following prior treatment and who have no satisfactory alternative treatment option based in part on the result of the keynote trial also in june the fda approved keytruda monotherapy for the treatment of patient with recurrent or metastatic cscc that is not curable by surgery or radiation based on data from the keynote trial additionally in june the fda approved keytruda monotherapy for the first line treatment of patient with unresectable or metastatic msi or dmmr colorectal cancer based on result from the keynote trial in october the fda approved an expanded label for keytruda monotherapy for the treatment of adult patient with relapsed or refractory chl based on result from the keynote trial the fda also approved an updated pediatric indication for keytruda for the treatment of pediatric patient with refractory chl or chl that ha relapsed after two or more line of therapy keytruda wa previously approved under the fda accelerated approval process for the treatment of adult and pediatric patient with refractory chl or who have relapsed after three or more prior line of therapy based on data from the keynote trial in accordance with accelerated approval regulation continued approval wa contingent upon verification and description of clinical benefit these accelerated approval requirement have been fulfilled with the data from keynote in november the fda granted accelerated approval for keytruda in combination with chemotherapy for the treatment of patient with locally recurrent unresectable or metastatic tnbc whose tumor express pd combined positive score cps determined by an fda approved test the approval is based on result from the keynote trial in june keytruda wa approved by the national medical product administration nmpa in china monotherapy for the second line treatment of patient with locally advanced or metastatic escc whose of contentstumors express pd cps this indication wa granted based on the keynote trial including data from an extension of the global study in chinese patient in december china nmpa approved keytruda monotherapy for the first line treatment of patient with metastatic or with unresectable recurrent hnscc whose tumor express pd cps determined by fully validated test in august keytruda wa approved by japan pharmaceutical and medical device agency pmda monotherapy for the treatment of patient whose tumor are pd positive and have radically unresectable advanced or recurrent escc who have progressed after chemotherapy the approval wa based on result from the keynote trial additionally keytruda wa approved by japan pmda for use at an additional recommended dosage of mg including monotherapy and combination therapy this new dosage option is available in addition to the current dose of mg in january keytruda wa approved by the european commission ec first line treatment in adult patient with msi or dmmr colorectal cancer based on the result of the keynote study the company is party to certain third party license agreement pursuant to which the company pay royalty on sale of keytruda under the term of the more significant of these agreement merck pay royalty of on worldwide sale of keytruda through to one third party this royalty will decline to for through and will terminate thereafter the company pay an additional royalty on worldwide sale of keytruda to another third party the termination date of which varies by country this royalty will expire in the united state in and in major european market in the royalty are included in cost of sale lynparza an oral poly adp ribose polymerase parp inhibitor being developed part of collaboration with astrazeneca see note to the consolidated financial statement is approved for the treatment of certain type of advanced ovarian breast pancreatic and prostate cancer alliance revenue related to lynparza grew in due to continued uptake across the multiple approved indication in the united state the eu china and japan in may the fda approved lynparza in combination with bevacizumab first line maintenance treatment of certain adult patient with advanced epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to first line platinum based chemotherapy in november lynparza wa approved in the eu for the maintenance treatment of adult patient with advanced high grade epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response following completion of first line platinum based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency hrd positive status these approval were based on the result from the paola trial also in may the fda approved lynparza for the treatment of adult patient with deleterious or suspected deleterious germline or somatic homologous recombination repair hrr gene mutated mcrpc who have progressed following prior treatment in november lynparza wa approved in the eu monotherapy for the treatment of adult patient with mcrpc and mutation germline and or somatic who have progressed following prior therapy these approval were based on the result from the profound trial in july lynparza wa approved in the eu monotherapy for the maintenance treatment of adult patient with germline mutation who have metastatic adenocarcinoma of the pancreas and have not progressed after first line chemotherapy regimen this approval wa based on the result from the polo trial in december lynparza wa approved in japan for the treatment of three type of advanced cancer ovarian prostate and pancreatic cancer the three approval authorize lynparza for use maintenance treatment after first line chemotherapy containing bevacizumab genetical recombination in patient with hrd ovarian cancer the treatment of patient with brca gene mutated brcam mcrpc and maintenance treatment after platinum based chemotherapy for patient with brcam curatively unresectable pancreas cancer the concurrent approval by the japanese ministry of health labor and welfare are based on result from the paola profound and polo trial lenvima an oral receptor tyrosine kinase inhibitor being developed part of collaboration with eisai see note to the consolidated financial statement is approved for the treatment of certain type of thyroid cancer hcc in combination with everolimus for certain patient with rcc and in combination with keytruda for the of contentstreatment of certain patient with endometrial carcinoma alliance revenue related to lenvima grew in due to higher demand in the united state china and the eu in november china nmpa approved lenvima monotherapy for the treatment of differentiated thyroid cancer global sale of emend for the prevention of certain chemotherapy induced nausea and vomiting declined in primarily due to lower demand and pricing in the united state due to generic competition for emend for injection following patent expiry in september also contributing to the emend sale decline wa lower demand in the eu and japan result of generic competition for the oral formulation of emend following loss of market exclusivity in may and december respectively market exclusivity for the oral formulation of emend previously expired in in april the fda approved koselugo selumetinib for the treatment of pediatric patient two year of age and older with neurofibromatosis type who have symptomatic inoperable plexiform neurofibroma pn the fda approval is based on positive result from the national cancer institute nci cancer therapy evaluation program ctep sponsored phase sprint stratum trial coordinated by the nci center for cancer research pediatric oncology branch this is the first regulatory approval of medicine for the treatment of pn rare and debilitating genetic condition koselugo is being jointly developed and commercialized with astrazeneca globally see note to the consolidated financial statement vaccine in million change change excluding change change excluding gardasil pneumovax worldwide sale of gardasil gardasil vaccine to help prevent certain cancer and other disease caused by certain type of hpv grew in primarily due to higher volume in china and the replenishment in of dos borrowed from the center for disease control and prevention cdc pediatric vaccine stockpile in the replenishment resulted in the recognition of sale of million in which when combined with the reduction of sale of million in due to the borrowing resulted in favorable impact to sale of million in lower demand in the united state and hong kong sar prc attributable to the covid pandemic partially offset the increase in sale of gardasil gardasil in june the fda approved an expanded indication for gardasil for the prevention of oropharyngeal and other head and neck cancer caused by hpv type and the oropharyngeal and head and neck cancer indication wa approved under accelerated approval based on effectiveness in preventing hpv related anogenital disease in july gardasil wa approved by the pmda in japan for use in woman and girl nine year and older for the prevention of cervical cancer certain cervical vaginal and vulvar precancers and genital wart caused by the hpv type covered by the vaccine in december silgard wa also approved in japan for the prevention of anal cancer and precursor lesion caused by hpv type and for individual nine year and older and for genital wart for men nine year and older gardasil is marketed in japan silgard the company is party to certain third party license agreement pursuant to which the company pay royalty on sale of gardasil gardasil under the term of the more significant of these agreement merck pay royalty on worldwide sale of gardasil gardasil to one third party royalty obligation under this agreement expire in december and an additional royalty on sale of gardasil gardasil in the united state to another third party these royalty obligation expire in december the royalty are included in cost of sale of contentsglobal sale of proquad pediatric combination vaccine to help protect against measles mumps rubella and varicella declined in driven primarily by lower demand in the united state resulting from fewer measles outbreak in compared with coupled with the unfavorable impact of the covid pandemic partially offset by higher pricing worldwide sale of ii vaccine to help protect against measles mumps and rubella declined in driven primarily by lower demand in the united state resulting from fewer measles outbreak in compared with coupled with the unfavorable impact of the covid pandemic lower demand in brazil also contributed to the ii sale decline in global sale of varivax vaccine to help prevent chickenpox varicella declined in driven primarily by lower demand in the united state resulting from the covid pandemic partially offset by higher pricing the varivax sale decline wa also attributable to lower government tender in brazil worldwide sale of pneumovax vaccine to help prevent pneumococcal disease grew in primarily due to higher volume in the eu and in the united state attributable in part to heightened awareness of pneumococcal vaccination higher pricing in the united state also contributed to pneumovax sale growth in hospital acute care in million change change excluding change change excluding global sale of bridion for the reversal of two type of neuromuscular blocking agent used during surgery grew in due to higher demand globally particularly in the united state however fewer elective surgery result of the covid pandemic unfavorably affected demand in worldwide sale of noxafil an antifungal agent for the prevention of certain invasive fungal infection declined in due to generic competition in the united state and in the eu the patent that provided market exclusivity for certain form of noxafil representing the majority of noxafil sale expired in july additionally the patent for noxafil expired in number of major european market in december result the company is experiencing volume and pricing decline in noxafil sale in these market result of generic competition and expects the decline to continue worldwide sale of prevymis medicine for prophylaxis prevention of cytomegalovirus cmv infection and disease in adult cmv seropositive recipient of an allogenic hematopoietic stem cell transplant grew in due to continued uptake since launch in the eu and in the united state prevymis wa approved by the ec in january and by the fda in november global sale of cubicin for injection an antibiotic for the treatment of certain bacterial infection declined in primarily due to ongoing generic competition in the eu and in the united state in december the company temporarily suspended sale of zerbaxa combination antibacterial and beta lactamase inhibitor for the treatment of certain bacterial infection and subsequently issued product recall following the identification of product sterility issue result the company recorded an intangible asset impairment charge related to zerbaxa see note to the consolidated financial statement the company doe not anticipate that zerbaxa will return to the market before in june the fda approved supplemental new drug application nda for recarbrio imipenem cilastatin and relebactam for the treatment of patient year of age and older with hospital acquired of contentsbacterial pneumonia and ventilator associated bacterial pneumonia caused by certain susceptible gram negative microorganism immunology in million change change excluding change change excluding sale of simponi once monthly subcutaneous treatment for certain inflammatory disease marketed by the company in europe russia and turkey were nearly flat in sale of simponi are being unfavorably affected by the launch of biosimilars for competing product the company expects this competition will continue to unfavorably affect sale of simponi sale of remicade treatment for inflammatory disease marketed by the company in europe russia and turkey declined in driven by ongoing biosimilar competition in the company marketing territory in europe the company lost market exclusivity for remicade in major european market in and no longer ha market exclusivity in any of it marketing territory the company is experiencing pricing and volume decline in these market result of biosimilar competition and expects the decline to continue the company marketing right with respect to these product will revert to janssen pharmaceutical inc in the second half of virology in million change change excluding change change excluding isentress hd worldwide sale of isentress isentress hd an hiv integrase inhibitor for use in combination with other antiretroviral agent for the treatment of hiv infection declined in primarily due to competitive pressure in the united state and in the eu the company expects competitive pressure for isentress isentress hd to continue global sale of zepatier treatment for adult patient with chronic hepatitis virus genotype gt or infection declined in driven by lower demand globally due to competition and declining patient volume coupled with the impact of the covid pandemic cardiovascular in million change change excluding change change excluding vytorin alliance revenue adempas alliance revenue represents merck share of profit from sale in bayer marketing territory which are product sale net of cost of sale and commercialization cost see note to the consolidated financial statement combined global sale of zetia marketed in most country outside the united state ezetrol and vytorin marketed outside the united state inegy medicine for lowering ldl cholesterol declined in driven primarily by lower sale of ezetrol in japan and ezetrol and inegy in the eu the patent that provided market exclusivity for ezetrol in japan expired in september and generic competition began in june the of contentseu patent for ezetrol and inegy expired in april and april respectively accordingly the company is experiencing sale decline in these market result of generic competition and expects the decline to continue the sale decline in wa also attributable to lower pricing following loss of exclusivity in australia higher demand for ezetrol in china partially offset the sale decline in merck lost market exclusivity in the united state for zetia in and vytorin in and subsequently lost nearly all sale of these product result of generic competition sale of atozet marketed outside of the united state medicine for lowering ldl cholesterol grew in primarily driven by higher demand in most market particularly in the eu japan and other country in the asia pacific region zetia vytorin atozet and rosuzet will be contributed to organon in connection with the spin off see note to the consolidated financial statement adempas cardiovascular drug for the treatment of pulmonary arterial hypertension is part of worldwide collaboration with bayer to market and develop soluble guanylate cyclase sgc modulators including adempas see note to the consolidated financial statement revenue from adempas includes merck share of profit from the sale of adempas in bayer marketing territory which grew in well sale in merck marketing territory which grew in in january the fda approved verquvo vericiguat an sgc stimulator to reduce the risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretic in adult with symptomatic chronic heart failure and reduced ejection fraction the approval wa based on the result of the pivotal phase victoria trial and follows priority regulatory review verquvo is part of the same worldwide clinical development collaboration with bayer that includes adempas referenced above diabetes in million change change excluding change change excluding janumet worldwide combined sale of januvia and janumet medicine that help lower blood sugar level in adult with type diabetes declined in result of continued pricing pressure in the united state partially offset by higher demand in certain international market particularly in china the company expects pricing pressure to continue januvia and janumet will lose market exclusivity in the united state in january the supplementary patent certificate that provide market exclusivity for januvia and janumet in the eu expire in september and april respectively the company anticipates sale of januvia and janumet in these market will decline substantially after loss of market exclusivity woman health in million change change excluding change change excluding worldwide sale of implanon nexplanon single rod subdermal contraceptive implant declined in primarily driven by lower demand in the united state and in the eu resulting from the covid pandemic worldwide sale of nuvaring vaginal contraceptive product declined in due to generic competition in the united state the patent that provided market exclusivity for nuvaring expired in april and generic competition began in december accordingly the company is experiencing rapid and substantial decline in nuvaring sale and expects the decline to continue of contentsimplanon nexplanon and nuvaring will be contributed to organon in connection with the spin off see note to the consolidated financial statement biosimilars in million change change excluding change change excluding calculation not meaningful biosimilar product are marketed by the company pursuant to an agreement with samsung bioepis co ltd samsung to develop and commercialize multiple pre specified biosimilar candidate currently the company market renflexis infliximab abda biosimilar to remicade infliximab for the treatment of certain inflammatory disease ontruzant trastuzumab dttb biosimilar to herceptin trastuzumab for the treatment of positive breast cancer and overexpressing gastric cancer brenzys etanercept biosimilar biosimilar to enbrel for the treatment of certain inflammatory disease and aybintio bevacizumab for the treatment of certain type of cancer merck commercialization territory under the agreement vary by product sale growth of biosimilars in wa primarily due to continued post launch uptake of renflexis in the united state and canada and the launch of ontruzant in brazil in in august the ec granted marketing authorization for aybintio for the treatment of metastatic carcinoma of the colon or rectum metastatic breast cancer nsclc advanced and or metastatic rcc epithelial ovarian fallopian tube and primary peritoneal cancer and cervical cancer an application seeking approval of aybintio in the united state wa filed in september the above biosimilar product will be contributed to organon in connection with the spin off see note to the consolidated financial statement animal health segment in million change change excluding change change excluding companion sale of livestock product grew in predominantly due to an additional five month of sale in related to the april acquisition of antelliq leader in digital animal identification traceability and monitoring solution see note to the consolidated financial statement sale of companion animal product grew in driven primarily by higher demand for the bravecto line of product for parasitic control well higher demand for companion animal vaccine cost expense and other in million of sale selling general and research and restructuring other income expense net calculation not meaningful of contentscost of salescost of sale wa billion in compared with billion in cost of sale includes the amortization of intangible asset recorded in connection with acquisition collaboration and licensing arrangement which totaled billion in compared with billion in respectively additionally cost in and include intangible asset impairment charge of billion and million related to marketed product and other intangible see note to the consolidated financial statement the company may recognize additional impairment charge in the future related to intangible asset that were measured at fair value and capitalized in connection with business acquisition and such charge could be material cost in also include charge of million in connection with the discontinuation of covid vaccine development program see note to the consolidated financial statement and inventory write offs of million related to recall for zerbaxa see note to the consolidated financial statement also included in cost of sale are expense associated with restructuring activity which amounted to million in compared with million in primarily reflecting accelerated depreciation and asset write offs related to the planned sale or closure of manufacturing facility separation cost associated with manufacturing related headcount reduction have been incurred and are reflected in restructuring cost discussed below gross margin wa in compared with in the gross margin decline in reflects the unfavorable effect of higher impairment charge noted above pricing pressure charge related to the discontinuation of covid vaccine development program and higher inventory write offs related to the recall of zerbaxa noted above partially offset by the favorable effect of product mix lower amortization of intangible asset and lower restructuring cost selling general and administrativeselling general and administrative sg expense were billion in decline of compared with the decline wa driven primarily by lower administrative selling and promotional cost including lower travel and meeting expense due in part to the covid pandemic and the favorable effect of foreign exchange partially offset by higher cost related to the spin off of organon and contribution to the merck foundation sg expense in include million of cost related to the spin off of organon sg expense in and include restructuring cost of million and million respectively related primarily to accelerated depreciation for facility to be closed or divested separation cost associated with sale force reduction have been incurred and are reflected in restructuring cost discussed below research and developmentresearch and development expense were billion in an increase of compared with the increase wa driven primarily by higher upfront payment related to acquisition and collaboration including billion charge in related to the acquisition of velosbio see note to the consolidated financial statement well higher expense related to clinical development and increased investment in discovery research and early drug development higher restructuring cost also contributed to the increase in expense in the increase in expense in wa partially offset by lower in process research and development ipr impairment charge and lower cost resulting from the covid pandemic net of spending on covid related vaccine and antiviral research program expense are comprised of the cost directly incurred by mrl the company research and development division that focus on human health related activity which were billion in compared with billion in also included in expense are animal health research cost licensing cost and cost incurred by other division in support of activity including depreciation production and general and administrative which in the aggregate were billion in and billion in additionally expense in include billion charge for the acquisition of velosbio noted above million charge for the acquisition of oncoimmune and charge of million related to transaction with seagen expense in include million charge for the acquisition of peloton see note to the consolidated financial statement for more information on these transaction expense also include ipr impairment charge of million and million in and respectively see note to the consolidated financial statement the company may recognize additional impairment charge in the future related to the cancellation or delay of other pipeline program that were measured at fair value and capitalized in connection with business acquisition and such of contentscharges could be material in addition expense in include million of cost associated with restructuring activity primarily relating to accelerated depreciation expense also include expense or income related to change in the estimated fair value measurement of liability for contingent consideration recorded in connection with business acquisition during and the company recorded net reduction in expense of million and million respectively related to change in these estimate restructuring costsin early merck approved new global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization build on prior restructuring program and doe not include any action associated with the planned spin off of organon the company continues to evaluate it global footprint and overall operating model it subsequently identified additional action under the restructuring program and could identify further action over time the action currently contemplated under the restructuring program are expected to be substantially completed by the end of with the cumulative pretax cost to be incurred by the company to implement the program now estimated to be approximately billion the company expects to record charge of approximately million in related to the restructuring program the company anticipates the action under the restructuring program to result in annual net cost saving of approximately million by the end of action under previous global restructuring program have been substantially completed restructuring cost primarily representing separation and other related cost associated with these restructuring activity were million in and million in separation cost incurred were associated with actual headcount reduction well estimated expense under existing severance program for headcount reduction that were probable and could be reasonably estimated also included in restructuring cost are asset abandonment facility shut down and other related cost well employee related cost such curtailment settlement and termination charge associated with pension and other postretirement benefit plan and share based compensation plan cost for segment reporting restructuring cost are unallocated expense additional cost associated with the company restructuring activity are included in cost of sale selling general and administrative expense and research and development cost the company recorded aggregate pretax cost of million in and million in related to restructuring program activity see note to the consolidated financial statement other income expense netother income expense net wa million of income in compared with million of expense in primarily due to higher income from investment in equity security net largely related to moderna inc for detail on the component of other income expense net see note to the consolidated financial statement segment profit in million segment profit animal health segment other non reportable segment other income before tax pharmaceutical segment profit are comprised of segment sale le standard cost well sg expense directly incurred by the segment animal health segment profit are comprised of segment sale le all cost of sale well sg and expense directly incurred by the segment for internal management reporting presented to the chief operating decision maker merck doe not allocate the remaining cost of sale not included in segment profit described above research and development expense incurred by mrl or general and administrative expense the cost of financing these activity separate division maintain responsibility for of contentsmonitoring and managing these cost including depreciation related to fixed asset utilized by these division and therefore they are not included in segment profit also excluded from the determination of segment profit are cost related to restructuring activity and acquisition and divestiture related cost including the amortization of purchase accounting adjustment intangible asset impairment charge and change in the estimated fair value measurement of liability for contingent consideration additionally segment profit do not reflect other expense from corporate and manufacturing cost center and other miscellaneous income or expense these unallocated item are reflected in other in the above table also included in other are miscellaneous corporate profit loss well operating profit loss related to third party manufacturing sale pharmaceutical segment profit grew in compared with driven primarily by higher sale well lower selling and promotional cost animal health segment profit grew in driven primarily by higher sale and lower promotional and selling cost partially offset by higher cost and the unfavorable effect of foreign exchange tax on incomethe effective income tax rate of in and in reflect the impact of acquisition and divestiture related cost and restructuring cost partially offset by the beneficial impact of foreign earnings including product mix the effective income tax rate in reflects the unfavorable impact of charge for the acquisition of velosbio for which no tax benefit wa recognized the effective income tax rate in reflects the favorable impact of million net tax benefit related to the settlement of certain federal income tax matter see note to the consolidated financial statement and the reversal of tax reserve established in connection with the divestiture of merck consumer care mcc business due to the lapse in the statute of limitation in addition the effective income tax rate in reflects the unfavorable impact of charge for the acquisition of peloton for which no tax benefit wa recognized and charge of million related to the finalization of treasury regulation for the transition tax associated with the enactment of tax legislation known the tax cut and job act tcja see note to the consolidated financial statement net income loss attributable to noncontrolling interestsnet income loss attributable to noncontrolling interest wa million in compared with million in the loss in wa driven primarily by the portion of goodwill impairment charge related to certain business in the healthcare service segment that were attributable to noncontrolling interest net income and earnings per common sharenet income attributable to merck co inc wa billion in and billion in eps wa in and in non gaap income and non gaap epsnon gaap income and non gaap eps are alternative view of the company performance that merck is providing because management belief this information enhances investor understanding of the company result it permit investor to understand how management ass performance non gaap income and non gaap eps exclude certain item because of the nature of these item and the impact that they have on the analysis of underlying business performance and trend the excluded item which should not be considered non recurring consist of acquisition and divestiture related cost restructuring cost and certain other item these excluded item are significant component in understanding and assessing financial performance non gaap income and non gaap eps are important internal measure for the company senior management receives monthly analysis of operating result that includes non gaap eps management us these measure internally for planning and forecasting purpose and to measure the performance of the company along with other metric in addition senior management annual compensation is derived in part using non gaap pretax income since non gaap income and non gaap eps are not measure determined in accordance with gaap they have no standardized meaning prescribed by gaap and therefore may not be comparable to the calculation of similar measure of other company the information on non gaap income and non gaap eps should be considered in addition to but not substitute for or superior to net income and eps prepared in accordance with generally accepted accounting principle in the united state gaap of contentsa reconciliation between gaap financial measure and non gaap financial measure is follows in million except per share amount before tax reported under gaap increase decrease for excluded item acquisition and divestiture related cost restructuring other item charge for the acquisition of charge for the formation of collaboration charge for the acquisition of charge for the discontinuation of covid vaccine development charge for the acquisition of peloton charge related to the termination of collaboration with samsung charge for the acquisition of viralytics limited other non gaap income before tax on income reported under estimated tax benefit on excluded item adjustment to tax benefit recorded in conjunction with the cubist pharmaceutical inc acquisition net tax benefit from the settlement of certain federal income tax matter tax benefit from the reversal of tax reserve related to the divestiture of mcc net tax charge related to the finalization of treasury regulation related to the enactment of the tcja non gaap tax on non gaap net le net income loss attributable to noncontrolling interest reported under acquisition and divestiture related cost attributable to noncontrolling interest non gaap net income attributable to noncontrolling non gaap net income attributable to merck co inc eps assuming dilution reported under gaap eps non gaap eps assuming dilution amount in includes billion intangible asset impairment charge related to zerbaxa amount in includes million intangible asset impairment charge related to sivextro see note to the consolidated financial statement amount in includes million related to transaction with seagen see note to the consolidated financial statement amount in represents charge for the formation of collaboration with eisai see note to the consolidated financial statement the estimated tax impact on the excluded item is determined by applying the statutory rate of the originating territory of the non gaap adjustment acquisition and divestiture related costsnon gaap income and non gaap eps exclude the impact of certain amount recorded in connection with business acquisition and divestiture these amount include the amortization of intangible asset and amortization of purchase accounting adjustment to inventory well intangible asset impairment charge and expense or income related to change in the estimated fair value measurement of liability for contingent consideration also excluded are integration transaction and certain other cost associated with business acquisition and divestiture restructuring costsnon gaap income and non gaap eps exclude cost related to restructuring action see note to the consolidated financial statement these amount include employee separation cost and accelerated depreciation of contentsassociated with facility to be closed or divested accelerated depreciation cost represent the difference between the depreciation expense to be recognized over the revised useful life of the asset based upon the anticipated date the site will be closed or divested or the equipment disposed of and depreciation expense determined utilizing the useful life prior to the restructuring action restructuring cost also include asset abandonment facility shut down and other related cost well employee related cost such curtailment settlement and termination charge associated with pension and other postretirement benefit plan and share based compensation cost certain other itemsthese item are adjusted for after evaluating them on an individual basis considering their quantitative and qualitative aspect typically these consist of item that are unusual in nature significant to the result of particular period or not indicative of future operating result excluded from non gaap income and non gaap eps in are charge for the acquisition of velosbio and oncoimmune charge related to collaboration including transaction with seagen see note to the consolidated financial statement charge for the discontinuation of covid vaccine development program and an adjustment to tax benefit recorded in conjunction with the cubist pharmaceutical inc acquisition excluded from non gaap income and non gaap eps in is charge for the acquisition of peloton see note to the consolidated financial statement tax charge related to the finalization of treasury regulation related to the tcja net tax benefit related to the settlement of certain federal income tax matter and tax benefit related to the reversal of tax reserve established in connection with the divestiture of mcc see note to the consolidated financial statement excluded from non gaap income and non gaap eps in is charge related to the formation of collaboration with eisai see note to the consolidated financial statement charge related to the termination of collaboration agreement with samsung for insulin glargine see note to the consolidated financial statement charge for the acquisition of viralytics see note to the consolidated financial statement and measurement period adjustment related to the provisional amount recorded for the tcja see note to the consolidated financial statement beginning in the company will be changing the treatment of certain item for the purpose of it non gaap reporting historically merck non gaap result excluded the amortization of intangible asset recognized in connection with business acquisition reflected part of acquisition and divestiture related cost but did not exclude the amortization of intangible originating from collaboration asset acquisition or licensing arrangement beginning in merck non gaap result will no longer differentiate between the nature of the intangible asset being amortized and will exclude all amortization of intangible asset also beginning in merck non gaap result will exclude gain and loss on investment in equity security prior period amount will be recast to conform to the new presentation research and developmentresearch pipelinethe company currently ha several candidate under regulatory review in the united state and internationally well in late stage clinical development chart reflecting the company current research pipeline of february and related discussion is set forth in item business research and development above acquired in process research and developmentin connection with business acquisition the company ha recorded the fair value of in process research project which at the time of acquisition had not yet reached technological feasibility at december the balance of ipr wa billion see note to the consolidated financial statement the ipr project that remain in development are subject to the inherent risk and uncertainty in drug development and it is possible that the company will not be able to successfully develop and complete the ipr program and profitably commercialize the underlying product candidate the time period to receive approval from the fda and other regulatory agency are subject to uncertainty significant delay in the approval process or the company failure to obtain approval at all would delay or prevent the company from realizing revenue from these product additionally if certain of the ipr program fail or are abandoned during development then the company will not realize the future cash flow it ha estimated and recorded ipr of of contentsthe acquisition date if such circumstance were to occur the company future operating result could be adversely affected and the company may recognize impairment charge and such charge could be material in and the company recorded ipr impairment charge within research and development expense of million million and million respectively see note to the consolidated financial statement additional research and development will be required before any of the remaining program reach technological feasibility the cost to complete the research project will depend on whether the project are brought to their final stage of development and are ultimately submitted to the fda or other regulatory agency for approval acquisition research collaboration and license agreementsmerck continues to remain focused on pursuing opportunity that have the potential to drive both near and long term growth certain recent transaction are summarized below additional detail are included in note to the consolidated financial statement merck is actively monitoring the landscape for growth opportunity that meet the company strategic criterion in january merck acquired arqule publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patient with cancer and other disease for billion arqule lead investigational candidate mk formerly arq is novel oral bruton tyrosine kinase btk inhibitor currently being evaluated for the treatment of cell malignancy the transaction wa accounted for an acquisition of business the company recorded ipr of billion related to mk goodwill of million and other net liability of million in july merck and ridgeback bio closely held biotechnology company closed collaboration agreement to develop molnupiravir mk also known eidd an orally available antiviral candidate in clinical development for the treatment of patient with covid merck gained exclusive worldwide right to develop and commercialize molnupiravir and related molecule under the term of the agreement ridgeback bio received an upfront payment and also is eligible to receive future contingent payment dependent upon the achievement of certain developmental and regulatory approval milestone well share of the net profit of molnupiravir and related molecule if approved molnupiravir is currently being evaluated in phase clinical trial in both the hospital and outpatient setting the primary completion date for the phase study is june the company anticipates interim efficacy data in the first quarter of in september merck and seagen announced an oncology collaboration to globally develop and commercialize seagen ladiratuzumab vedotin mk an investigational antibody drug conjugate targeting liv which is currently in phase clinical trial for breast cancer and other solid tumor under the term of the agreement merck made an upfront payment of million and billion equity investment in million share of seagen common stock at price of per share merck recorded million in research and development expense in related to this transaction seagen is also eligible to receive future contingent milestone payment dependent upon the achievement of certain developmental and sale based milestone concurrent with the above transaction seagen granted merck an exclusive license to commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor for the treatment of positive cancer in asia the middle east and latin america and other region outside of the united state canada and europe under the term of the agreement merck made upfront payment aggregating million which were recorded research and development expense in seagen is also eligible to receive future contingent regulatory approval milestone and tiered royalty based on annual sale level of tukysa in merck territory in december merck acquired oncoimmune privately held clinical stage biopharmaceutical company for an upfront payment of million in addition oncoimmune shareholder will be eligible to receive future contingent regulatory approval milestone payment and tiered royalty oncoimmune lead therapeutic candidate mk also known is being evaluated for the treatment of patient hospitalized with covid topline result from pre planned interim efficacy analysis from phase study of mk were released in september full result from this phase study which were consistent with the topline result were received in february and will be submitted for publication in the future the transaction wa accounted of contentsfor an acquisition of an asset under the agreement prior to the completion of the acquisition oncoimmune spun out certain right and asset unrelated to the mk program to new entity owned by the existing shareholder of oncoimmune in connection with the closing of the acquisition merck invested million for ownership interest in the new entity which wa valued at million resulting in million premium merck also recognized other net liability of million the company recorded research and development expense of million in related to this transaction in december merck announced it had entered into an agreement with the government to support the development manufacture and initial distribution of mk upon approval or emergency use authorization eua from the fda by june under the agreement merck wa to receive up to approximately million for manufacturing and supply of approximately dos of mk to the government by june to help meet the government pandemic response goal following the execution of this agreement merck received feedback from the fda that additional data beyond the study conducted by oncoimmune would be needed to support potential eua application based on this fda feedback merck no longer expects to supply the government with mk in the first half of merck is actively working with fda to address the agency comment in december merck acquired velosbio privately held clinical stage biopharmaceutical company for billion velosbio lead investigational candidate is mk formerly known vls an antibody drug conjugate targeting receptor tyrosine kinase like orphan receptor that is currently being evaluated for the treatment of patient with hematologic malignancy and solid tumor the transaction wa accounted for an acquisition of an asset merck recorded net asset of million primarily cash and research and development expense of billion in related to the transaction in february merck and pandion therapeutic inc pandion entered into definitive agreement under which merck will acquire pandion clinical stage biotechnology company developing novel therapeutic designed to address the unmet need of patient living with autoimmune disease for per share in cash representing an approximate total equity value of billion pandion is advancing pipeline of precision immune modulators targeting critical immune control node under the term of the acquisition agreement merck through subsidiary will initiate tender offer to acquire all outstanding share of pandion the closing of the tender offer is subject to certain condition including the tender of share representing at least majority of the total number of pandion share of fully diluted common stock the expiration of the waiting period under the hart scott rodino antitrust improvement act and other customary condition the transaction is expected to close in the first half of capital expenditurescapital expenditure were billion in billion in and billion in expenditure in the united state were billion in billion in and billion in the increased capital expenditure in and reflect investment in new capital project focused primarily on increasing manufacturing capacity for merck key product the increased capital expenditure in also reflect the purchase of manufacturing facility in dunboyne ireland to support upcoming product launch see note to the consolidated financial statement the company plan to invest more than billion in new capital project from depreciation expense wa billion in billion in and billion in of which billion in billion in and billion in related to location in the united state total depreciation expense in and included accelerated depreciation of million and million respectively associated with restructuring activity see note to the consolidated financial statement of contentsanalysis of liquidity and capital resourcesmerck strong financial profile enables it to fund research and development focus on external alliance support in line product and maximize upcoming launch while providing significant cash return to shareholder selected data in million capital total debt to total liability and cash provided by operation to total decline in working capital in compared with is primarily related to increased short term debt supporting the funding of business development activity and capital expenditure cash provided by operating activity wa billion in compared with billion in reflecting higher payment related to collaboration which were billion in compared with million in cash provided by operating activity continues to be the company primary source of fund to finance operating need capital expenditure treasury stock purchase and dividend paid to shareholder cash used in investing activity wa billion in compared with billion in the increase wa driven primarily by lower proceeds from the sale of security and other investment higher use of cash for acquisition and higher capital expenditure partially offset by lower purchase of security and other investment cash used in financing activity wa billion in compared with billion in the lower use of cash in financing activity wa driven primarily by net increase in short term borrowing in compared with net decrease in short term borrowing in well lower purchase of treasury stock partially offset by higher payment on debt see below lower proceeds from the issuance of debt see below higher dividend paid to shareholder and lower proceeds from the exercise of stock option the company ha account receivable factoring agreement with financial institution in certain country to sell account receivable see note to the consolidated financial statement the company factored billion and billion of account receivable in the fourth quarter of and respectively under these factoring arrangement which reduced outstanding account receivable the cash received from the financial institution is reported within operating activity in the consolidated statement of cash flow in certain of these factoring arrangement for ease of administration the company will collect customer payment related to the factored receivables which it then remit to the financial institution at december and the company had collected million and million respectively on behalf of the financial institution which wa remitted to them in january and respectively the net cash flow from these collection are reported financing activity in the consolidated statement of cash flow of contentsthe company contractual obligation of december are follows payment due by period in million obligation loan payable and current portion of long term long term interest related to debt unrecognized tax benefit transition tax related to the enactment of the tcja milestone payment related to collaboration lease includes future inventory purchase the company ha committed to in connection with certain divestiture of december the company consolidated balance sheet reflects liability for unrecognized tax benefit including interest and penalty of billion including million reflected current liability due to the high degree of uncertainty regarding the timing of future cash outflow of liability for unrecognized tax benefit beyond one year reasonable estimate of the period of cash settlement for year beyond can not be made in connection with the enactment of the tcja the company is required to pay one time transition tax which the company ha elected to pay over period of eight year through permitted under the tcja see note to the consolidated financial statement reflects payment under collaborative agreement for sale based milestone that were achieved in and therefore deemed to be contractual obligation but not paid until see note to the consolidated financial statement amount exclude reasonably certain lease renewal that have not yet been executed see note to the consolidated financial statement purchase obligation are enforceable and legally binding obligation for purchase of good and service including minimum inventory contract research and development and advertising amount do not include contingent milestone payment related to collaborative arrangement or acquisition they are not considered contractual obligation until the successful achievement of developmental regulatory approval or commercial milestone at december the company ha recognized liability for contingent sale based milestone payment related to collaboration with astrazeneca and eisai where payment remains subject to the achievement of the related sale milestone aggregating billion see note to the consolidated financial statement excluded from research and development obligation are potential future funding commitment of up to approximately million for investment in research venture capital fund loan payable and current portion of long term debt reflects million of long dated note that are subject to repayment at the option of the holder required funding obligation for relating to the company pension and other postretirement benefit plan are not expected to be material however the company currently anticipates contributing approximately million to it pension plan million to it international pension plan and million to it other postretirement benefit plan during in june the company issued billion principal amount of senior unsecured note consisting of billion of note due billion of note due billion of note due and billion of note due merck used the net proceeds from the offering for general corporate purpose including without limitation the repayment of outstanding commercial paper borrowing and other indebtedness with upcoming maturity in march the company issued billion principal amount of senior unsecured note consisting of million of note due billion of note due billion of note due and billion of note due the company used the net proceeds from the offering for general corporate purpose including the repayment of outstanding commercial paper borrowing the company ha billion credit facility that matures in june the facility provides backup liquidity for the company commercial paper borrowing facility and is to be used for general corporate purpose the company ha not drawn funding from this facility of contentsin march the company filed security registration statement with the security and exchange commission sec under the automatic shelf registration process available to well known seasoned issuer which is effective for three year effective of november the company executed full and unconditional guarantee of the then existing debt of it subsidiary merck sharp dohme corp msd and msd executed full and unconditional guarantee of the then existing debt of the company excluding commercial paper including for payment of principal and interest these guarantee do not extend to debt issued subsequent to that date the company continues to maintain conservative financial profile the company place it cash and investment in instrument that meet high credit quality standard specified in it investment policy guideline these guideline also limit the amount of credit exposure to any one issuer the company doe not participate in any off balance sheet arrangement involving unconsolidated subsidiary that provide financing or potentially expose the company to unrecorded financial obligation in november merck board of director declared quarterly dividend of per share on the company outstanding common stock that wa paid in january in january the board of director declared quarterly dividend of per share on the company common stock for the second quarter of payable in april in october merck board of director authorized purchase of up to billion of merck common stock for it treasury the treasury stock purchase authorization ha no time limit and will be made over time in open market transaction block transaction on or off an exchange or in privately negotiated transaction the company spent billion to purchase million share of it common stock for it treasury during under this program in march the company temporarily suspended it share repurchase program of december the company remaining share repurchase authorization wa billion the company purchased billion and billion of it common stock during and respectively under authorized share repurchase program in the company entered into accelerated share repurchase asr agreement with two third party financial institution the dealer under the asr agreement merck agreed to purchase billion of merck common stock in total with an initial delivery of million share of merck common stock based on the then current market price made by the dealer to merck and payment of billion made by merck to the dealer in which were funded with existing cash and investment well short term borrowing upon settlement of the asr agreement in merck received an additional million share determined by the average daily volume weighted average price of merck common stock during the term of the asr program le negotiated discount bringing the total share received by merck under this program to million financial instrument market risk disclosuresthe company manages the impact of foreign exchange rate movement and interest rate movement on it earnings cash flow and fair value of asset and liability through operational mean and through the use of various financial instrument including derivative instrument significant portion of the company revenue and earnings in foreign affiliate is exposed to change in foreign exchange rate the objective of the company foreign currency risk management program well it interest rate risk management activity are discussed below foreign currency risk managementthe company ha established revenue hedging balance sheet risk management and net investment hedging program to protect against volatility of future foreign currency cash flow and change in fair value caused by change in foreign exchange rate the objective of the revenue hedging program is to reduce the variability caused by change in foreign exchange rate that would affect the dollar value of future cash flow derived from foreign currency denominated sale primarily the euro japanese yen and chinese renminbi to achieve this objective the company will hedge portion of it forecasted foreign currency denominated third party and intercompany distributor entity sale forecasted sale that are expected to occur over it planning cycle typically no more than two year into the of contentsfuture the company will layer in hedge over time increasing the portion of forecasted sale hedged it get closer to the expected date of the forecasted sale the portion of forecasted sale hedged is based on assessment of cost benefit profile that consider natural offsetting exposure revenue and exchange rate volatility and correlation and the cost of hedging instrument the company manages it anticipated transaction exposure principally with purchased local currency put option forward contract and purchased collar option the fair value of these derivative contract are recorded either asset gain position or liability loss position in the consolidated balance sheet change in the fair value of derivative contract are recorded each period in either current earnings or other comprehensive income loss oci depending on whether the derivative is designated part of hedge transaction and if so the type of hedge transaction for derivative that are designated cash flow hedge the unrealized gain or loss on these contract are recorded in accumulated other comprehensive income loss aoci and reclassified into sale when the hedged anticipated revenue is recognized for those derivative which are not designated cash flow hedge but serve economic hedge of forecasted sale unrealized gain or loss are recorded in sale each period the cash flow from both designated and non designated contract are reported operating activity in the consolidated statement of cash flow the company doe not enter into derivative for trading or speculative purpose because merck principally sell foreign currency in it revenue hedging program uniform weakening of the dollar would yield the largest overall potential loss in the market value of these hedge instrument the market value of merck hedge would have declined by an estimated million and million at december and respectively from uniform weakening of the dollar the market value wa determined using foreign exchange option pricing model and holding all factor except exchange rate constant although not predictive in nature the company belief that threshold reflects reasonably possible near term change in merck major foreign currency exposure relative to the dollar the company manages operating activity and net asset position at each local subsidiary in order to mitigate the effect of exchange on monetary asset and liability the company also us balance sheet risk management program to mitigate the exposure of net monetary asset that are denominated in currency other than subsidiary functional currency from the effect of volatility in foreign exchange in these instance merck principally utilizes forward exchange contract to offset the effect of exchange on exposure denominated in developed country currency primarily the euro and japanese yen for exposure in developing country currency the company will enter into forward contract to partially offset the effect of exchange on exposure when it is deemed economical to do so based on cost benefit analysis that considers the magnitude of the exposure the volatility of the exchange rate and the cost of the hedging instrument the cash flow from these contract are reported operating activity in the consolidated statement of cash flow sensitivity analysis to change in the value of the dollar on foreign currency denominated derivative investment and monetary asset and liability indicated that if the dollar uniformly weakened by against all currency exposure of the company at december and income before tax would have declined by approximately million and million in and respectively because the company wa in net short payable position relative to it major foreign currency after consideration of forward contract uniform weakening of the dollar will yield the largest overall potential net loss in earnings due to exchange this measurement assumes that change in one foreign currency relative to the dollar would not affect other foreign currency relative to the dollar although not predictive in nature the company belief that threshold reflects reasonably possible near term change in merck major foreign currency exposure relative to the dollar the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the economy of argentina wa determined to be hyperinflationary in consequently in accordance with gaap the company began remeasuring it monetary asset and liability for those operation in earnings the impact to the company result wa immaterial the company also us forward exchange contract to hedge portion of it net investment in foreign operation against movement in exchange rate the forward contract are designated hedge of the net investment in foreign operation the unrealized gain or loss on these contract are recorded in foreign currency translation adjustment within oci and remain in aoci until either the sale or complete or substantially complete liquidation of the subsidiary the company excludes certain portion of the change in fair value of it derivative of contentsinstruments from the assessment of hedge effectiveness excluded component change in fair value of the excluded component are recognized in oci the company recognizes in earnings the initial value of the excluded component on straight line basis over the life of the derivative instrument rather than using the mark to market approach the cash flow from these contract are reported investing activity in the consolidated statement of cash flow foreign exchange risk is also managed through the use of foreign currency debt the company senior unsecured euro denominated note have been designated and are effective economic hedge of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument are included in foreign currency translation adjustment within oci interest rate risk managementthe company may use interest rate swap contract on certain investing and borrowing transaction to manage it net exposure to interest rate change and to reduce it overall cost of borrowing the company doe not use leveraged swap and in general doe not leverage any of it investment activity that would put principal capital at risk at december the company wa party to pay floating receive fixed interest rate swap contract designated fair value hedge of fixed rate note in which the notional amount match the amount of the hedged fixed rate note detailed in the table below in million instrumentpar value of debtnumber of interest rate swap heldtotal swap notional note due note due note due these interest rate swap matured in january the interest rate swap contract are designated hedge of the fair value change in the note attributable to change in the benchmark london interbank offered rate libor swap rate the fair value change in the note attributable to change in the libor swap rate are recorded in interest expense along with the offsetting fair value change in the swap contract the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the company investment portfolio includes cash equivalent and short term investment the market value of which are not significantly affected by change in interest rate the market value of the company medium to long term fixed rate investment is modestly affected by change in interest rate change in medium to long term interest rate have more significant impact on the market value of the company fixed rate borrowing which generally have longer maturity sensitivity analysis to measure potential change in the market value of merck investment and debt from change in interest rate indicated that one percentage point increase in interest rate at december and would have positively affected the net aggregate market value of these instrument by billion and billion respectively one percentage point decrease at december and would have negatively affected the net aggregate market value by billion and billion respectively the fair value of merck debt wa determined using pricing model reflecting one percentage point shift in the appropriate yield curve the fair value of merck investment were determined using combination of pricing and duration model critical accounting estimatesthe company consolidated financial statement are prepared in conformity with gaap and accordingly include certain amount that are based on management best estimate and judgment estimate are used when accounting for amount recorded in connection with acquisition including initial fair value determination of asset and liability primarily ipr other intangible asset and contingent consideration well subsequent fair value measurement additionally estimate are used in determining such item provision for sale discount and return depreciable and amortizable life recoverability of inventory including of contentsthose produced in preparation for product launch amount recorded for contingency environmental liability accrual for contingent sale based milestone payment and other reserve pension and other postretirement benefit plan assumption share based compensation assumption restructuring cost impairment of long lived asset including intangible asset and goodwill and investment and tax on income because of the uncertainty inherent in such estimate actual result may differ from these estimate application of the following accounting policy result in accounting estimate having the potential for the most significant impact on the financial statement acquisition and dispositionsto determine whether transaction should be accounted for acquisition or disposal of asset or business the company make certain judgment which include assessment of the input process and output associated with the acquired set of activity if the company determines that substantially all of the fair value of gross asset included in transaction is concentrated in single asset or group of similar asset the asset would not represent business to be considered business the asset in transaction need to include an input and substantive process that together significantly contribute to the ability to create output in business combination the acquisition method of accounting requires that the asset acquired and liability assumed be recorded of the date of the acquisition at their respective fair value with limited exception asset acquired and liability assumed in business combination that arise from contingency are generally recognized at fair value if fair value can not be determined the asset or liability is recognized if probable and reasonably estimable if these criterion are not met no asset or liability is recognized fair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date accordingly the company may be required to value asset at fair value measure that do not reflect the company intended use of those asset any excess of the purchase price consideration transferred over the estimated fair value of net asset acquired is recorded goodwill transaction cost and cost to restructure the acquired company are expensed incurred the operating result of the acquired business are reflected in the company consolidated financial statement after the date of the acquisition the fair value of intangible asset including acquired ipr are determined utilizing information available near the acquisition date based on expectation and assumption that are deemed reasonable by management given the considerable judgment involved in determining fair value the company typically obtains assistance from third party valuation specialist for significant item amount allocated to acquired ipr are capitalized and accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each project merck will make determination to the then useful life of the intangible asset generally determined by the period in which the substantial majority of the cash flow are expected to be generated and begin amortization certain of the company business acquisition involve the potential for future payment of consideration that is contingent upon the achievement of performance milestone including product development milestone and royalty payment on future product sale the fair value of contingent consideration liability is determined at the acquisition date using unobservable input these input include the estimated amount and timing of projected cash flow the probability of success achievement of the contingent event and the risk adjusted discount rate used to present value the probability weighted cash flow subsequent to the acquisition date at each reporting period until the contingency is resolved the contingent consideration liability is remeasured at current fair value with change either expense or income recorded in earnings change in any of the input may result in significantly different fair value adjustment the judgment made in determining estimated fair value assigned to asset acquired and liability assumed in business combination well asset life can materially affect the company result of operation the fair value of identifiable intangible asset related to currently marketed product and product right are primarily determined by using an income approach through which fair value is estimated based on each asset discounted projected net cash flow the company estimate of market participant net cash flow consider historical and projected pricing margin and expense level the performance of competing product where applicable relevant industry and therapeutic area growth driver and factor current and expected trend in technology and product life cycle the time and investment that will be required to develop product and technology the ability to obtain marketing and regulatory approval the ability to manufacture and commercialize of contentsthe product the extent and timing of potential new product introduction by the company competitor and the life of each asset underlying patent if any the net cash flow are then probability adjusted where appropriate to consider the uncertainty associated with the underlying assumption well the risk profile of the net cash flow utilized in the valuation the probability adjusted future net cash flow of each product are then discounted to present value utilizing an appropriate discount rate the fair value of identifiable intangible asset related to ipr are also determined using an income approach through which fair value is estimated based on each asset probability adjusted future net cash flow which reflect the different stage of development of each product and the associated probability of successful completion the net cash flow are then discounted to present value using an appropriate discount rate if the company determines the transaction will not be accounted for an acquisition of business the transaction will be accounted for an asset acquisition rather than business combination and therefore no goodwill will be recorded in an asset acquisition acquired ipr with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date in these instance product development milestone are recognized upon achievement and sale based milestone are recognized when the milestone is deemed probable by the company of being achieved revenue recognitionrecognition of revenue requires evidence of contract probable collection of sale proceeds and completion of substantially all performance obligation merck act the principal in substantially all of it customer arrangement and therefore record revenue on gross basis the majority of the company contract related to the pharmaceutical and animal health segment have single performance obligation the promise to transfer good shipping is considered immaterial in the context of the overall customer arrangement and damage or loss of good in transit are rare therefore shipping is not deemed separately recognized performance obligation the vast majority of revenue from sale of product are recognized at point in time when control of the good is transferred to the customer which the company ha determined is when title and risk and reward of ownership transfer to the customer and the company is entitled to payment for certain service in the animal health segment revenue is recognized over time generally ratably over the contract term service are provided these service revenue are not material the nature of the company business give rise to several type of variable consideration including discount and return which are estimated at the time of sale generally using the expected value method although the most likely amount method is used for prompt pay discount in the united state sale discount are issued to customer at the point of sale through an intermediary wholesaler known chargebacks or in the form of rebate additionally sale are generally made with limited right of return under certain condition revenue are recorded net of provision for sale discount and return which are established at the time of sale in addition revenue are recorded net of time value of money discount if collection of account receivable is expected to be in excess of one year the provision for aggregate customer discount cover chargebacks and rebate chargebacks are discount that occur when contracted customer purchase through an intermediary wholesaler the contracted customer generally purchase product from the wholesaler at it contracted price plus mark up the wholesaler in turn charge the company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer the provision for chargebacks is based on expected sell through level by the company wholesale customer to contracted customer well estimated wholesaler inventory level rebate are amount owed based upon definitive contractual agreement or legal requirement with private sector and public sector medicaid and medicare part benefit provider after the final dispensing of the product by pharmacy to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider the company us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision amount accrued for aggregate customer discount are evaluated on quarterly of contentsbasis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued the company continually monitor it provision for aggregate customer discount there were no material adjustment to estimate associated with the aggregate customer discount provision in or summarized information about change in the aggregate customer discount accrual related to sale is follows in million january current adjustment to prior year payment balance december accrual for chargebacks are reflected direct reduction to account receivable and accrual for rebate current liability the accrued balance relative to these provision included in account receivable and accrued and other current liability were million and billion respectively at december and were million and billion respectively at december outside of the united state variable consideration in the form of discount and rebate are combination of commercially driven discount in highly competitive product class discount required to gain or maintain reimbursement or legislatively mandated rebate in certain european country legislatively mandated rebate are calculated based on an estimate of the government total unbudgeted spending and the company specific payback obligation rebate may also be required based on specific product sale threshold the company applies an estimated factor against it actual invoiced sale to represent the expected level of future discount or rebate obligation associated with the sale the company maintains return policy that allows it pharmaceutical customer to return product within specified period prior to and subsequent to the expiration date generally three to six month before and month after product expiration the estimate of the provision for return is based upon historical experience with actual return additionally the company considers factor such level of inventory in the distribution channel product dating and expiration period whether product have been discontinued entrance in the market of generic competition change in formulary or launch of over the counter product among others the product return provision for pharmaceutical sale percentage of net pharmaceutical sale wa in in and in outside of the united state return are only allowed in certain country on limited basis merck payment term for pharmaceutical customer are typically day from receipt of invoice and for animal health customer are typically day from receipt of invoice however certain product including keytruda have longer payment term some of which are up to day outside of the united state payment term are typically day to day although certain market have longer payment term through it distribution program with wholesaler the company encourages wholesaler to align purchase with underlying demand and maintain inventory below specified level the term of the program allow the wholesaler to earn fee upon providing visibility into their inventory level well by achieving certain performance parameter such inventory management customer service level reducing shortage claim and reducing product return information provided through the wholesaler distribution program includes item such sale trend inventory on hand on order quantity and product return wholesaler generally provide only the above mentioned data to the company there is no regulatory requirement to report lot level information to manufacturer which is the level of information needed to determine the remaining shelf life and original sale date of inventory given current wholesaler inventory level which are generally le than month the company belief that collection of order lot information across all wholesale customer would have limited use in estimating sale discount and return of contentsinventories produced in preparation for product launchesthe company capitalizes inventory produced in preparation for product launch sufficient to support estimated initial market demand typically capitalization of such inventory doe not begin until the related product candidate are in phase clinical trial and are considered to have high probability of regulatory approval the company monitor the status of each respective product within the regulatory approval process however the company generally doe not disclose specific timing for regulatory approval if the company is aware of any specific risk or contingency other than the normal regulatory approval process or if there are any specific issue identified during the research process relating to safety efficacy manufacturing marketing or labeling the related inventory would generally not be capitalized expiry date of the inventory are affected by the stage of completion the company manages the level of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issue for inventory that are capitalized anticipated future sale and shelf life support the realization of the inventory value the inventory shelf life is sufficient to meet initial product launch requirement inventory produced in preparation for product launch capitalized at december and were million and million respectively contingency and environmental liabilitiesthe company is involved in various claim and legal proceeding of nature considered normal to it business including product liability intellectual property and commercial litigation well certain additional matter including governmental and environmental matter see note to the consolidated financial statement the company record accrual for contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated these accrual are adjusted periodically assessment change or additional information becomes available for product liability claim portion of the overall accrual is actuarially determined and considers such factor past experience number of claim reported and estimate of claim incurred but not yet reported individually significant contingent loss are accrued when probable and reasonably estimable legal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable some of the significant factor considered in the review of these legal defense reserve are follows the actual cost incurred by the company the development of the company legal defense strategy and structure in light of the scope of it litigation the number of case being brought against the company the cost and outcome of completed trial and the most current information regarding anticipated timing progression and related cost of pre trial activity and trial in the associated litigation the amount of legal defense reserve of december and of approximately million and million respectively represents the company best estimate of the minimum amount of defense cost to be incurred in connection with it outstanding litigation however event such additional trial and other event that could arise in the course of it litigation could affect the ultimate amount of legal defense cost to be incurred by the company the company will continue to monitor it legal defense cost and review the adequacy of the associated reserve and may determine to increase the reserve at any time in the future if based upon the factor set forth it belief it would be appropriate to do so the company and it subsidiary are party to number of proceeding brought under the comprehensive environmental response compensation and liability act commonly known superfund and other federal and state equivalent when legitimate claim for contribution is asserted liability is initially accrued based upon the estimated transaction cost to manage the site accrual are adjusted site investigation feasibility study and related cost assessment of remedial technique are completed and the extent to which other potentially responsible party who may be jointly and severally liable can be expected to contribute is determined the company is also remediating environmental contamination resulting from past industrial activity at certain of it site and take an active role in identifying and accruing for these cost in the past merck performed worldwide survey to ass all site for potential contamination resulting from past industrial activity where assessment indicated that physical investigation wa warranted such investigation wa performed providing better evaluation of the need for remedial action where such need wa identified remedial action wa then initiated definitive information became available during the course of investigation and or remedial effort at each site estimate were refined and accrual were established or adjusted accordingly these estimate and related accrual continue to be refined annually of contentsthe company belief that there are no compliance issue associated with applicable environmental law and regulation that would have material adverse effect on the company expenditure for remediation and environmental liability were million in and are estimated at million in the aggregate for the year through in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million at both december and these liability are undiscounted do not consider potential recovery from other party and will be paid out over the period of remediation for the applicable site which are expected to occur primarily over the next year although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed approximately million in the aggregate management also doe not believe that these expenditure should result in material adverse effect on the company financial condition result of operation or liquidity for any year share based compensationthe company expense all share based payment award to employee including grant of stock option over the requisite service period based on the grant date fair value of the award the company determines the fair value of certain share based award using the black scholes option pricing model which us both historical and current market data to estimate the fair value this method incorporates various assumption such the risk free interest rate expected volatility expected dividend yield and expected life of the option total pretax share based compensation expense wa million in million in and million in at december there wa million of total pretax unrecognized compensation expense related to nonvested stock option restricted stock unit and performance share unit award which will be recognized over weighted average period of year for segment reporting share based compensation cost are unallocated expense pension and other postretirement benefit plansnet periodic benefit cost for pension plan totaled million in million in and million in net periodic benefit credit for other postretirement benefit plan wa million in million in and million in pension and other postretirement benefit plan information for financial reporting purpose is calculated using actuarial assumption including discount rate for plan benefit obligation and an expected rate of return on plan asset the change in net periodic benefit cost year over year for pension plan are largely attributable to change in the discount rate affecting net loss amortization the company reassesses it benefit plan assumption on regular basis for both the pension and other postretirement benefit plan the discount rate is evaluated on measurement date and modified to reflect the prevailing market rate of portfolio of high quality fixed income debt instrument that would provide the future cash flow needed to pay the benefit included in the benefit obligation they come due the discount rate for the company pension and other postretirement benefit plan ranged from to at december compared with range of to at december the expected rate of return for both the pension and other postretirement benefit plan represents the average rate of return to be earned on plan asset over the period the benefit included in the benefit obligation are to be paid in developing the expected rate of return the company considers long term compound annualized return of historical market data current market condition and actual return on the company plan asset using this reference information the company develops forward looking return expectation for each asset category and weighted average expected long term rate of return for target portfolio allocated across these investment category the expected portfolio performance reflects the contribution of active management appropriate for the expected rate of return for the company pension and other postretirement benefit plan will range from to compared to range of to in the company ha established investment guideline for it pension and other postretirement plan to create an asset allocation that is expected to deliver rate of return sufficient to meet the long term obligation of each plan given an acceptable level of risk the target investment portfolio of the company pension and other postretirement benefit plan is allocated to in equity to in international equity to in fixed income investment and up to in cash and other investment the portfolio equity weighting is consistent with the long term nature of the plan benefit obligation the expected annual standard of contentsdeviation of return of the target portfolio which approximates reflects both the equity allocation and the diversification benefit among the asset class in which the portfolio invests for non pension plan the targeted investment portfolio varies based on the duration of pension liability and local government rule and regulation although significant percentage of plan asset are invested in equity concentration risk is mitigated through the use of strategy that are diversified within management guideline actuarial assumption are based upon management best estimate and judgment reasonably possible change of plus minus basis point in the discount rate assumption with other assumption held constant would have had an estimated million favorable unfavorable impact on the company net periodic benefit cost in reasonably possible change of plus minus basis point in the expected rate of return assumption with other assumption held constant would have had an estimated million favorable unfavorable impact on merck net periodic benefit cost in required funding obligation for relating to the company pension and other postretirement benefit plan are not expected to be material the preceding hypothetical change in the discount rate and expected rate of return assumption would not impact the company funding requirement net loss amount which primarily reflect difference between expected and actual return on plan asset well the effect of change in actuarial assumption are recorded component of aoci expected return for pension plan are based on calculated market related value of asset net loss amount in aoci in excess of certain threshold are amortized into net periodic benefit cost over the average remaining service life of employee restructuring costsrestructuring cost have been recorded in connection with restructuring program designed to streamline the company cost structure result the company ha made estimate and judgment regarding it future plan including future termination benefit and other exit cost to be incurred when the restructuring action take place when accruing termination cost the company will recognize the amount within range of cost that is the best estimate within the range when no amount within the range is better estimate than any other amount the company recognizes the minimum amount within the range in connection with these action management also ass the recoverability of long lived asset employed in the business in certain instance asset life have been shortened based on change in the expected useful life of the affected asset severance and other related cost are reflected within restructuring cost asset related charge are reflected within cost of sale selling general and administrative expense and research and development expense depending upon the nature of the asset impairment of long lived assetsthe company ass change in economic regulatory and legal condition and make assumption regarding estimated future cash flow in evaluating the value of the company property plant and equipment goodwill and other intangible asset the company periodically evaluates whether current fact or circumstance indicate that the carrying value of it long lived asset to be held and used may not be recoverable if such circumstance are determined to exist an estimate of the undiscounted future cash flow of these asset or appropriate asset grouping is compared to the carrying value to determine whether an impairment exists if the asset is determined to be impaired the loss is measured based on the difference between the asset fair value and it carrying value if quoted market price are not available the company will estimate fair value using discounted value of estimated future cash flow approach goodwill represents the excess of the consideration transferred over the fair value of net asset of business acquired goodwill is assigned to reporting unit and evaluated for impairment on at least an annual basis or more frequently if impairment indicator exist by first assessing qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount some of the factor considered in the assessment include general macroeconomic condition condition specific to the industry and market cost factor which could have significant effect on earnings or cash flow the overall financial performance of the reporting unit and whether there have been sustained decline in the company share price if the company concludes it is more likely than not that the fair value of reporting unit is le than it carrying amount quantitative fair value test is performed if the carrying value of reporting unit is greater than it fair value goodwill impairment charge will be recorded for the difference up to the carrying value of goodwill of contentsother acquired intangible asset excluding ipr are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life when event or circumstance warrant review the company will ass recoverability from future operation using pretax undiscounted cash flow derived from the lowest appropriate asset grouping impairment are recognized in operating result to the extent that the carrying value of the intangible asset exceeds it fair value which is determined based on the net present value of estimated future cash flow ipr that the company acquires in conjunction with the acquisition of business represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility the amount are capitalized and accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project the company evaluates ipr for impairment at least annually or more frequently if impairment indicator exist by performing quantitative test that compare the fair value of the ipr intangible asset with it carrying value for impairment testing purpose the company may combine separately recorded ipr intangible asset into one unit of account based on the relevant fact and circumstance generally the company will combine ipr intangible asset for testing purpose if they operate single asset and are essentially inseparable if the fair value is le than the carrying amount an impairment loss is recognized in operating result the judgment made in evaluating impairment of long lived intangible can materially affect the company result of operation impairment of investmentsthe company review it investment in marketable debt security for impairment based on the determination of whether the decline in market value of the investment below the carrying value is other than temporary the company considers available evidence in evaluating potential impairment of it investment in marketable debt security including the duration and extent to which fair value is le than cost change in fair value that are considered temporary are reported net of tax in oci an other than temporary impairment ha occurred if the company doe not expect to recover the entire amortized cost basis of the marketable debt security if the company doe not intend to sell the impaired debt security and it is not more likely than not it will be required to sell the debt security before the recovery of it amortized cost basis the amount of the other than temporary impairment recognized in earnings recorded in other income expense net is limited to the portion attributed to credit loss the remaining portion of the other than temporary impairment related to other factor is recognized in oci investment in publicly traded equity security are reported at fair value determined using quoted market price in active market for identical asset or quoted price for similar asset or other input that are observable or can be corroborated by observable market data change in fair value are included in other income expense net investment in equity security without readily determinable fair value are recorded at cost plus or minus subsequent observable price change in orderly transaction for identical or similar investment minus impairment such adjustment are recognized in other income expense net realized gain and loss for equity security are included in other income expense net tax on incomethe company effective tax rate is based on pretax income statutory tax rate and tax planning opportunity available in the various jurisdiction in which the company operates an estimated effective tax rate for year is applied to the company quarterly operating result in the event that there is significant unusual or one time item recognized or expected to be recognized in the company quarterly operating result the tax attributable to that item would be separately calculated and recorded at the same time the unusual or one time item the company considers the resolution of prior year tax matter to be such item significant judgment is required in determining the company tax provision and in evaluating it tax position the recognition and measurement of tax position is based on management best judgment given the fact circumstance and information available at the reporting date the company evaluates tax position to determine whether the benefit of tax position are more likely than not of being sustained upon audit based on the technical merit of the tax position for tax position that are more likely than not of being sustained upon audit the company recognizes the largest amount of the benefit that is greater than likely of being realized upon ultimate settlement in the of contentsfinancial statement for tax position that are not more likely than not of being sustained upon audit the company doe not recognize any portion of the benefit in the financial statement if the more likely than not threshold is not met in the period for which tax position is taken the company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled the statute of limitation expires or if the more likely than not threshold is met in subsequent period see note to the consolidated financial statement tax regulation require item to be included in the tax return at different time than the item are reflected in the financial statement timing difference create deferred tax asset and liability deferred tax asset generally represent item that can be used tax deduction or credit in the tax return in future year for which the company ha already recorded the tax benefit in the financial statement the company establishes valuation allowance for it deferred tax asset when the amount of expected future taxable income is not likely to support the use of the deduction or credit deferred tax liability generally represent tax expense recognized in the financial statement for which payment ha been deferred or expense for which the company ha already taken deduction on the tax return but ha not yet recognized expense in the financial statement recently issued accounting standardsfor discussion of recently issued accounting standard see note to the consolidated financial statement cautionary factor that may affect future resultsthis report and other written report and oral statement made from time to time by the company may contain so called forward looking statement all of which are based on management current expectation and are subject to risk and uncertainty which may cause result to differ materially from those set forth in the statement one can identify these forward looking statement by their use of word such anticipates expects plan will estimate forecast project and other word of similar meaning or negative variation of any of the foregoing one can also identify them by the fact that they do not relate strictly to historical or current fact these statement are likely to address the company growth strategy financial result product approval product potential development program and include statement related to the expected impact of the covid pandemic one must carefully consider any such statement and should understand that many factor could cause actual result to differ materially from the company forward looking statement these factor include inaccurate assumption and broad variety of other risk and uncertainty including some that are known and some that are not no forward looking statement can be guaranteed and actual future result may vary materially the company doe not assume the obligation to update any forward looking statement one should carefully evaluate such statement in light of factor including risk factor described in the company filing with the security and exchange commission especially on this form and form and in item risk factor of this annual report on form the company discus in more detail various important risk factor that could cause actual result to differ from expected or historic result the company note these factor for investor permitted by the private security litigation reform act of one should understand that it is not possible to predict or identify all such factor consequently the reader should not consider any such list to be complete statement of all potential risk or uncertainty item quantitative and qualitative disclosure about market risk the information required by this item is incorporated by reference to the discussion under financial instrument market risk disclosure in item management discussion and analysis of financial condition and result of operation of contentsitem financial statement and supplementary data financial statementsthe consolidated balance sheet of merck co inc and subsidiary of december and and the related consolidated statement of income of comprehensive income of equity and of cash flow for each of the three year in the period ended december the note to consolidated financial statement and the report dated february of pricewaterhousecoopers llp independent registered public accounting firm are follows consolidated statement of incomemerck co inc and subsidiariesyears ended december in million except per share amount cost expense and othercost of selling general and research and restructuring other income expense net income before tax on net le net income loss attributable to noncontrolling net income attributable to merck co inc basic earnings per common share attributable to merck co inc common shareholder earnings per common share assuming dilution attributable to merck co inc common shareholder consolidated statement of comprehensive incomemerck co inc and subsidiariesyears ended december in million income attributable to merck co inc other comprehensive loss net of tax net unrealized loss gain on derivative net of reclassification net unrealized loss gain on investment net of reclassification benefit plan net loss gain and prior service cost credit net of amortization cumulative translation comprehensive income attributable to merck co inc the accompanying note are an integral part of these consolidated financial statement of contentsconsolidated balance sheetmerck co inc and subsidiariesdecember in million except per share amount assetscash and cash equivalent short term investment account receivable net of allowance for doubtful account of in in inventory excludes inventory of in and in in other asset see note other current total current property plant and equipment at cost machinery equipment and office construction in le accumulated other intangible other liability and equitycurrent liabilitiesloans payable and current portion of long term debt trade account accrued and other current income tax dividend total current long term deferred income other noncurrent merck co inc stockholder equitycommon stock par valueauthorized sharesissued share in and other paid in retained accumulated other comprehensive loss le treasury stock at cost share in and share in total merck co inc stockholder noncontrolling total the accompanying note are an integral part of this consolidated financial statement of contentsconsolidated statement of equitymerck co inc and subsidiariesyears ended december in million except per share amount commonstockotherpaid incapitalretainedearningsaccumulatedothercomprehensivelosstreasurystocknon controllingintereststotalbalance january net income attributable to merck co inc adoption of new accounting standard other comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net loss attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other balance december net income attributable to merck co inc other comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net loss attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other balance december net income attributable to merck co inc other comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net income attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other balance december the accompanying note are an integral part of this consolidated financial statement of contentsconsolidated statement of cash flowsmerck co inc and subsidiariesyears ended december in million flow from operating activitiesnet income adjustment to reconcile net income to net cash provided by operating activity intangible asset impairment charge for the acquisition of velosbio inc charge for the acquisition of peloton therapeutic inc charge for future payment related to collaboration license option deferred income tax share based other net change in asset and liability account receivable inventory trade account accrued and other current liability income tax noncurrent liability other net cash provided by operating cash flow from investing activitiescapital expenditure purchase of seagen inc common stock purchase of security and other investment proceeds from sale of security and other acquisition of velosbio inc net of cash acquired acquisition of arqule inc net of cash acquired acquisition of antelliq corporation net of cash acquired acquisition of peloton therapeutic inc net of cash acquired other acquisition net of cash acquired net cash used in provided by investing activity cash flow from financing activitiesnet change in short term payment on debt proceeds from issuance of purchase of treasury stock dividend paid to stockholder proceeds from exercise of stock other net cash used in financing activity effect of exchange rate change on cash cash equivalent and restricted net decrease increase in cash cash equivalent and restricted cash cash cash equivalent and restricted cash at beginning of year includes of restricted cash at january included in other asset see note cash cash equivalent and restricted cash at end of year includes of restricted cash at december included in other asset see note the accompanying note are an integral part of this consolidated financial statement of contentsnotes to consolidated financial statementsmerck co inc and subsidiary in million except per share amount nature of operationsmerck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously had healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment in the first quarter of the company previously had an alliance segment that primarily included activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in planned spin off of woman health biosimilars and established brand into new company in february merck announced it intention to spin off product from it woman health biosimilars and established brand business into new independent publicly traded company named organon co organon through distribution of organon publicly traded stock to company shareholder the distribution is expected to qualify tax free to the company and it shareholder for federal income tax purpose the established brand included in the transaction consist of dermatology non opioid pain management respiratory and select cardiovascular product including zetia and vytorin well the rest of merck diversified brand franchise merck existing research pipeline program will continue to be owned and developed within merck planned organon will have development capability initially focused on late stage development and life cycle management and is expected over time to develop research capability in selected therapeutic area the spin off is expected to be completed late in the second quarter of subject to market and certain other condition subsequent to the spin off the historical result of the woman health biosimilars and established brand business will be reflected discontinued operation in the company consolidated financial statement summary of accounting policiesprinciples of consolidation the consolidated financial statement include the account of the company and all of it subsidiary in which controlling interest is maintained intercompany balance and transaction are eliminated controlling interest is determined by majority ownership interest and the absence of substantive third party participating right or in the case of variable interest entity by majority exposure to expected loss residual return or both for those consolidated subsidiary where merck ownership is le than the outside shareholder interest are shown noncontrolling interest in equity investment in affiliate of contentsover which the company ha significant influence but not controlling interest such interest in entity owned equally by the company and third party that are under shared control are carried on the equity basis acquisition in business combination the acquisition method of accounting requires that the asset acquired and liability assumed be recorded of the date of the acquisition at their respective fair value with limited exception asset acquired and liability assumed in business combination that arise from contingency are generally recognized at fair value if fair value can not be determined the asset or liability is recognized if probable and reasonably estimable if these criterion are not met no asset or liability is recognized fair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date accordingly the company may be required to value asset at fair value measure that do not reflect the company intended use of those asset any excess of the purchase price consideration transferred over the estimated fair value of net asset acquired is recorded goodwill transaction cost and cost to restructure the acquired company are expensed incurred the operating result of the acquired business are reflected in the company consolidated financial statement after the date of the acquisition if the company determines the asset acquired do not meet the definition of business under the acquisition method of accounting the transaction will be accounted for an acquisition of asset rather than business combination and therefore no goodwill will be recorded in an asset acquisition acquired in process research and development ipr with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date foreign currency translation the net asset of international subsidiary where the local currency have been determined to be the functional currency are translated into dollar using current exchange rate the dollar effect that arise from translating the net asset of these subsidiary at changing rate are recorded in the foreign currency translation account which is included in accumulated other comprehensive income loss aoci and reflected separate component of equity for those subsidiary that operate in highly inflationary economy and for those subsidiary where the dollar ha been determined to be the functional currency non monetary foreign currency asset and liability are translated using historical rate while monetary asset and liability are translated at current rate with the dollar effect of rate change included in other income expense net cash equivalent cash equivalent are comprised of certain highly liquid investment with original maturity of le than three month inventory inventory are valued at the lower of cost or net realizable value the cost of substantial majority of pharmaceutical and vaccine inventory is determined using the last in first out lifo method for both financial reporting and tax purpose the cost of all other inventory is determined using the first in first out fifo method inventory consist of currently marketed product well certain inventory produced in preparation for product launch that are considered to have high probability of regulatory approval in evaluating the recoverability of inventory produced in preparation for product launch the company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process investment investment in marketable debt security classified available for sale are reported at fair value fair value of the company investment in marketable debt security are determined using quoted market price in active market for identical asset or liability or quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability change in fair value that are considered temporary are reported net of tax in other comprehensive income oci the company considers available evidence in evaluating potential impairment of it investment in marketable debt security including the duration and extent to which fair value is le than cost an other than temporary impairment ha occurred if the company doe not expect to recover the entire amortized cost basis of the marketable debt security if the company doe not intend to sell the impaired debt security and it is not more likely than not it will be required to sell the debt security before the recovery of it amortized cost basis the amount of the other than temporary impairment recognized in earnings recorded in other income expense net is limited to the portion attributed to credit loss the remaining portion of the other than temporary impairment related of contentsto other factor is recognized in oci realized gain and loss for debt security are included in other income expense net investment in publicly traded equity security are reported at fair value determined using quoted market price in active market for identical asset or quoted price for similar asset or other input that are observable or can be corroborated by observable market data change in fair value are included in other income expense net investment in equity security without readily determinable fair value are recorded at cost plus or minus subsequent observable price change in orderly transaction for identical or similar investment minus impairment such adjustment are recognized in other income expense net realized gain and loss for equity security are included in other income expense net revenue recognition recognition of revenue requires evidence of contract probable collection of sale proceeds and completion of substantially all performance obligation merck act the principal in substantially all of it customer arrangement and therefore record revenue on gross basis the majority of the company contract related to the pharmaceutical and animal health segment have single performance obligation the promise to transfer good shipping is considered immaterial in the context of the overall customer arrangement and damage or loss of good in transit are rare therefore shipping is not deemed separately recognized performance obligation the vast majority of revenue from sale of product are recognized at point in time when control of the good is transferred to the customer which the company ha determined is when title and risk and reward of ownership transfer to the customer and the company is entitled to payment the company recognizes revenue from the sale of vaccine to the federal government for placement into vaccine stockpile in accordance with security and exchange commission sec interpretation commission guidance regarding accounting for sale of vaccine and bioterror countermeasure to the federal government for placement into the pediatric vaccine stockpile or the strategic national stockpile this interpretation allows company to recognize revenue for sale of vaccine into government stockpile even though these sale might not meet the criterion for revenue recognition under other accounting guidance for certain service in the animal health segment revenue is recognized over time generally ratably over the contract term service are provided these service revenue are not material the nature of the company business give rise to several type of variable consideration including discount and return which are estimated at the time of sale generally using the expected value method although the most likely amount method is used for prompt pay discount in the united state sale discount are issued to customer at the point of sale through an intermediary wholesaler known chargebacks or in the form of rebate additionally sale are generally made with limited right of return under certain condition revenue are recorded net of provision for sale discount and return which are established at the time of sale in addition revenue are recorded net of time value of money discount if collection of account receivable is expected to be in excess of one year the provision for aggregate customer discount covering chargebacks and rebate wa billion in billion in and billion in chargebacks are discount that occur when contracted customer purchase through an intermediary wholesaler the contracted customer generally purchase product from the wholesaler at it contracted price plus mark up the wholesaler in turn charge the company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer the provision for chargebacks is based on expected sell through level by the company wholesale customer to contracted customer well estimated wholesaler inventory level rebate are amount owed based upon definitive contractual agreement or legal requirement with private sector and public sector medicaid and medicare part benefit provider after the final dispensing of the product by pharmacy to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider the company us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision amount accrued for aggregate customer discount are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued the accrued balance relative to the provision for chargebacks and rebate included in account receivable and accrued and other current liability were of contentsmillion and billion respectively at december and were million and billion respectively at december outside of the united state variable consideration in the form of discount and rebate are combination of commercially driven discount in highly competitive product class discount required to gain or maintain reimbursement or legislatively mandated rebate in certain european country legislatively mandated rebate are calculated based on an estimate of the government total unbudgeted spending and the company specific payback obligation rebate may also be required based on specific product sale threshold the company applies an estimated factor against it actual invoiced sale to represent the expected level of future discount or rebate obligation associated with the sale the company maintains return policy that allows it pharmaceutical customer to return product within specified period prior to and subsequent to the expiration date generally three to six month before and month after product expiration the estimate of the provision for return is based upon historical experience with actual return additionally the company considers factor such level of inventory in the distribution channel product dating and expiration period whether product have been discontinued entrance in the market of generic competition change in formulary or launch of over the counter product among others outside of the united state return are only allowed in certain country on limited basis merck payment term for pharmaceutical customer are typically day from receipt of invoice and for animal health customer are typically day from receipt of invoice however certain product including keytruda have longer payment term some of which are up to day outside of the united state payment term are typically day to day although certain market have longer payment term see note for disaggregated revenue disclosure depreciation depreciation is provided over the estimated useful life of the asset principally using the straight line method for tax purpose accelerated tax method are used the estimated useful life primarily range from to year for building and from to year for machinery equipment and office furnishing depreciation expense wa billion in billion in and billion in advertising and promotion cost advertising and promotion cost are expensed incurred the company recorded advertising and promotion expense of billion in billion in and billion in software capitalization the company capitalizes certain cost incurred in connection with obtaining or developing internal use software including external direct cost of material and service and payroll cost for employee directly involved with the software development these cost are included in property plant and equipment in addition the company capitalizes certain cost incurred to implement cloud computing arrangement that is considered service agreement which are included in other asset capitalized software cost are being amortized over period ranging from to year with the longer life generally associated with enterprise wide project implemented over multiple year cost incurred during the preliminary project stage and post implementation stage well maintenance and training cost are expensed incurred goodwill goodwill represents the excess of the consideration transferred over the fair value of net asset of business acquired goodwill is assigned to reporting unit and evaluated for impairment on at least an annual basis or more frequently if impairment indicator exist by first assessing qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount if the company concludes it is more likely than not that the fair value of reporting unit is le than it carrying amount quantitative fair value test is performed if the carrying value of reporting unit is greater than it fair value goodwill impairment charge will be recorded for the difference up to the carrying value of goodwill acquired intangible acquired intangible include product and product right license trade name and patent which are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life ranging from to year see note the company periodically evaluates whether current fact or circumstance indicate that the carrying value of it acquired intangible may not be recoverable if such circumstance are determined to exist an estimate of the undiscounted of contentsfuture cash flow of these asset or appropriate asset grouping is compared to the carrying value to determine whether an impairment exists if the asset is determined to be impaired the loss is measured based on the difference between the carrying value of the intangible asset and it fair value which is determined based on the net present value of estimated future cash flow acquired in process research and development ipr that the company acquires in conjunction with the acquisition of business represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility the amount are capitalized and are accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each project merck will make determination to the then useful life of the intangible asset generally determined by the period in which the substantial majority of the cash flow are expected to be generated and begin amortization the company evaluates ipr for impairment at least annually or more frequently if impairment indicator exist by performing quantitative test that compare the fair value of the ipr intangible asset with it carrying value if the fair value is le than the carrying amount an impairment loss is recognized in operating result contingent consideration certain of the company acquisition involve the potential for future payment of consideration that is contingent upon the achievement of performance milestone including product development milestone and royalty payment on future product sale if the transaction is accounted for an acquisition of business the fair value of contingent consideration liability is determined at the acquisition date using unobservable input these input include the estimated amount and timing of projected cash flow the probability of success achievement of the contingent event and the risk adjusted discount rate used to present value the probability weighted cash flow subsequent to the acquisition date at each reporting period until the contingency is resolved the contingent consideration liability is remeasured at current fair value with change either expense or income recorded in earnings significant event that increase or decrease the probability of achieving development and regulatory milestone or that increase or decrease projected cash flow will result in corresponding increase or decrease in the fair value of the related contingent consideration obligation if the transaction is accounted for an acquisition of an asset rather than business contingent consideration is not recognized at the acquisition date in these instance product development milestone are recognized upon achievement and sale based milestone are recognized when the milestone is deemed probable by the company of being achieved research and development research and development is expensed incurred nonrefundable advance payment for good and service that will be used in future research and development activity are expensed when the activity ha been performed or when the good have been received rather than when the payment is made research and development expense include restructuring cost and ipr impairment charge in addition research and development expense include expense or income related to change in the estimated fair value measurement of liability for contingent consideration research and development expense also include upfront and milestone payment related to asset acquisition and licensing transaction involving clinical development program that have not yet received regulatory approval collaborative arrangement merck ha entered into collaborative arrangement that provide the company with varying right to develop produce and market product together with it collaborative partner when merck is the principal on sale transaction with third party the company recognizes sale cost of sale and selling general and administrative expense on gross basis profit sharing amount it pay to it collaborative partner are recorded within cost of sale when the collaborative partner is the principal on sale transaction with third party the company record profit sharing amount received from it collaborative partner alliance revenue within sale alliance revenue is recorded net of cost of sale and includes an adjustment to share commercialization cost between the partner in accordance with the collaboration agreement the adjustment is determined by comparing the commercialization cost merck ha incurred directly and reported within selling general and administrative expense with the cost the collaborative partner ha incurred research and development cost merck incurs related to collaboration are recorded within research and development expense cost reimbursement to the collaborative partner or payment received from the collaborative partner to share these cost pursuant to the term of the collaboration agreement are recorded increase or decrease to research and development expense of contentsin addition the term of the collaboration agreement may require the company to make payment based upon the achievement of certain developmental regulatory approval or commercial milestone upfront and milestone payment payable by merck to collaborative partner prior to regulatory approval are expensed incurred and included in research and development expense payment due to collaborative partner upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to cost of sale provided that future cash flow support the amount capitalized sale based milestone payable by merck to collaborative partner are accrued and capitalized subject to cumulative amortization catch up when probable of being achieved the amortization catch up is calculated either from the time of the first regulatory approval for indication that were unapproved at the time the collaboration wa formed or from time of the formation of the collaboration for approved product the related intangible asset that is recognized is amortized to cost of sale over it remaining useful life subject to impairment testing share based compensation the company expense all share based payment to employee over the requisite service period based on the grant date fair value of the award restructuring cost the company record liability for cost associated with exit or disposal activity in the period in which the liability is incurred in accordance with existing benefit arrangement employee termination cost are accrued when the restructuring action are probable and estimable when accruing these cost the company will recognize the amount within range of cost that is the best estimate within the range when no amount within the range is better estimate than any other amount the company recognizes the minimum amount within the range cost for one time termination benefit in which the employee is required to render service until termination in order to receive the benefit are recognized ratably over the future service period contingency and legal defense cost the company record accrual for contingency and legal defense cost expected to be incurred in connection with loss contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated tax on income deferred tax are recognized for the future tax effect of temporary difference between financial and income tax reporting based on enacted tax law and rate the company evaluates tax position to determine whether the benefit of tax position are more likely than not of being sustained upon audit based on the technical merit of the tax position for tax position that are more likely than not of being sustained upon audit the company recognizes the largest amount of the benefit that is greater than likely of being realized upon ultimate settlement in the financial statement for tax position that are not more likely than not of being sustained upon audit the company doe not recognize any portion of the benefit in the financial statement the company recognizes interest and penalty associated with uncertain tax position component of tax on income the company account for the tax effect of the tax on global intangible low taxed income gilti of certain foreign subsidiary in the income tax provision in the period the tax arises use of estimate the consolidated financial statement are prepared in conformity with accounting principle generally accepted in the united state gaap and accordingly include certain amount that are based on management best estimate and judgment estimate are used when accounting for amount recorded in connection with acquisition including initial fair value determination of asset and liability primarily ipr other intangible asset and contingent consideration well subsequent fair value measurement additionally estimate are used in determining such item provision for sale discount and return depreciable and amortizable life recoverability of inventory including those produced in preparation for product launch amount recorded for contingency environmental liability accrual for contingent sale based milestone payment and other reserve pension and other postretirement benefit plan assumption share based compensation assumption restructuring cost impairment of long lived asset including intangible asset and goodwill and investment and tax on income because of the uncertainty inherent in such estimate actual result may differ from these estimate reclassification certain reclassification have been made to prior year amount to conform to the current year presentation of contentsrecently adopted accounting standard in june the financial accounting standard board fasb issued new guidance on the accounting for credit loss on financial instrument the new guidance introduces an expected loss model for estimating credit loss replacing the incurred loss model the new guidance also change the impairment model for available for sale debt security requiring the use of an allowance to record estimated credit loss and subsequent recovery the company adopted the new guidance effective january there wa no impact to the company consolidated financial statement upon adoption in november the fasb issued new guidance for collaborative arrangement intended to reduce diversity in practice by clarifying whether certain transaction between collaborative arrangement participant should be accounted for under revenue recognition guidance asc the company retrospectively adopted the new guidance effective january which resulted in minor change to the presentation of information related to the company collaborative arrangement see note and note in december the fasb issued amended guidance on the accounting and reporting of income tax the guidance is intended to simplify the accounting for income tax by removing exception related to certain intraperiod tax allocation and deferred tax liability clarifying guidance primarily related to evaluating the step up tax basis for goodwill in business combination and reflecting enacted change in tax law or rate in the annual effective tax rate the company adopted the new guidance effective january there wa no impact to the company consolidated financial statement upon adoption in january the fasb issued new guidance intended to clarify certain interaction between accounting standard related to equity security equity method investment and certain derivative the guidance address accounting for the transition into and out of the equity method of accounting and measuring certain purchased option and forward contract to acquire investment the company adopted the new guidance effective january there wa no impact to the company consolidated financial statement upon adoption recently issued accounting standard not yet adopted in march the fasb issued optional guidance to ease the potential burden in accounting for or recognizing the effect of reference rate reform on financial reporting and subsequently issued clarifying amendment the guidance provides optional expedient and exception for applying gaap to contract hedging relationship and other transaction that reference the london interbank offered rate libor or another reference rate expected to be discontinued because of reference rate reform the optional guidance is effective upon issuance and can be applied on prospective basis at any time between january through december the company is currently evaluating the impact of adoption on it consolidated financial statement acquisition divestiture research collaboration and license agreementsthe company continues to pursue acquisition and the establishment of external alliance such research collaboration and licensing agreement to complement it internal research capability these arrangement often include upfront payment well expense reimbursement or payment to the third party and milestone royalty or profit share arrangement contingent upon the occurrence of certain future event linked to the success of the asset in development the company also review it marketed product and pipeline to examine candidate which may provide more value through out licensing and part of it portfolio assessment process may also divest certain asset pro forma financial information for acquired business is not presented if the historical financial result of the acquired entity are not significant when compared with the company financial result transactionsin december merck acquired oncoimmune privately held clinical stage biopharmaceutical company for an upfront payment of million in addition oncoimmune shareholder will be eligible to receive up to million of future contingent regulatory approval milestone payment and tiered royalty ranging from to oncoimmune lead therapeutic candidate mk also known is being evaluated for the treatment of patient hospitalized with coronavirus disease covid the transaction wa accounted for an acquisition of an asset under the agreement prior to the completion of the acquisition oncoimmune spun out certain right and asset unrelated to the mk program to new entity owned by the existing shareholder of oncoimmune in connection with the closing of the acquisition merck invested million for ownership interest in the new entity which wa valued at million resulting in million premium merck also of contentsrecognized other net liability of million the company recorded research and development expense of million in related to this transaction also in december merck acquired velosbio inc velosbio privately held clinical stage biopharmaceutical company for billion velosbio lead investigational candidate is mk formerly known vls an antibody drug conjugate targeting receptor tyrosine kinase like orphan receptor that is currently being evaluated for the treatment of patient with hematologic malignancy and solid tumor the transaction wa accounted for an acquisition of an asset merck recorded net asset of million primarily cash and research and development expense of billion in related to the transaction in september merck and seagen inc seagen formerly known seattle genetics inc announced an oncology collaboration to globally develop and commercialize seagen ladiratuzumab vedotin mk an investigational antibody drug conjugate targeting liv which is currently in phase clinical trial for breast cancer and other solid tumor the collaboration will pursue broad joint development program evaluating ladiratuzumab vedotin monotherapy and in combination with keytruda pembrolizumab in triple negative breast cancer hormone receptor positive breast cancer and other liv expressing solid tumor the company will equally share profit worldwide under the term of the agreement merck made an upfront payment of million and billion equity investment in million share of seagen common stock at price of per share merck recorded million in research and development expense in related to this transaction reflecting the upfront payment well million premium relating to the equity share based on the price of seagen common stock on the closing date seagen is also eligible to receive future contingent milestone payment of up to billion including million in development milestone and billion in sale based milestone concurrent with the above transaction seagen granted merck an exclusive license to commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor for the treatment of positive cancer in asia the middle east and latin america and other region outside of the united state canada and europe merck will be responsible for marketing application seeking approval in it territory supported by the positive result from the clinical trial merck will also co fund portion of the tukysa global development plan which encompasses several ongoing and planned trial across positive cancer including breast colorectal gastric and other cancer set forth in global product development plan merck will solely fund and conduct country specific clinical trial necessary to support anticipated regulatory application in it territory under the term of the agreement merck made upfront payment aggregating million which were recorded research and development expense in seagen is also eligible to receive future contingent regulatory approval milestone of up to million and will receive tiered royalty ranging from to based on annual sale level of tukysa in merck territory additionally in september merck acquired biologics manufacturing facility located in dunboyne ireland from takeda pharmaceutical company limited for million million the transaction wa accounted for an acquisition of an asset merck recorded property plant and equipment of million and other net asset of million there are no future contingent payment associated with the acquisition in july merck acquired the right to sentinel flavor tab and sentinel spectrum chew from virbac corporation for million sentinel product provide protection against common parasite in dog the transaction wa accounted for an acquisition of an asset merck recognized intangible asset of million related to currently marketed product and inventory of million at the acquisition date the estimated fair value of the identifiable intangible asset related to currently marketed product were determined using an income approach actual cash flow are likely to be different than those assumed the intangible asset related to currently marketed product will be amortized over their estimated useful life of year there are no future contingent payment associated with the acquisition also in july merck and ridgeback biotherapeutics lp ridgeback bio closely held biotechnology company closed collaboration agreement to develop molnupiravir mk also known eidd an orally available antiviral candidate in clinical development for the treatment of patient with covid merck gained exclusive worldwide right to develop and commercialize molnupiravir and related molecule under the term of the agreement ridgeback bio received an upfront payment and also is eligible to receive future contingent payment dependent upon the achievement of certain developmental and regulatory approval milestone well share of the net profit of molnupiravir and related molecule if approved merck of contentsand ridgeback are committed to ensure that any medicine developed for sars cov the causative agent of covid will be accessible and affordable globally in june merck acquired privately held themis bioscience gmbh themis company focused on vaccine including covid vaccine candidate and immune modulation therapy for infectious disease and cancer for million the acquisition originally provided for merck to make additional contingent payment of up to million the transaction wa accounted for an acquisition of business the company determined the fair value of the contingent consideration wa million at the acquisition date utilizing probability weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment merck recognized intangible asset for ipr of million cash of million deferred tax asset of million and other net liability of million the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill that wa allocated to the pharmaceutical segment and is not deductible for tax purpose the fair value of the identifiable intangible asset related to ipr were determined using an income approach actual cash flow are likely to be different than those assumed in january the company announced it wa discontinuing development of discussed below result in the company recorded an ipr impairment charge of million within research and development expense the company also recorded reduction in research and development expense resulting from decrease in the related liability for contingent consideration of million since future contingent milestone payment have been reduced to million in the aggregate including up to million for development milestone up to million for regulatory approval milestone and up to million for commercial milestone in may merck and the international aid vaccine initiative inc iavi nonprofit scientific research organization dedicated to addressing urgent unmet global health challenge announced collaboration to develop an investigational vaccine against sars cov being studied for the prevention of covid the agreement provided for an upfront payment by merck of million and also provided for future contingent payment based on sale merck also signed an agreement with the biomedical advanced research and development authority barda part of the office of the assistant secretary for preparedness and response within an agency of the united state department of health and human service to provide initial funding support to merck for this effort in january the company announced it wa discontinuing development of discussed below in january the company announced the discontinuation of the development program for it covid vaccine candidate and following merck review of finding from phase clinical study for the vaccine in these study both and were generally well tolerated but the immune response were inferior to those seen following natural infection and those reported for other sars cov covid vaccine due to the discontinuation the company recorded charge of million in of which million wa reflected in cost of sale and related to fixed asset and material write offs well the recognition of liability for purchase commitment the remaining million of cost were reflected in research and development expense and represent amount related to the themis acquisition noted above an ipr impairment charge partially offset by reduction in the related liability for contingent consideration in january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patient with cancer and other disease total consideration paid of billion included million of share based compensation payment to settle equity award attributable to precombination service and cash paid for transaction cost on behalf of arqule the company incurred million of transaction cost directly related to the acquisition of arqule consisting almost entirely of share based compensation payment to settle non vested equity award attributable to postcombination service these cost were included in selling general and administrative expense in arqule lead investigational candidate mk formerly known arq is novel oral bruton tyrosine kinase btk inhibitor currently being evaluated for the treatment of cell malignancy the transaction wa accounted for an acquisition of business of contentsthe estimated fair value of asset acquired and liability assumed from arqule is follows in million january and cash equivalent ipr mk formerly arq licensing arrangement for arq deferred income tax liability other asset and liability total identifiable net goodwill consideration transferred the estimated fair value of the identifiable intangible asset related to ipr wa determined using an income approach the future net cash flow were discounted to present value utilizing discount rate of actual cash flow are likely to be different than those assumed the goodwill wa allocated to the pharmaceutical segment and is not deductible for tax purpose transactionsin july merck acquired peloton therapeutic inc peloton clinical stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidate targeting hypoxia inducible factor hif for the treatment of patient with cancer and other non oncology disease peloton lead candidate mk formerly known is novel investigational oral hif inhibitor in late stage development for renal cell carcinoma merck made an upfront payment of billion additionally former peloton shareholder will be eligible to receive million upon regulatory approval million upon first commercial sale in the united state and up to billion of sale based milestone the transaction wa accounted for an acquisition of an asset merck recorded cash of million deferred tax liability of million and other net liability of million at the acquisition date well research and development expense of million in related to the transaction on april merck acquired antelliq corporation antelliq leader in digital animal identification traceability and monitoring solution these solution help veterinarian farmer and pet owner gather critical data to improve management health and well being of livestock and pet merck paid billion to acquire all outstanding share of antelliq and spent billion to repay antelliq debt the transaction wa accounted for an acquisition of business the estimated fair value of asset acquired and liability assumed from antelliq is follows in million april and cash equivalent account property plant and identifiable intangible asset useful life ranging from year deferred income tax liability other asset and liability net total identifiable net goodwill consideration transferred the estimated fair value of identifiable intangible asset relate primarily to trade name and were determined using an income approach the future net cash flow were discounted to present value utilizing discount rate of actual cash flow are likely to be different than those assumed the goodwill recognized is largely attributable to anticipated synergy expected to arise after the acquisition and wa allocated to the animal health segment the goodwill is not deductible for tax purpose of contentsthe company result for include eight month of activity for antelliq while the company result in include month of activity the company incurred million of transaction cost directly related to the acquisition of antelliq consisting largely of advisory fee which are reflected in selling general and administrative expense in also in april merck acquired immune design late stage immunotherapy company employing next generation in vivo approach to enable the body immune system to fight disease for million in cash the transaction wa accounted for an acquisition of business merck recognized intangible asset of million cash of million and other net asset of million the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill that wa allocated to the pharmaceutical segment and is not deductible for tax purpose the fair value of the identifiable intangible asset related to ipr were determined using an income approach actual cash flow are likely to be different than those assumed transactionsin the company recorded an aggregate charge of million within cost of sale in conjunction with the termination of collaboration agreement entered into in with samsung bioepis co ltd samsung for insulin glargine the charge reflects termination payment of million which represents the reimbursement of all fee previously paid by samsung to merck under the agreement plus interest well the release of merck ongoing obligation under the agreement the charge also included fixed asset abandonment charge of million inventory write offs of million well other related cost of million the termination of this agreement had no impact on the company other collaboration with samsung in june merck acquired viralytics limited viralytics an australian publicly traded company focused on oncolytic immunotherapy treatment for range of cancer for aud million million the transaction provided merck with full right to formerly known an investigational oncolytic immunotherapy the transaction wa accounted for an acquisition of an asset merck recorded net asset of million primarily cash at the acquisition date and research and development expense of million in related to the transaction there are no future contingent payment associated with the acquisition in march merck and eisai co ltd eisai entered into strategic collaboration for the worldwide co development and co commercialization of lenvima an orally available tyrosine kinase inhibitor discovered by eisai see note remicade simponiin subsidiary of schering plough entered into licensing agreement with centocor ortho biotech inc centocor johnson johnson company to market remicade which is prescribed for the treatment of inflammatory disease in schering plough subsidiary exercised an option under it contract with centocor for license right to develop and commercialize simponi fully human monoclonal antibody the company ha marketing right to both product throughout europe russia and turkey remicade lost market exclusivity in major european market in and the company no longer ha market exclusivity in any of it marketing territory the company continues to have market exclusivity for simponi in all of it marketing territory all profit derived from merck distribution of the two product in these country are equally divided between merck and the company marketing right with respect to these product will revert to janssen pharmaceutical inc in the second half of collaborative arrangementsmerck ha entered into collaborative arrangement that provide the company with varying right to develop produce and market product together with it collaborative partner both party in these arrangement are active participant and exposed to significant risk and reward dependent on the commercial success of the activity of the collaboration merck more significant collaborative arrangement are discussed below astrazenecain july merck and astrazeneca plc astrazeneca entered into global strategic oncology collaboration to co develop and co commercialize astrazeneca lynparza olaparib for multiple cancer type lynparza is an oral poly adp ribose polymerase parp inhibitor currently approved for certain type of of contentsadvanced ovarian breast pancreatic and prostate cancer the company are jointly developing and commercializing lynparza both monotherapy and in combination trial with other potential medicine independently merck and astrazeneca will develop and commercialize lynparza in combination with their respective pd and pd medicine keytruda and imfinzi the company are also jointly developing and commercializing astrazeneca koselugo selumetinib an oral selective inhibitor of mek part of the mitogen activated protein kinase mapk pathway for multiple indication in april koselugo wa approved by the food and drug administration fda for the treatment of pediatric patient two year of age and older with neurofibromatosis type who have symptomatic inoperable plexiform neurofibroma under the term of the agreement astrazeneca and merck will share the development and commercialization cost for lynparza and koselugo monotherapy and non pd pd combination therapy opportunity profit from lynparza and koselugo product sale generated through monotherapies or combination therapy are shared equally merck will fund all development and commercialization cost of keytruda in combination with lynparza or koselugo astrazeneca will fund all development and commercialization cost of imfinzi in combination with lynparza or koselugo astrazeneca is the principal on lynparza and koselugo sale transaction merck record it share of lynparza and koselugo product sale net of cost of sale and commercialization cost alliance revenue and it share of development cost associated with the collaboration part of research and development expense reimbursement received from astrazeneca for research and development expense are recognized reduction to research and development cost part of the agreement merck made an upfront payment to astrazeneca of billion in and made payment of million over multi year period for certain license option of which million wa paid in december million wa paid in december and million wa paid in december the upfront payment and license option payment were reflected in research and development expense in in addition the agreement provides for additional contingent payment from merck to astrazeneca related to the successful achievement of sale based and regulatory milestone in merck determined it wa probable that sale of lynparza in the future would trigger million of sale based milestone payment from merck to astrazeneca accordingly merck recorded million of liability and corresponding increase to the intangible asset related to lynparza prior to merck accrued sale based milestone payment aggregating billion related to lynparza of which million million and million wa paid to astrazeneca in and respectively potential future sale based milestone payment of billion have not yet been accrued they are not deemed by the company to be probable at this time in and lynparza received regulatory approval triggering capitalized milestone payment of million million and million respectively in the aggregate from merck to astrazeneca potential future regulatory milestone payment of billion remain under the agreement the intangible asset balance related to lynparza which includes capitalized sale based and regulatory milestone payment wa billion at december and is included in other intangible net the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing of contentssummarized financial information related to this collaboration is follows year ended december revenue lynparza alliance revenue total alliance revenue cost of sale selling general and research and december from astrazeneca included in other current asset payable to astrazeneca included in accrued and other current liability represents amortization of capitalized milestone payment includes accrued milestone payment eisaiin march merck and eisai co ltd eisai announced strategic collaboration for the worldwide co development and co commercialization of lenvima lenvatinib an orally available tyrosine kinase inhibitor discovered by eisai lenvima is currently approved for the treatment of certain type of thyroid cancer hepatocellular carcinoma in combination with everolimus for certain patient with renal cell carcinoma and in combination with keytruda for the treatment of certain patient with endometrial carcinoma under the agreement merck and eisai will develop and commercialize lenvima jointly both monotherapy and in combination with keytruda eisai record lenvima product sale globally eisai is the principal on lenvima sale transaction and merck and eisai share applicable profit equally merck record it share of lenvima product sale net of cost of sale and commercialization cost alliance revenue expense incurred during co development are shared by the two company in accordance with the collaboration agreement and reflected in research and development expense certain expense incurred solely by merck or eisai are not shareable under the collaboration agreement including cost incurred in excess of agreed upon cap and cost related to certain combination study of keytruda and lenvima under the agreement merck made an upfront payment to eisai of million in and agreed to make payment of up to million for certain option right through of which million wa paid in march million wa paid in march and million is expected to be paid in march the company recorded an aggregate charge of billion in research and development expense in related to the upfront payment and future option payment in addition the agreement provides for additional contingent payment from merck to eisai related to the successful achievement of sale based and regulatory milestone in merck determined it wa probable that sale of lenvima in the future would trigger sale based milestone payment aggregating million from merck to eisai accordingly merck recorded liability of million and corresponding increase to the intangible asset related to lenvima prior to merck accrued sale based milestone payment aggregating million related to lenvima of which million and million wa paid to eisai in and respectively potential future sale based milestone payment of billion have not yet been accrued they are not deemed by the company to be probable at this time in and lenvima received regulatory approval triggering capitalized milestone payment of million and million respectively from merck to eisai potential future regulatory milestone payment of million remain under the agreement the intangible asset balance related to lenvima which includes capitalized sale based and regulatory milestone payment wa billion at december and is included in other intangible net the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing of contentssummarized financial information related to this collaboration is follows year ended december revenue lenvima cost of sale selling general and research and development december from eisai included in other current asset payable to eisai included in accrued and other current liability payable to eisai included in other noncurrent liability represents amortization of capitalized milestone payment amount for includes billion related to the upfront payment and option payment includes accrued milestone and future option payment includes accrued milestone payment bayer ag in the company entered into worldwide clinical development collaboration with bayer ag bayer to market and develop soluble guanylate cyclase sgc modulators including bayer adempas riociguat which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension the two company have implemented joint development and commercialization strategy the collaboration also includes clinical development of bayer verquvo vericiguat which wa approved by the fda in january to reduce the risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretic in adult verquvo is under review by regulatory authority in other territory including the eu and japan under the agreement bayer commercializes adempas in the america while merck commercializes in the rest of the world for verquvo merck will commercialize in the united state and bayer will commercialize in the rest of the world both company share in development cost and profit on sale merck record sale of adempas and will record sale of verquvo in it marketing territory well alliance revenue alliance revenue represents merck share of profit from sale in bayer marketing territory which are product sale net of cost of sale and commercialization cost in addition the agreement provides for contingent payment from merck to bayer related to the successful achievement of sale based milestone prior to merck accrued million of sale based milestone payment for this collaboration of which million and million wa paid to bayer in and respectively following the fda approval of verquvo noted above merck determined it wa probable that sale of adempas and verquvo in the future would trigger the remaining million sale based milestone payment accordingly merck will record liability of million and corresponding increase in intangible asset related to this collaboration in the first quarter of the intangible asset balance related to this collaboration which includes the acquired intangible asset balance well capitalized sale based milestone payment wa million at december and is included in other intangible net the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing of contentssummarized financial information related to this collaboration is follows year ended december revenue adempas net sale of adempas recorded by total sale cost of sale selling general and research and december from bayer included in other current asset payable to bayer included in other noncurrent liability includes amortization of intangible asset represents accrued milestone payment restructuringin early merck approved new global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization build on prior restructuring program and doe not include any action associated with the planned spin off of organon the company continues to evaluate it global footprint and overall operating model it subsequently identified additional action under the restructuring program and could identify further action over time the action currently contemplated under the restructuring program are expected to be substantially completed by the end of with the cumulative pretax cost to be incurred by the company to implement the program now estimated to be approximately billion the company estimate that approximately of the cumulative pretax cost will result in cash outlay primarily related to employee separation expense and facility shut down cost approximately of the cumulative pretax cost will be non cash relating primarily to the accelerated depreciation of facility to be closed or divested the company expects to record charge of approximately million in related to the restructuring program action under previous global restructuring program have been substantially completed the company recorded total pretax cost of million in million in and million in related to restructuring program activity since inception of the restructuring program through december merck ha recorded total pretax accumulated cost of approximately billion for segment reporting restructuring charge are unallocated expense of contentsthe following table summarizes the charge related to restructuring program activity by type of cost separationcostsaccelerateddepreciationothertotalyear ended december of sale selling general and administrative research and development restructuring year ended december cost of sale selling general and administrative research and development restructuring year ended december cost of sale selling general and administrative research and development restructuring separation cost are associated with actual headcount reduction well those headcount reduction which were probable and could be reasonably estimated accelerated depreciation cost primarily relate to manufacturing research and administrative facility and equipment to be sold or closed part of the program accelerated depreciation cost represent the difference between the depreciation expense to be recognized over the revised useful life of the asset based upon the anticipated date the site will be closed or divested or the equipment disposed of and depreciation expense determined utilizing the useful life prior to the restructuring action all the site have and will continue to operate up through the respective closure date and since future undiscounted cash flow are sufficient to recover the respective book value merck is recording accelerated depreciation over the revised useful life of the site asset anticipated site closure date particularly related to manufacturing location have been and may continue to be adjusted to reflect change resulting from regulatory or other factor other activity in and includes asset abandonment facility shut down and other related cost well pretax gain and loss resulting from the sale of facility and related asset additionally other activity includes certain employee related cost associated with pension and other postretirement benefit plan see note and share based compensation the following table summarizes the charge and spending relating to restructuring program activity separationcostsaccelerateddepreciationothertotalrestructuring reserve january payment receipt net non cash activity restructuring reserve december payment receipt net non cash activity restructuring reserve december the remaining cash outlay are expected to be substantially completed by the end of of financial instrumentsderivative instrument and hedging activitiesthe company manages the impact of foreign exchange rate movement and interest rate movement on it earnings cash flow and fair value of asset and liability through operational mean and through the use of various financial instrument including derivative instrument significant portion of the company revenue and earnings in foreign affiliate is exposed to change in foreign exchange rate the objective and accounting related to the company foreign currency risk management program well it interest rate risk management activity are discussed below foreign currency risk managementthe company ha established revenue hedging balance sheet risk management and net investment hedging program to protect against volatility of future foreign currency cash flow and change in fair value caused by change in foreign exchange rate the objective of the revenue hedging program is to reduce the variability caused by change in foreign exchange rate that would affect the dollar value of future cash flow derived from foreign currency denominated sale primarily the euro japanese yen and chinese renminbi to achieve this objective the company will hedge portion of it forecasted foreign currency denominated third party and intercompany distributor entity sale forecasted sale that are expected to occur over it planning cycle typically no more than two year into the future the company will layer in hedge over time increasing the portion of forecasted sale hedged it get closer to the expected date of the forecasted sale the portion of forecasted sale hedged is based on assessment of cost benefit profile that consider natural offsetting exposure revenue and exchange rate volatility and correlation and the cost of hedging instrument the company manages it anticipated transaction exposure principally with purchased local currency put option forward contract and purchased collar option the fair value of these derivative contract are recorded either asset gain position or liability loss position in the consolidated balance sheet change in the fair value of derivative contract are recorded each period in either current earnings or oci depending on whether the derivative is designated part of hedge transaction and if so the type of hedge transaction for derivative that are designated cash flow hedge the unrealized gain or loss on these contract are recorded in aoci and reclassified into sale when the hedged anticipated revenue is recognized for those derivative which are not designated cash flow hedge but serve economic hedge of forecasted sale unrealized gain or loss are recorded in sale each period the cash flow from both designated and non designated contract are reported operating activity in the consolidated statement of cash flow the company doe not enter into derivative for trading or speculative purpose the company manages operating activity and net asset position at each local subsidiary in order to mitigate the effect of exchange on monetary asset and liability the company also us balance sheet risk management program to mitigate the exposure of net monetary asset that are denominated in currency other than subsidiary functional currency from the effect of volatility in foreign exchange in these instance merck principally utilizes forward exchange contract to offset the effect of exchange on exposure denominated in developed country currency primarily the euro and japanese yen for exposure in developing country currency the company will enter into forward contract to partially offset the effect of exchange on exposure when it is deemed economical to do so based on cost benefit analysis that considers the magnitude of the exposure the volatility of the exchange rate and the cost of the hedging instrument the cash flow from these contract are reported operating activity in the consolidated statement of cash flow monetary asset and liability denominated in currency other than the functional currency of given subsidiary are remeasured at spot rate in effect on the balance sheet date with the effect of change in spot rate reported in other income expense net the forward contract are not designated hedge and are marked to market through other income expense net accordingly fair value change in the forward contract help mitigate the change in the value of the remeasured asset and liability attributable to change in foreign currency exchange rate except to the extent of the spot forward difference these difference are not significant due to the short term nature of the contract which typically have average maturity at inception of le than one year of contentsthe company also us forward exchange contract to hedge portion of it net investment in foreign operation against movement in exchange rate the forward contract are designated hedge of the net investment in foreign operation the unrealized gain or loss on these contract are recorded in foreign currency translation adjustment within oci and remain in aoci until either the sale or complete or substantially complete liquidation of the subsidiary the company excludes certain portion of the change in fair value of it derivative instrument from the assessment of hedge effectiveness excluded component change in fair value of the excluded component are recognized in oci the company recognizes in earnings the initial value of the excluded component on straight line basis over the life of the derivative instrument rather than using the mark to market approach the cash flow from these contract are reported investing activity in the consolidated statement of cash flow foreign exchange risk is also managed through the use of foreign currency debt the company senior unsecured euro denominated note have been designated and are effective economic hedge of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument are included in foreign currency translation adjustment within oci the effect of the company net investment hedge on oci and the consolidated statement of income are shown below amount of pretax gain loss recognized in other comprehensive income amount of pretax gain loss recognized in other income expense net for amount excluded from effectiveness testingyears ended december investment hedging relationshipsforeign exchange contract euro denominated no amount were reclassified from aoci into income related to the sale of subsidiary interest rate risk managementthe company may use interest rate swap contract on certain investing and borrowing transaction to manage it net exposure to interest rate change and to reduce it overall cost of borrowing the company doe not use leveraged swap and in general doe not leverage any of it investment activity that would put principal capital at risk in february five interest rate swap with notional amount of million each matured these swap effectively converted the company billion fixed rate note due to variable rate debt at december the company wa party to pay floating receive fixed interest rate swap contract designated fair value hedge of fixed rate note in which the notional amount match the amount of the hedged fixed rate note detailed in the table below instrumentpar value of debtnumber of interest rate swap heldtotal swap notional note due note due note due these interest rate swap matured in january the interest rate swap contract are designated hedge of the fair value change in the note attributable to change in the benchmark libor swap rate the fair value change in the note attributable to change in the libor swap rate are recorded in interest expense along with the offsetting fair value change in the swap contract the cash flow from these contract are reported operating activity in the consolidated statement of cash flow of contentsthe table below present the location of amount recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedge of december carrying amount of hedged liabilitiescumulative amount of fair value hedging adjustment increase decrease included in the carrying sheet line item in which hedged item is includedloans payable and current portion of long term debt long term presented in the table below is the fair value of derivative on gross basis segregated between those derivative that are designated hedging instrument and those that are not designated hedging instrument of december fair value ofderivativeu dollarnotionalfair value ofderivativeu dollarnotional balance sheet captionassetliabilityassetliabilityderivatives designated hedging instrument interest rate swap contractsother current asset interest rate swap contractsother interest rate swap contractsaccrued and other current liability foreign exchange contractsother current foreign exchange contractsother foreign exchange contractsaccrued and other current liability foreign exchange contractsother noncurrent liability derivative not designated hedging instrument foreign exchange contractsother current asset foreign exchange contractsaccrued and other current liability noted above the company record it derivative on gross basis in the consolidated balance sheet the company ha master netting agreement with several of it financial institution counterparties see concentration of credit risk below the following table provides information on the company derivative position subject to these master netting arrangement if they were presented on net basis allowing for the right of offset by counterparty and cash collateral exchanged per the master agreement and related credit support annex at december amount recognized in the consolidated balance sheet gross amount subject to offset in master netting arrangement not offset in the consolidated balance sheet cash collateral posted received net amount of contentsthe table below provides information regarding the location and amount of pretax gain loss of derivative designated in fair value or cash flow hedging relationship salesother income expense net other comprehensive income loss year ended december statement line item in which effect of fair value or cash flow hedge are recorded gain loss on fair value hedging relationshipsinterest rate swap contractshedged item derivative designated hedging instrument impact of cash flow hedging relationshipsforeign exchange contractsamount of loss gain recognized in oci on derivative decrease increase in sale result of aoci reclassification interest rate contractsamount of gain recognized in other income expense net on derivative amount of loss recognized in oci on derivative interest expense is component of other income expense net the table below provides information regarding the income statement effect of derivative not designated hedging instrument amount of derivative pretax gain loss recognized in incomeyears ended december not designated hedging instrumentsincome statement captionforeign exchange contract other income expense net foreign exchange contract interest rate contract other income expense forward contract related to seagen common stockresearch and development these derivative contract mitigate change in the value of remeasured foreign currency denominated monetary asset and liability attributable to change in foreign currency exchange rate these derivative contract serve economic hedge of forecasted transaction these derivative serve economic hedge against rising treasury rate at december the company estimate million of pretax net unrealized loss on derivative maturing within the next month that hedge foreign currency denominated sale over that same period will be reclassified from aoci to sale the amount ultimately reclassified to sale may differ foreign exchange rate change realized gain and loss are ultimately determined by actual exchange rate at maturity of contentsinvestments in debt and equity securitiesinformation on investment in debt and equity security at december is follows amortizedcostgross unrealizedfairvalueamortizedcostgross unrealizedfairvalue gainslossesgainslossesu government and agency security foreign government commercial paper corporate note and bond asset backed security total debt publicly traded equity security total debt and publicly traded equity security unrealized net gain recognized in other income expense net on equity security still held at december were million during unrealized net gain recognized in other income expense net on equity security still held at december were million during at december and the company also had million and million respectively of equity investment without readily determinable fair value included in other asset during and the company recognized unrealized gain of million and million respectively in other income expense net on certain of these equity investment based on favorable observable price change from transaction involving similar investment of the same investee in addition during and the company recognized unrealized loss of million and million respectively in other income expense net related to certain of these investment based on unfavorable observable price change cumulative unrealized gain and cumulative unrealized loss based on observable price change for investment in equity investment without readily determinable fair value were million and million respectively fair value measurementsfair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date the company us fair value hierarchy which maximizes the use of observable input and minimizes the use of unobservable input when measuring fair value there are three level of input used to measure fair value with level having the highest priority and level having the lowest level quoted price unadjusted in active market for identical asset or liability level observable input other than level price such quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability level unobservable input that are supported by little or no market activity level asset or liability are those whose value are determined using pricing model discounted cash flow methodology or similar technique with significant unobservable input well asset or liability for which the determination of fair value requires significant judgment or estimation if the input used to measure the financial asset and liability fall within more than one level described above the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument of contentsfinancial asset and liability measured at fair value on recurring basisfinancial asset and liability measured at fair value on recurring basis at december are summarized below fair value measurement usingfair value measurement using level government bond commercial paper corporate note and bond asset backed security government and agency security publicly traded equity other asset government and agency publicly traded equity derivative asset forward exchange contract interest rate swap purchased currency option total asset liabilitiesother liabilitiescontingent consideration derivative liability forward exchange contract written currency option interest rate swap total liability investment included in other asset are restricted to use including for the payment of benefit under employee benefit plan the fair value determination of derivative includes the impact of the credit risk of counterparties to the derivative and the company own credit risk the effect of which were not significant of december and cash and cash equivalent include billion and billion respectively of cash equivalent which would be considered level in the fair value hierarchy of contentscontingent considerationsummarized information about the change in liability for contingent consideration associated with business acquisition is follows value january change in estimated fair value payment fair value december recorded in cost of sale research and development expense and other income expense net includes cumulative translation adjustment balance at december includes million recorded current liability for amount expected to be paid within the next month at december and million and million respectively of the liability relate to the termination of the sanofi pasteur msd joint venture in part of the termination merck recorded liability for contingent future royalty payment of on net sale of all merck product that were previously sold by the joint venture through december the fair value of this liability is determined utilizing the estimated amount and timing of projected cash flow and risk adjusted discount rate of to present value the cash flow the addition to contingent consideration in relate to the acquisition of themis the change in the estimated fair value of liability for contingent consideration in and were largely attributable to increase in the liability recorded in connection with the termination of the sanofi pasteur msd spmsd joint venture in in the increase wa partially offset by decline related to the discontinuation of covid vaccine program obtained through the acquisition of themis the payment of contingent consideration in both year relate to the spmsd liability described above other fair value measurementssome of the company financial instrument such cash and cash equivalent receivables and payable are reflected in the balance sheet at carrying value which approximates fair value due to their short term nature the estimated fair value of loan payable and long term debt including current portion at december wa billion compared with carrying value of billion and at december wa billion compared with carrying value of billion fair value wa estimated using recent observable market price and would be considered level in the fair value hierarchy concentration of credit riskon an ongoing basis the company monitor concentration of credit risk associated with corporate and government issuer of security and financial institution with which it conduct business credit exposure limit are established to limit concentration with any single issuer or institution cash and investment are placed in instrument that meet high credit quality standard specified in the company investment policy guideline the majority of the company account receivable arise from product sale in the united state europe and china and are primarily due from drug wholesaler and retailer hospital government agency managed health care provider and pharmacy benefit manager the company monitor the financial performance and creditworthiness of it customer so that it can properly ass and respond to change in their credit profile the company also continues to monitor global economic condition including the volatility associated with international sovereign economy and associated impact on the financial market and it business the company customer with the largest account receivable balance are mckesson corporation amerisourcebergen corporation and cardinal health inc which represented in aggregate approximately of total account receivable at december the company monitor the creditworthiness of it customer to which it grant credit term in the normal course of business bad debt have been minimal the company doe not normally require collateral or other security to support credit sale the company ha account receivable factoring agreement with financial institution in certain country to sell account receivable the company factored billion and billion of account receivable in the fourth quarter of and respectively under these factoring arrangement which reduced outstanding account receivable the cash received from the financial institution is reported within operating activity in the of contentsconsolidated statement of cash flow in certain of these factoring arrangement for ease of administration the company will collect customer payment related to the factored receivables which it then remit to the financial institution at december and the company had collected million and million respectively on behalf of the financial institution which is reflected restricted cash in other current asset and the related obligation to remit the cash within accrued and other current liability the company remitted the cash to the financial institution in january and respectively the net cash flow relating to these collection are reported financing activity in the consolidated statement of cash flow the cost of factoring such account receivable wa de minimis derivative financial instrument are executed under international swap and derivative association master agreement the master agreement with several of the company financial institution counterparties also include credit support annex these annex contain provision that require collateral to be exchanged depending on the value of the derivative asset and liability the company credit rating and the credit rating of the counterparty cash collateral advanced by the company to counterparties wa million at december cash collateral received by the company from various counterparties wa million at december the obligation to return such collateral is recorded in accrued and other current liability inventoriesinventories at december consisted of good raw material and work in total approximates current cost decrease to lifo cost recognized inventory other inventory valued under the lifo method comprised approximately billion and billion at december and respectively amount recognized other asset are comprised almost entirely of raw material and work in process inventory at december and these amount included billion and billion respectively of inventory not expected to be sold within one year in addition these amount included million and million at december and respectively of inventory produced in preparation for product launch goodwill and other intangiblesthe following table summarizes goodwill activity by segment pharmaceuticalanimal healthall othertotalbalance january impairment other balance december divestiture other balance december other includes cumulative translation adjustment on goodwill balance and certain other adjustment accumulated goodwill impairment loss were million at both december and of content the addition to goodwill in the pharmaceutical segment in were primarily related to the acquisition of arqule and themis see note the addition to goodwill within the animal health segment in primarily relate to the acquisition of antelliq see note the impairment of goodwill within other non reportable segment in relate to certain business within the healthcare service segment the healthcare service segment wa fully divested in the first quarter of other intangible at december consisted of grosscarryingamountaccumulatedamortizationnetgrosscarryingamountaccumulatedamortizationnetproducts and product right ipr trade acquired intangible include product and product right license trade name and patent which are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life some of the company more significant acquired intangible on net basis related to human health marketed product included in product and product right above at december include zerbaxa million implanon nexplanon million gardasil gardasil million dificid million bridion million sivextro million and simponi million additionally the company had billion of net acquired intangible related to animal health marketed product at december of which billion relate primarily to trade name obtained through the acquisition of antelliq see note some of the company more significant net intangible asset included in license above at december include lynparza billion and lenvima billion result of collaboration with astrazeneca and eisai see note at december ipr primarily relates to mk obtained through the acquisition of arqule in see note and mk gefapixant obtained through the acquisition of afferent pharmaceutical in the company ha an intangible asset related to collaboration with bayer see note that had carrying value of million at december reflected in other in the table above in the company recorded an impairment charge of billion within cost of sale related to zerbaxa for injection combination antibacterial and beta lactamase inhibitor for the treatment of certain bacterial infection in december the company temporarily suspended sale of zerbaxa and subsequently issued product recall following the identification of product sterility issue the recall constituted triggering event requiring the evaluation of the zerbaxa intangible asset for impairment the company revised it cash flow forecast for zerbaxa utilizing certain assumption around the return to market timeline and anticipated uptake in sale thereafter these revised cash flow forecast indicated that the zerbaxa intangible asset value wa not fully recoverable on an undiscounted cash flow basis the company utilized market participant assumption to determine it best estimate of the fair value of the intangible asset related to zerbaxa that when compared with it related carrying value resulted in the impairment charge noted above the company also wrote off inventory of million to cost of sale in related to the zerbaxa recall the remaining intangible asset balance related to zerbaxa wa million at december in the company recorded impairment charge related to marketed product and other intangible of million of this amount million related to sivextro product for the treatment of acute bacterial skin and skin structure infection caused by designated susceptible gram positive organism part of reorganization and reprioritization of it internal sale force the company made the decision to cease promotion of sivextro in the market by the end of this decision resulted in reduced cash flow projection for sivextro which indicated that the sivextro intangible asset value wa not fully recoverable on an undiscounted cash flow basis the company utilized market participant assumption to determine it best estimate of the fair value of the intangible asset related to sivextro that when compared with it related carrying value resulted in the impairment charge noted above of contentsipr that the company acquires through business combination represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility amount capitalized ipr are accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each project the company will make separate determination to the then useful life of the asset and begin amortization in the company recorded million ipr impairment charge within research and development expense related to decision to discontinue the development program for covid vaccine candidate following merck review of finding from phase clinical study for the vaccine in the study wa generally well tolerated but the immune response were inferior to those seen following natural infection and those reported for other sars cov covid vaccine the discontinuation of this development program also resulted in reversal of the related liability for contingent consideration of million see note in the company recorded million of ipr impairment charge of this amount million relates to the write off of the intangible asset balance for program obtained in connection with the acquisition of iomet pharma ltd following review of clinical trial result conducted by merck along with external clinical trial result for similar compound the discontinuation of this clinical development program also resulted in reversal of the related liability for contingent consideration of million in the company recorded million of ipr impairment charge of this amount million relates to the write off of the remaining intangible asset balance for program obtained in connection with the smartcells acquisition following decision to terminate the program due to product development issue the discontinuation of this clinical development program also resulted in reversal of the related liability for contingent consideration of million the ipr project that remain in development are subject to the inherent risk and uncertainty in drug development and it is possible that the company will not be able to successfully develop and complete the ipr program and profitably commercialize the underlying product candidate the company may recognize additional non cash impairment charge in the future related to other marketed product or pipeline program and such charge could be material aggregate amortization expense primarily recorded within cost of sale wa billion in billion in and billion in the estimated aggregate amortization expense for each of the next five year is follows billion billion billion billion billion loan payable long term debt and leasesloans payableloans payable at december included billion of note due in billion of commercial paper and million of long dated note that are subject to repayment at the option of the holder loan payable at december included billion of note due in billion of commercial paper and million of long dated note that are subject to repayment at the option of the holder the weighted average interest rate of commercial paper borrowing wa and for the year ended december and respectively of contentslong term debtlong term debt at december consisted of note due note due note due note due note due note due note due note due euro denominated note due note due note due note due note due note due note due note due euro denominated note due euro denominated note due euro denominated note due note due note due note due debenture due note due debenture due debenture due note due euro denominated note due other presented in the table above includes million and million at december and respectively of borrowing at variable rate that resulted in effective interest rate of and for and respectively with the exception of the debenture due the note listed in the table above are redeemable in whole or in part at merck option at any time at varying redemption price in june the company issued billion principal amount of senior unsecured note consisting of billion of note due billion of note due billion of note due and billion of note due merck used the net proceeds from the offering for general corporate purpose including without limitation the repayment of outstanding commercial paper borrowing and other indebtedness with upcoming maturity effective of november the company executed full and unconditional guarantee of the then existing debt of it subsidiary merck sharp dohme corp msd and msd executed full and unconditional guarantee of the then existing debt of the company excluding commercial paper including for payment of principal and interest these guarantee do not extend to debt issued subsequent to that date certain of the company borrowing require that merck comply with covenant and at december the company wa in compliance with these covenant of contentsthe aggregate maturity of long term debt for each of the next five year are follows billion billion billion billion billion the company ha billion credit facility that matures in june the facility provides backup liquidity for the company commercial paper borrowing facility and is to be used for general corporate purpose the company ha not drawn funding from this facility leasesthe company ha operating lease primarily for manufacturing facility research and development facility corporate office employee housing vehicle and certain equipment the company determines if an arrangement is lease at inception when evaluating contract for embedded lease the company exercise judgment to determine if there is an explicit or implicit identified asset in the contract and if merck control the use of that asset embedded lease primarily associated with contract manufacturing organization are immaterial the lease term includes option to extend or terminate the lease when it is reasonably certain that merck will exercise that option real estate lease for facility have an average remaining lease term of eight year which include option to extend the lease for up to four year where applicable vehicle lease are generally in effect for four year the company doe not record short term lease lease with an initial term of month or le on the balance sheet however merck currently ha no short term lease lease expense for operating lease payment is recognized on straight line basis over the term of the lease operating lease asset and liability are recognized based on the present value of lease payment over the lease term since the company lease do not have readily determinable implicit discount rate the company us it incremental borrowing rate to calculate the present value of lease payment by asset class on quarterly basis an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the company pretax cost of debt for that same term the updated rate for each asset class are applied prospectively to new lease the company doe not separate lease component payment for rent real estate tax and insurance cost from non lease component common area maintenance cost in the event that the agreement contains both merck includes both the lease and non lease component for purpose of calculating the right of use asset and related lease liability if the non lease component are fixed for vehicle lease and employee housing the company applies portfolio approach to effectively account for the operating lease asset and liability certain of the company lease agreement contain variable lease payment that are adjusted periodically for inflation or for actual operating expense true ups compared with estimated amount however these amount are immaterial sublease income and activity related to sale and leaseback transaction are immaterial merck lease agreement do not contain any material residual value guarantee or material restrictive covenant operating lease cost wa million in and million in rental expense under operating lease net of sublease income wa million in cash paid for amount included in the measurement of operating lease liability wa million in and million in operating lease asset obtained in exchange for lease obligation wa million in and million in supplemental balance sheet information related to operating lease is follows december asset liabilitiesaccrued and other current other noncurrent weighted average remaining lease term year average discount includes prepaid lease that have no related lease liability of contentsmaturities of operating lease liability are follows total lease le imputed at december the company had entered into additional real estate operating lease that had not yet commenced the obligation associated with these lease total million contingency and environmental liability the company is involved in various claim and legal proceeding of nature considered normal to it business including product liability intellectual property and commercial litigation well certain additional matter including governmental and environmental matter in the opinion of the company it is unlikely that the resolution of these matter will be material to the company financial condition result of operation or cash flow given the nature of the litigation discussed below and the complexity involved in these matter the company is unable to reasonably estimate possible loss or range of possible loss for such matter until the company know among other factor what claim if any will survive dispositive motion practice ii the extent of the claim including the size of any potential class particularly when damage are not specified or are indeterminate iii how the discovery process will affect the litigation iv the settlement posture of the other party to the litigation and any other factor that may have material effect on the litigation the company record accrual for contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated these accrual are adjusted periodically assessment change or additional information becomes available for product liability claim portion of the overall accrual is actuarially determined and considers such factor past experience number of claim reported and estimate of claim incurred but not yet reported individually significant contingent loss are accrued when probable and reasonably estimable legal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable the company decision to obtain insurance coverage is dependent on market condition including cost and availability existing at the time such decision are made the company ha evaluated it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such ha no insurance for most product liability product liability litigationfosamaxas previously disclosed merck is defendant in product liability lawsuit in the united state involving fosamax fosamax litigation of december approximately case are pending against merck in either federal or state court plaintiff in the vast majority of these case generally allege that they sustained femur fracture and or other bone injury femur fracture in association with the use of fosamax all federal case involving allegation of femur fracture have been or will be transferred to multidistrict litigation in the district of new jersey femur fracture mdl in the only bellwether case tried to date in the femur fracture mdl glynn merck the jury returned verdict in merck favor in addition in june the femur fracture mdl court granted merck motion for judgment matter of law in the glynn case and held that the plaintiff failure to warn claim wa preempted by federal law of contentsin august the femur fracture mdl court entered an order requiring plaintiff in the femur fracture mdl to show cause those case asserting claim for femur fracture injury that took place prior to september should not be dismissed based on the court preemption decision in the glynn case pursuant to the show cause order in march the femur fracture mdl court dismissed with prejudice approximately case on preemption ground plaintiff in approximately of those case appealed that decision to the court of appeal for the third circuit third circuit in march the third circuit issued decision reversing the femur fracture mdl court preemption ruling and remanding the appealed case back to the femur fracture mdl court in may the supreme court decided that the third circuit had incorrectly concluded that the issue of preemption should be resolved by jury and accordingly vacated the judgment of the third circuit and remanded the proceeding back to the third circuit to address the issue in manner consistent with the supreme court opinion in november the third circuit remanded the case back to the district court in order to allow that court to determine in the first instance whether the plaintiff state law claim are preempted by federal law under the standard described by the supreme court in it opinion briefing on the issue is closed and the party await the decision of the district court accordingly of december approximately case were actively pending in the femur fracture mdl of december approximately case alleging femur fracture have been filed in new jersey state court and are pending before judge james hyland in middlesex county the party selected an initial group of case to be reviewed through fact discovery and merck ha continued to select additional case to be reviewed of december approximately case alleging femur fracture have been filed and are pending in california state court all of the femur fracture case filed in california state court have been coordinated before single judge in orange county california additionally there are four femur fracture case pending in other state court discovery is presently stayed in the femur fracture mdl and in the state court in california merck intends to defend against these lawsuit januvia janumetas previously disclosed merck is defendant in product liability lawsuit in the united state involving januvia and or janumet of december merck is aware of approximately product user alleging that januvia and or janumet caused the development of pancreatic cancer and other injury most claim have been filed in multidistrict litigation before the district court for the southern district of california mdl outside of the mdl the majority of claim have been filed in coordinated proceeding before the superior court of california county of los angeles california state court in november the mdl and california state court in separate opinion granted summary judgment to defendant on ground of federal preemption plaintiff appealed in both forum in november the court of appeal for the ninth circuit vacated the judgment and remanded for further discovery in november the california state appellate court reversed and remanded on similar ground in march the party in the mdl and the california coordinated proceeding agreed to coordinate and adopt schedule for completing discovery on general causation and preemption issue and for renewing summary judgment and expert motion briefing of those motion is complete and hearing before both the mdl and california state court judge took place on october and december respectively of december six product user have claim pending against merck in state court other than california including illinois in june the illinois trial court denied merck motion for summary judgment based on federal preemption merck appealed and the illinois appellate court affirmed in december merck filed petition for leave to appeal to the illinois supreme court in february in april the illinois supreme court stayed consideration of the pending petition to appeal until the supreme court issued it opinion in merck sharp dohme corp albrecht relating to the fosamax matter discussed above merck filed of contentsthe opinion in albrecht with the illinois supreme court in june the petition for leave to appeal wa decided in september in which the illinois supreme court directed the intermediate appellate court to reconsider it earlier ruling the illinois appellate court issued favorable decision concluding consistent with albrecht that preemption present legal question to be resolved by the court in may the illinois appellate court issued mandate to the state trial court which of december had not scheduled case management conference in addition to the claim noted above the company ha agreed to toll the statute of limitation for approximately additional claim the company intends to continue defending against these lawsuit vioxxmerck reached settlement with the attorney general of utah to fully resolve the state previously disclosed civil lawsuit alleging that merck misrepresented the safety of vioxx part of the resolution merck paid the state million the settlement doe not constitute an admission by merck of any liability or wrongdoing this agreement mark the final resolution of litigation involving vioxx in the united state there is ongoing vioxx litigation in certain country outside the united state governmental proceedingsas previously disclosed in the fall of the company received record subpoena from the attorney office for the district of vermont vt usao pursuant to section of the health insurance portability and accountability act of hipaa relating to an investigation of potential health care offense the subpoena sought information relating to any actual or potential business relationship or arrangement merck ha had with practice fusion inc pfi cloud based electronic health record ehr company that wa acquired by allscripts in january the company cooperated with the government and responded to that subpoena subsequently in may merck received second record subpoena from the vt usao that broadened the government information request by seeking information relating to merck relationship with any ehr company shortly thereafter the vt usao served civil investigation demand cid upon merck similarly seeking information on the company relationship with ehr vendor the cid explains that the government is conducting false claim act investigation concerning whether merck and or pfi submitted claim to federal health care program that violate the federal anti kickback statute merck is cooperating with the government investigation previously disclosed in april merck received set of investigative interrogatory from the california attorney general office pursuant to it investigation of conduct and agreement that allegedly affected or delayed competition to lantus in the insulin market the interrogatory seek information concerning merck development of an insulin glargine product and it subsequent termination well merck patent litigation against sanofi concerning lantus and the resolution of that litigation merck is cooperating with the california attorney general investigation previously disclosed in june merck received cid from the department of justice the cid request answer to interrogatory well various document regarding temperature excursion at third party storage facility containing certain merck product merck is cooperating with the government investigation and intends to produce information and or document necessary in response to the cid previously disclosed the company subsidiary in china have received and may continue to receive inquiry regarding their operation from various chinese governmental agency some of these inquiry may be related to matter involving other multinational pharmaceutical company well chinese entity doing business with such company the company policy is to cooperate with these authority and to provide response appropriate previously disclosed from time to time the company receives inquiry and is the subject of preliminary investigation activity from competition and other governmental authority in market outside the united state these authority may include regulator administrative authority and law enforcement and other similar official and these preliminary investigation activity may include site visit formal or informal request or demand for document or material inquiry or interview and similar matter certain of these preliminary inquiry or activity may lead to the commencement of formal proceeding should those proceeding be determined adversely to the company monetary fine and or remedial undertaking may be required of contentscommercial and other litigationzetia antitrust litigationas previously disclosed merck msd schering corporation and msp singapore company llc collectively the merck defendant are defendant in putative class action and opt out lawsuit filed in on behalf of direct and indirect purchaser of zetia alleging violation of federal and state antitrust law well other state statutory and common law cause of action the case have been consolidated for pretrial purpose in federal multidistrict litigation before judge rebecca beach smith in the eastern district of virginia in december the court denied the merck defendant motion to dismiss or stay the direct purchaser putative class action pending bilateral arbitration in august the district court adopted in full the report and recommendation of the magistrate judge with respect to the merck defendant motion to dismiss on non arbitration issue thereby granting in part and denying in part merck defendant motion to dismiss in addition in june the representative of the putative direct purchaser class filed an amended complaint and in august retailer opt out plaintiff filed an amended complaint in december the district court granted the merck defendant motion to dismiss to the extent the motion sought dismissal of claim for overcharge paid by entity that purchased generic ezetimibe from par pharmaceutical inc par pharmaceutical and dismissed any claim for such overcharge in november the direct purchaser plaintiff and the indirect purchaser plaintiff filed motion for class certification on august the district court granted in part the direct purchaser motion for class certification and certified class of direct purchaser and on november the court of appeal for the fourth circuit granted the merck defendant motion for permission to appeal the district court order also on august the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class the merck defendant objected to this report and recommendation and are awaiting decision from the district court on august the merck defendant filed motion for summary judgment and other motion and plaintiff filed motion for partial summary judgment and other motion those motion are now fully briefed and the court will likely hold hearing on the competing motion trial in this matter ha been adjourned on september united healthcare service inc filed lawsuit in the united state district court for the district of minnesota against merck and others the uhc action the uhc action make similar allegation those made in the zetia class action on september the united state judicial panel on multidistrict litigation transferred the case to the eastern district of virginia to proceed with the multidistrict zetia litigation already in progress on december humana inc filed lawsuit in the superior court of the state of california county of san francisco against merck and others alleging defendant violated state antitrust law in multiple state also on december centene corporation and others filed lawsuit in the superior court of the state of california county of san francisco against the same defendant humana both lawsuit allege similar anticompetitive act to those alleged in the zetia class action rotavirus vaccine antitrust litigationas previously disclosed msd is defendant in putative class action lawsuit filed in on behalf of direct purchaser of rotateq alleging violation of federal antitrust law the case were consolidated in the eastern district of pennsylvania in january the court denied msd motion to compel arbitration and to dismiss the consolidated complaint in february msd appealed the court order on arbitration to the third circuit in october the third circuit vacated the district court order and remanded for limited discovery on the issue of arbitrability on july msd filed renewed motion to compel arbitration and plaintiff filed cross motion for summary judgment to arbitrability on november the district court denied msd motion and granted plaintiff motion on december msd filed notice of appeal to the third circuit bravecto litigationas previously disclosed in january the company wa served with complaint in the united state district court for the district of new jersey seeking to certify nationwide class action of purchaser or user of bravecto fluralaner product in the united state or it territory between may and december the complaint contends bravecto cause neurological event and alleges violation of the new jersey consumer of contentsfraud act breach of warranty product liability and related theory similar case wa filed in quebec canada in may qui tam litigationas previously disclosed in june the district court for the eastern district of pennsylvania unsealed complaint that had been filed against the company under the federal false claim act by two former employee alleging among other thing that the company defrauded the government by falsifying data in connection with clinical study conducted on the mumps component of the company ii vaccine the complaint alleges the fraud took place between and the government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right the two former employee are pursuing the lawsuit without the involvement of the government in addition previously disclosed two putative class action lawsuit on behalf of direct purchaser of the ii vaccine which charge that the company misrepresented the efficacy of the ii vaccine in violation of federal antitrust law and various state consumer protection law are pending in the eastern district of pennsylvania in september the court denied merck motion to dismiss the false claim act suit and granted in part and denied in part it motion to dismiss the then pending antitrust suit result both the false claim act suit and the antitrust suit have proceeded into discovery which is now complete and the party have filed and briefed cross motion for summary judgment which are currently pending before the court the company continues to defend against these lawsuit merck kgaa litigationas previously disclosed in january to protect it long established brand right in the united state the company filed lawsuit against merck kgaa darmstadt germany kgaa historically operating the emd group in the united state alleging it improperly us the name merck in the united state kgaa ha filed suit against the company in france the uk germany switzerland mexico india australia singapore hong kong and china alleging among other thing unfair competition trademark infringement and or corporate name infringement in the uk australia singapore hong kong and india kgaa also alleges breach of the party coexistence agreement the litigation is ongoing in the united state with no trial date set and also ongoing in numerous jurisdiction outside of the united state the company is defending those suit in each jurisdiction patent litigationfrom time to time generic manufacturer of pharmaceutical product file abbreviated new drug application ndas with the fda seeking to market generic form of the company product prior to the expiration of relevant patent owned by the company to protect it patent right the company may file patent infringement lawsuit against such generic company similar lawsuit defending the company patent right may exist in other country the company intends to vigorously defend it patent which it belief are valid against infringement by company attempting to market product prior to the expiration of such patent with any litigation there can be no assurance of the outcome which if adverse could result in significantly shortened period of exclusivity for these product and with respect to product acquired through acquisition potentially significant intangible asset impairment charge bridion between january and november the company received multiple paragraph iv certification letter under the hatch waxman act notifying the company that generic drug company have filed application to the fda seeking pre patent expiry approval to sell generic version of bridion sugammadex injection in march april and december the company filed patent infringement lawsuit in the district court for the district of new jersey and the northern district of west virginia against those generic company all action in the district of new jersey have been consolidated these lawsuit which assert one or more patent covering sugammadex and method of using sugammadex automatically stay fda approval of the generic application until june or until adverse court decision if any whichever may occur earlier mylan pharmaceutical inc mylan api llc and mylan inc mylan have filed motion to dismiss in the district of new jersey for lack of venue and failure to state claim against certain defendant and in the northern district of west virginia for failure to state claim against certain defendant the new jersey motion ha not yet been decided and the west virginia action is stayed pending resolution of the new jersey motion of contentsjanuvia janumet janumet xr the fda ha granted pediatric exclusivity with respect to januvia janumet and janumet xr which provides further six month of exclusivity in the united state beyond the expiration of all patent listed in the fda orange book including this exclusivity key patent protection extends to january the company anticipates that sale of januvia and janumet in the united state will decline significantly after this loss of market exclusivity however januvia janumet and janumet xr contain sitagliptin phosphate monohydrate and the company ha another patent covering certain phosphate salt and polymorphic form of sitagliptin which if determined to be valid would preclude generic manufacturer from making sitagliptin phosphate salt and polymorphic form before that patent inclusive of pediatric exclusivity expires in salt polymorph patent in par pharmaceutical filed suit against the company in the district court for the district of new jersey seeking declaratory judgment of invalidity of the salt polymorph patent in response the company filed patent infringement lawsuit in the district court for the district of delaware against par pharmaceutical and additional company that also indicated an intent to market generic version of januvia janumet and janumet xr following expiration of key patent protection but prior to the expiration of the salt polymorph patent and later granted patent owned by the company covering the janumet formulation which inclusive of pediatric exclusivity expires in the company also filed patent infringement lawsuit against mylan in the northern district of west virginia the judicial panel of multidistrict litigation entered an order transferring the company lawsuit against mylan to the district court for the district of delaware for coordinated and consolidated pretrial proceeding with the other case pending in that district the district court for the district of delaware ha scheduled the lawsuit for single three day trial on invalidity issue in october the court ha scheduled separate one day trial on infringement issue in november through january to the extent such trial are necessary in the company case against mylan the district court for the northern district of west virginia ha conditionally scheduled three day trial in december on all issue the company ha settled with nine generic company providing that these generic company can bring their product to the market in may or earlier under certain circumstance additionally in mylan filed petition for inter partes review ipr at the united state patent and trademark office uspto seeking invalidity of some but not all of the claim of the salt polymorph patent which other manufacturer joined the uspto instituted ipr proceeding in may finding reasonable likelihood that the challenged claim are not valid trial wa held in february and final decision is expected in may if the challenge are successful the unchallenged claim of the salt polymorph patent will remain valid subject to the court proceeding described above in germany two generic company have sought the revocation of the supplementary protection certificate spc for janumet if the generic company are successful janumet could lose market exclusivity in germany early july challenge to the janumet spc have also occurred in portugal and finland and could occur in other european country nexplanon in june microspherix llc microspherix sued the company in the district court for the district of new jersey asserting that the manufacturing use sale and importation of nexplanon infringed several of microspherix patent that claim radio opaque implantable drug delivery device microspherix is claiming damage from september until those patent expire in may the company brought ipr proceeding in the uspto and successfully stayed the district court action the uspto invalidated some but not all of the claim asserted against the company the company appealed the decision finding claim valid and the court of appeal for the federal circuit affirmed the uspto decision the matter is no longer stayed in the district court and the company is currently litigating the invalidity and non infringement of the remaining asserted claim other litigationthere are various other pending legal proceeding involving the company principally product liability and intellectual property lawsuit while it is not feasible to predict the outcome of such proceeding in the opinion of the company either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceeding is not expected to be material to the company financial condition result of operation or cash flow either individually or in the aggregate of contentslegal defense reserveslegal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable some of the significant factor considered in the review of these legal defense reserve are follows the actual cost incurred by the company the development of the company legal defense strategy and structure in light of the scope of it litigation the number of case being brought against the company the cost and outcome of completed trial and the most current information regarding anticipated timing progression and related cost of pre trial activity and trial in the associated litigation the amount of legal defense reserve of december and of approximately million and million respectively represents the company best estimate of the minimum amount of defense cost to be incurred in connection with it outstanding litigation however event such additional trial and other event that could arise in the course of it litigation could affect the ultimate amount of legal defense cost to be incurred by the company the company will continue to monitor it legal defense cost and review the adequacy of the associated reserve and may determine to increase the reserve at any time in the future if based upon the factor set forth it belief it would be appropriate to do so environmental matter the company and it subsidiary are party to number of proceeding brought under the comprehensive environmental response compensation and liability act commonly known superfund and other federal and state equivalent these proceeding seek to require the operator of hazardous waste disposal facility transporter of waste to the site and generator of hazardous waste disposed of at the site to clean up the site or to reimburse the government for cleanup cost the company ha been made party to these proceeding an alleged generator of waste disposed of at the site in each case the government alleges that the defendant are jointly and severally liable for the cleanup cost although joint and several liability is alleged these proceeding are frequently resolved so that the allocation of cleanup cost among the party more nearly reflects the relative contribution of the party to the site situation the company potential liability varies greatly from site to site for some site the potential liability is de minimis and for others the final cost of cleanup have not yet been determined while it is not feasible to predict the outcome of many of these proceeding brought by federal or state agency or private litigant in the opinion of the company such proceeding should not ultimately result in any liability which would have material adverse effect on the financial condition result of operation or liquidity of the company the company ha taken an active role in identifying and accruing for these cost and such amount do not include any reduction for anticipated recovery of cleanup cost from former site owner or operator or other recalcitrant potentially responsible party in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million at both december and these liability are undiscounted do not consider potential recovery from other party and will be paid out over the period of remediation for the applicable site which are expected to occur primarily over the next year although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed approximately million in the aggregate management also doe not believe that these expenditure should result in material adverse effect on the company financial condition result of operation or liquidity for any year of equitythe merck certificate of incorporation authorizes share of common stock and share of preferred stock capital stocka summary of common stock and treasury stock transaction share in million is follows commonstocktreasurystockcommonstocktreasurystockcommonstocktreasurystockbalance january purchase of treasury stock issuance balance december issuance primarily reflect activity under share based compensation plan in the company entered into accelerated share repurchase asr agreement with two third party financial institution the dealer under the asr agreement merck agreed to purchase billion of merck common stock in total with an initial delivery of million share of merck common stock based on the then current market price made by the dealer to merck and payment of billion made by merck to the dealer which were funded with existing cash and investment well short term borrowing upon settlement of the asr agreement in merck received an additional million share determined by the average daily volume weighted average price of merck common stock during the term of the asr program le negotiated discount bringing the total share received by merck under this program to million share based compensation plansthe company ha share based compensation plan under which the company grant restricted stock unit rsus and performance share unit psus to certain management level employee in addition employee and non employee director may be granted option to purchase share of company common stock at the fair market value at the time of grant these plan were approved by the company shareholder at december million share collectively were authorized for future grant under the company share based compensation plan these award are settled with treasury share employee stock option are granted to purchase share of company stock at the fair market value at the time of grant these award generally vest one third each year over three year period with contractual term of year rsus are stock award that are granted to employee and entitle the holder to share of common stock the award vest the fair value of the stock option and rsu award is determined and fixed on the grant date based on the company stock price psus are stock award where the ultimate number of share issued will be contingent on the company performance against pre set objective or set of objective the fair value of each psu is determined on the date of grant based on the company stock price for rsus and psus dividend declared during the vesting period are payable to the employee only upon vesting over the psu performance period the number of share of stock that are expected to be issued will be adjusted based on the probability of achievement of performance target and final compensation expense will be recognized based on the ultimate number of share issued rsu and psu distribution will be in share of company stock after the end of the vesting or performance period subject to the term applicable to such award psu award generally vest after three year rsu award generally vest one third each year over three year period total pretax share based compensation cost recorded in and wa million million and million respectively with related income tax benefit of million million and million respectively the company us the black scholes option pricing model for determining the fair value of option grant in applying this model the company us both historical data and current market data to estimate the fair value of it option the black scholes model requires several assumption including expected dividend yield risk of contentsfree interest rate volatility and term of the option the expected dividend yield is based on historical pattern of dividend payment the risk free interest rate is based on the rate at grant date of zero coupon treasury note with term equal to the expected term of the option expected volatility is estimated using blend of historical and implied volatility the historical component is based on historical monthly price change the implied volatility is obtained from market data on the company traded option the expected life represents the amount of time that option granted are expected to be outstanding based on historical and forecasted exercise behavior the weighted average exercise price of option granted in and wa and per option respectively the weighted average fair value of option granted in and wa and per option respectively and were determined using the following assumption year ended december dividend risk free interest expected expected life year information relative to stock option plan activity option in thousand is follows numberof optionsweightedaverageexercisepriceweightedaverageremainingcontractualterm year aggregateintrinsicvalueoutstanding january exercised forfeited outstanding december exercisable december additional information pertaining to stock option plan is provided in the table below year ended december intrinsic value of stock option exercised fair value of stock option cash received from the exercise of stock summary of nonvested rsu and psu activity share in thousand is follows rsuspsus numberof sharesweightedaveragegrant datefair valuenumberof sharesweightedaveragegrant datefair valuenonvested january vested forfeited nonvested december at december there wa million of total pretax unrecognized compensation expense related to nonvested stock option rsu and psu award which will be recognized over weighted average period of year for segment reporting share based compensation cost are unallocated expense of pension and other postretirement benefit plansthe company ha defined benefit pension plan covering eligible employee in the united state and in certain of it international subsidiary in addition the company provides medical benefit principally to it eligible retiree and their dependent through it other postretirement benefit plan the company us december the year end measurement date for all of it pension plan and other postretirement benefit plan net periodic benefit costthe net periodic benefit cost credit for pension and other postretirement benefit plan consisted of the following component pension benefitsu internationalother postretirement benefitsyears ended december cost interest expected return on plan asset amortization of unrecognized prior service cost net loss gain termination net periodic benefit cost credit the change in net periodic benefit cost year over year for pension plan are largely attributable to change in the discount rate affecting net loss amortization in connection with restructuring action see note termination charge were recorded in and on pension and other postretirement benefit plan related to expanded eligibility for certain employee exiting merck also in connection with these restructuring activity curtailment were recorded on pension and other postretirement benefit plan and settlement were recorded on certain and international pension plan reflected in the table above the component of net periodic benefit cost credit other than the service cost component are included in other income expense net see note with the exception of certain amount for termination benefit curtailment and settlement which are recorded in restructuring cost if the event giving rise to the termination benefit curtailment or settlement is related to restructuring action noted above of contentsobligations and funded statussummarized information about the change in plan asset and benefit obligation the funded status and the amount recorded at december is follows pension benefitsotherpostretirementbenefitsu international value of plan asset january actual return on plan company effect of exchange rate change benefit paid settlement other fair value of plan asset december benefit obligation january service interest actuarial loss gain benefit paid effect of exchange rate change plan amendment termination settlement other benefit obligation december funded status december recognized other asset accrued and other current liability other noncurrent liability actuarial loss gain primarily reflect change in discount rate at december and the accumulated benefit obligation wa billion and billion respectively for all pension plan of which billion and billion respectively related to pension plan of contentsinformation related to the funded status of selected pension plan at december is follows plan with projected benefit obligation in excess of plan assetsprojected benefit obligation fair value of plan pension plan with an accumulated benefit obligation in excess of plan assetsaccumulated benefit obligation fair value of plan plan assetsentities are required to use fair value hierarchy which maximizes the use of observable input and minimizes the use of unobservable input when measuring fair value there are three level of input used to measure fair value with level having the highest priority and level having the lowest level quoted price unadjusted in active market for identical asset or liability level observable input other than level price such quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability level unobservable input that are supported by little or no market activity the level asset are those whose value are determined using pricing model discounted cash flow methodology or similar technique with significant unobservable input well instrument for which the determination of fair value requires significant judgment or estimation at december and million and million respectively or approximately of the company pension investment were categorized level asset if the input used to measure the financial asset fall within more than one level described above the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument of contentsthe fair value of the company pension plan asset at december by asset category are follows fair value measurement usingfair value measurement using level totallevel pension planscash and cash equivalent investment fundsdeveloped market emerging market mortgage and asset backed security government and agency obligation equity securitiesdeveloped fixed income security government and agency obligation corporate obligation mortgage and asset backed security other investment plan asset at fair value international pension planscash and cash equivalent investment fundsdeveloped market government and agency emerging market corporate other fixed income real estate equity securitiesdeveloped fixed income securitiesgovernment and agency corporate mortgage and asset backed security other investmentsinsurance contract plan asset at fair value certain investment that were measured at net asset value nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan asset at december and the plan level investment in insurance contract are generally valued using crediting rate that approximates market return and invest in underlying security whose market value are unobservable and determined using pricing model discounted cash flow methodology or similar technique of contentsthe table below provides summary of the change in fair value including transfer in and or out of all financial asset measured at fair value using significant unobservable input level for the company pension plan asset insurancecontractsrealestateothertotalinsurancecontractsrealestateothertotalu pension plansbalance january actual return on plan asset relating to asset still held at december relating to asset sold during the year purchase and sale net balance december international pension plansbalance january actual return on plan asset relating to asset still held at december purchase and sale net transfer out of level balance december the fair value of the company other postretirement benefit plan asset at december by asset category are follows fair value measurement usingfair value measurement using level totallevel total cash and cash equivalent investment fundsdeveloped market emerging market government and agency mortgage and asset backed security equity security developed fixed income securitiesgovernment and agency obligation corporate obligation mortgage and asset backed security plan asset at fair value certain investment that were measured at net asset value nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan asset at december and the company ha established investment guideline for it pension and other postretirement plan to create an asset allocation that is expected to deliver rate of return sufficient to meet the long term obligation of each plan given an acceptable level of risk the target investment portfolio of the company pension and other postretirement benefit plan is allocated to in equity to in international equity to in fixed income investment and up to in cash and other investment the portfolio equity weighting is consistent with the long term nature of the plan benefit obligation the expected annual standard deviation of return of the target portfolio which approximates reflects both the equity allocation and the diversification benefit among the asset class in which the portfolio invests for international pension plan the of contentstargeted investment portfolio varies based on the duration of pension liability and local government rule and regulation although significant percentage of plan asset are invested in equity concentration risk is mitigated through the use of strategy that are diversified within management guideline expected contributionsexpected contribution during are approximately million for pension plan approximately million for international pension plan and approximately million for other postretirement benefit plan expected benefit paymentsexpected benefit payment are follows pension benefitsinternational expected benefit payment are based on the same assumption used to measure the benefit obligation and include estimated future employee service amount recognized in other comprehensive incomenet loss amount reflect difference between expected and actual return on plan asset well the effect of change in actuarial assumption net loss amount in excess of certain threshold are amortized into net periodic benefit cost over the average remaining service life of employee the following amount were reflected component of oci pension plansother postretirementbenefit plansu internationalyears ended december loss gain arising during the period prior service cost credit arising during the period net loss gain amortization included in benefit cost prior service credit amortization included in benefit cost of contentsactuarial assumptionsthe company reassesses it benefit plan assumption on regular basis the weighted average assumption used in determining pension and other postretirement benefit plan and international pension plan information are follows pension and otherpostretirement benefit plansinternational pension plansdecember periodic benefit cost discount expected rate of return on plan salary growth interest crediting benefit obligation discount salary growth interest crediting for both the pension and other postretirement benefit plan the discount rate is evaluated on measurement date and modified to reflect the prevailing market rate of portfolio of high quality fixed income debt instrument that would provide the future cash flow needed to pay the benefit included in the benefit obligation they come due the expected rate of return for both the pension and other postretirement benefit plan represents the average rate of return to be earned on plan asset over the period the benefit included in the benefit obligation are to be paid and is determined on plan basis the expected rate of return for each plan is developed considering long term historical return data current market condition and actual return on the plan asset using this reference information the long term return expectation for each asset category and weighted average expected return for each plan target portfolio is developed according to the allocation among those investment category the expected portfolio performance reflects the contribution of active management appropriate for the expected rate of return for the company pension and other postretirement benefit plan will range from to compared to range of to in the health care cost trend rate assumption for other postretirement benefit plan are follows december care cost trend rate assumed for next rate to which the cost trend rate is assumed to year that the trend rate reach the ultimate trend plansthe company also maintains defined contribution saving plan in the united state the company match percentage of each employee contribution consistent with the provision of the plan for which the employee is eligible total employer contribution to these plan in and were million million and million respectively of other income expense netother income expense net consisted of year ended december income interest exchange income from investment in equity security net net periodic defined benefit plan credit cost other than service cost other net includes net realized and unrealized gain and loss from investment in equity security either owned directly or through ownership interest in investment fund unrealized gain and loss from investment that are directly owned are determined at the end of the reporting period while ownership interest in investment fund are accounted for on one quarter lag other net presented in the table above in includes million of goodwill impairment charge related to certain business in the healthcare service segment see note other net in includes gain of million related to the settlement of certain patent litigation income of million related to astrazeneca option exercise in in connection with the termination of the company relationship with astrazeneca lp azlp and gain of million resulting from the receipt of milestone payment for an out licensed migraine clinical development program other net in also includes million of goodwill impairment charge related to certain business in the healthcare service segment see note well million of charge related to the write down of asset held for sale to fair value in anticipation of the dissolution of the company joint venture with supera farma laboratorios in brazil interest paid wa million in million in and million in tax on incomea reconciliation between the effective tax rate and the statutory rate is follows amounttax rateamounttax rateamounttax rateu statutory rate applied to income before tax differential arising from foreign earnings gilti and the foreign derived intangible income tax credit tax settlement acquisition of acquisition of state acquisition related cost including valuation acquisition of peloton tax cut and job act of other of contentsthe tax cut and job act tcja wa enacted in december and the company reflected the impact of the tcja in it financial statement however since application of certain provision of the tcja remained subject to further interpretation in certain instance the company made reasonable estimate of the effect of the tcja which were since finalized and resulted in additional income tax expense in and the company remaining transition tax liability under the tcja which ha been reduced by payment and the utilization of foreign tax credit wa billion at december of which million is included in income tax payable and the remainder of billion is included in other noncurrent liability result of the transition tax under the tcja the company is no longer indefinitely reinvested with respect to it undistributed earnings from foreign subsidiary and ha provided deferred tax liability for foreign withholding tax that would apply the company remains indefinitely reinvested with respect to it financial statement basis in excess of tax basis of it foreign subsidiary determination of the deferred tax liability with respect to this basis difference is not practicable the foreign earnings tax rate differential in the tax rate reconciliation above primarily reflect the impact of operation in jurisdiction with different tax rate than the united state particularly ireland and switzerland well singapore and puerto rico which operate under tax incentive grant which begin to expire in thereby yielding favorable impact on the effective tax rate compared with the statutory rate of towards the end of new reduced tax rate arrangement wa agreed to in switzerland for certain newly active legal entity income before tax consisted of year ended december tax on income consisted of year ended december provisionfederal deferred provisionfederal foreign state of contentsdeferred income tax at december consisted of assetsliabilitiesassetsliabilitiesproduct intangible and license inventory accelerated depreciation equity investment pension and other postretirement compensation unrecognized tax net operating loss and other tax credit valuation allowance total deferred tax net deferred income tax recognized other asset deferred income tax the company ha net operating loss nol carryforwards in several jurisdiction of december million of deferred tax on nol carryforwards relate to foreign jurisdiction valuation allowance of million have been established on these foreign nol carryforwards and other foreign deferred tax asset in addition the company ha million of deferred tax asset relating to various tax credit carryforwards and nol carryforwards all of which are expected to be fully utilized prior to expiry income tax paid in and were billion billion and billion respectively tax benefit relating to stock option exercise were million in million in and million in reconciliation of the beginning and ending amount of unrecognized tax benefit is follows january addition related to current year addition related to prior year reduction for tax position of prior year settlement lapse of statute of limitation balance december amount in reflects the settlement with the irs discussed below amount in includes million related to the divestiture of merck consumer care business in if the company were to recognize the unrecognized tax benefit of billion at december the income tax provision would reflect favorable net impact of billion of contentsthe company is under examination by numerous tax authority in various jurisdiction globally the company belief that it is reasonably possible that the total amount of unrecognized tax benefit of december could decrease by up to approximately million in the next month result of various audit closure settlement or the expiration of the statute of limitation the ultimate finalization of the company examination with relevant taxing authority can include formal administrative and legal proceeding which could have significant impact on the timing of the reversal of unrecognized tax benefit the company belief that it reserve for uncertain tax position are adequate to cover existing risk or exposure interest and penalty associated with uncertain tax position amounted to an expense benefit of million in million in and million in these amount reflect the beneficial impact of various tax settlement including the settlement discussed below liability for accrued interest and penalty were million and million of december and respectively in the internal revenue service irs concluded it examination of merck federal income tax return result the company wa required to make payment of million the company reserve for unrecognized tax benefit for the year under examination exceeded the adjustment relating to this examination period and therefore the company recorded million net tax benefit in this net benefit reflects reduction in reserve for unrecognized tax benefit for tax position relating to the year that were under examination partially offset by additional reserve for tax position not previously reserved for the irs is currently conducting examination of the company tax return for the year and in addition various state and foreign tax examination are in progress and for these jurisdiction the company income tax return are open for examination for the period through earnings per sharethe calculation of earnings per share share in million are follows year ended december income attributable to merck co inc average common share common share issuable average common share outstanding assuming basic earnings per common share attributable to merck co inc common shareholder earnings per common share assuming dilution attributable to merck co inc common shareholder issuable primarily under share based compensation plan in and million million and million respectively of common share issuable under share based compensation plan were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive of other comprehensive income loss change in aoci by component are follows derivativesinvestmentsemployeebenefitplanscumulativetranslationadjustmentaccumulated othercomprehensiveincome loss balance january net of tax other comprehensive income loss before reclassification adjustment tax other comprehensive income loss before reclassification adjustment net of reclassification adjustment tax reclassification adjustment net of other comprehensive income loss net of adoption of asu adoption of asu balance at december net of other comprehensive income loss before reclassification adjustment tax other comprehensive income loss before reclassification adjustment net of reclassification adjustment pretax reclassification adjustment net of tax other comprehensive income loss net of tax balance at december net of other comprehensive income loss before reclassification adjustment pretax other comprehensive income loss before reclassification adjustment net of tax reclassification adjustment tax reclassification adjustment net of other comprehensive income loss net of tax balance at december net of tax relates to foreign currency cash flow hedge that were reclassified from aoci to sale represents net realized gain loss on the sale of available for sale investment that were reclassified from aoci to other income expense net includes net amortization of prior service cost and actuarial gain and loss included in net periodic benefit cost see note includes pension plan net loss of billion and billion at december and respectively and other postretirement benefit plan net gain of million and million at december and respectively well pension plan prior service credit of million and million at december and respectively and other postretirement benefit plan prior service credit of million and million at december and respectively of segment reportingthe company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine primarily administered at physician office the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity large component of pediatric and adolescent vaccine sale are made to the center for disease control and prevention vaccine for child program which is funded by the government additionally the company sell vaccine to the federal government for placement into vaccine stockpile the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously had healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment in the first quarter of the company previously had an alliance segment that primarily included activity from the company relationship with astrazeneca lp related to sale of nexium and prilosec which concluded in of contentssales of the company product were follows year ended december int ltotalu int ltotalu int ltotalpharmaceutical oncologykeytruda alliance revenue lynparza alliance revenue lenvima vaccinesgardasil gardasil proquad ii pneumovax hospital acute immunologysimponi remicade virologyisentress isentress cardiovascularzetia atozet alliance revenue adempas adempas woman healthimplanon diversified cozaar arcoxia follistim other pharmaceutical total pharmaceutical segment animal health companion total animal health segment other segment sale total segment other plus international may not equal total due to rounding alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost see note alliance revenue represents merck share of profit from sale in bayer marketing territory which are product sale net of cost of sale and commercialization cost see note other pharmaceutical primarily reflects sale of other human health pharmaceutical product including product within the franchise not listed separately represents sale for the non reportable segment of healthcare service fully divested in the first quarter of and alliance which concluded in other is primarily comprised of miscellaneous corporate revenue including revenue hedging activity well third party manufacturing sale of contentsconsolidated sale by geographic area where derived are follows year ended december state europe middle east and asia pacific other than china and japan latin reconciliation of segment profit to income before tax is follows year ended december profit pharmaceutical segment animal health other total segment other unallocated interest interest expense depreciation and amortization research and development amortization of purchase accounting adjustment restructuring cost charge related to the termination of collaboration with samsung other unallocated net income before tax pharmaceutical segment profit are comprised of segment sale le standard cost well selling general and administrative expense directly incurred by the segment animal health segment profit are comprised of segment sale le all cost of sale well selling general and administrative expense and research and development cost directly incurred by the segment for internal management reporting presented to the chief operating decision maker merck doe not allocate the remaining cost of sale not included in segment profit described above research and development expense incurred in merck research laboratory the company research and development division that focus on human health related activity or general and administrative expense nor the cost of financing these activity separate division maintain responsibility for monitoring and managing these cost including depreciation related to fixed asset utilized by these division and therefore they are not included in segment profit in addition cost related to restructuring activity well the amortization of purchase accounting adjustment are not allocated to segment other profit are primarily comprised of miscellaneous corporate profit well operating profit related to third party manufacturing sale other unallocated net includes expense from corporate and manufacturing cost center goodwill and other intangible asset impairment charge gain or loss on sale of business expense or income related to change in the estimated fair value of liability for contingent consideration and other miscellaneous income or expense item of contentsequity income loss from affiliate and depreciation and amortization included in segment profit is follows pharmaceuticalanimal healthall othertotalyear ended december included in segment profit equity income loss from affiliate depreciation and year ended december included in segment profit equity income loss from affiliate depreciation and year ended december included in segment profit equity income loss from affiliate depreciation and property plant and equipment net by geographic area where located is follows december state europe middle east and asia pacific other than china and japan latin the company doe not disaggregate asset on product and service basis for internal management reporting and therefore such information is not presented of contentsreport of independent registered public accounting firmto the board of director and stockholder of merck co inc opinion on the financial statement and internal control over financial reportingwe have audited the accompanying consolidated balance sheet of merck co inc and it subsidiary the company of december and and the related consolidated statement of income of comprehensive income of equity and of cash flow for each of the three year in the period ended december including the related note collectively referred to the consolidated financial statement also have audited the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso in opinion the consolidated financial statement referred to above present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with accounting principle generally accepted in the united state of america also in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the coso basis for opinionsthe company management is responsible for these consolidated financial statement for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in management report on internal control over financial reporting appearing under item our responsibility is to express opinion on the company consolidated financial statement and on the company internal control over financial reporting based on our audit we are public accounting firm registered with the public company accounting oversight board united state pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud and whether effective internal control over financial reporting wa maintained in all material respect our audit of the consolidated financial statement included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provide reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement of contentsbecause of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate critical audit mattersthe critical audit matter communicated below is matter arising from the current period audit of the consolidated financial statement that wa communicated or required to be communicated to the audit committee and that relates to account or disclosure that are material to the consolidated financial statement and ii involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which it relates customer discount accrual in the medicaid managed care and medicare part rebatesas described in note to the consolidated financial statement the company record certain variable consideration including discount which are estimated at the time of sale generally using the expected value method amount accrued for aggregate customer discount of december in the are billion and are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued certain of these discount take the form of rebate which are amount owed based upon definitive contractual agreement or legal requirement with private sector managed care and public sector medicaid and medicare part benefit provider after the final dispensing of the product by pharmacy to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider management us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision the principal consideration for our determination that performing procedure relating to customer discount accrual in the medicaid managed care and medicare part rebate is critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the provision the provision include assumption related to change to price and historical customer segment utilization mix pertaining to forecasted customer claim that may not be fully paid until subsequent period this in turn led to high degree of auditor judgment subjectivity and effort in applying the procedure related to those assumption and in evaluating the evidence obtained from these procedure addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to customer discount accrual in the medicaid managed care and medicare part rebate including management control over the assumption used to estimate the corresponding rebate accrual these procedure also included among others developing an independent estimate of the rebate accrual by utilizing third party data on historical customer segment utilization mix in the change to price the term of the specific rebate program and the historical trend of actual rebate claim paid ii comparing the independent estimate to the rebate accrual recorded by management and iii testing actual rebate claim paid including evaluating those claim for consistency with the contractual term of the company rebate agreement pricewaterhousecoopers llpflorham park new jerseyfebruary have served the company auditor since of contentsitem change in and disagreement with accountant on accounting and financial disclosure not applicable item control and procedure management of the company with the participation of it chief executive officer and chief financial officer ha evaluated the effectiveness of the company disclosure control and procedure based on their evaluation of the end of the period covered by this form the company chief executive officer and chief financial officer have concluded that the company disclosure control and procedure defined in rule or under the security exchange act of amended the act are effective for the fourth quarter of there have been no change in internal control over financial reporting that materially affected or are reasonably likely to materially affect the company internal control over financial reporting management is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule of the act management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in internal control integrated framework issued in by the committee of sponsoring organization of the treadway commission based on this evaluation management concluded that internal control over financial reporting wa effective of december pricewaterhousecoopers llp an independent registered public accounting firm ha performed it own assessment of the effectiveness of the company internal control over financial reporting and it attestation report is included in this form filing management reportmanagement responsibility for financial statementsresponsibility for the integrity and objectivity of the company financial statement rest with management the financial statement report on management stewardship of company asset these statement are prepared in conformity with generally accepted accounting principle and accordingly include amount that are based on management best estimate and judgment nonfinancial information included in the annual report on form ha also been prepared by management and is consistent with the financial statement to assure that financial information is reliable and asset are safeguarded management maintains an effective system of internal control and procedure important element of which include careful selection training and development of operating and financial manager an organization that provides appropriate division of responsibility and communication aimed at assuring that company policy and procedure are understood throughout the organization staff of internal auditor regularly monitor the adequacy and application of internal control on worldwide basis to ensure that personnel continue to understand the system of internal control and procedure and policy concerning good and prudent business practice annually all employee of the company are required to complete code of conduct training this training reinforces the importance and understanding of internal control by reviewing key corporate policy procedure and system in addition the company ha compliance program including an ethical business practice program to reinforce the company long standing commitment to high ethical standard in the conduct of it business the financial statement and other financial information included in the annual report on form fairly present in all material respect the company financial condition result of operation and cash flow our formal certification to the security and exchange commission is included in this form filing management report on internal control over financial reportingmanagement is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule under the security exchange act of the company internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle in the united state of america management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in internal control integrated of contentsframework issued in by the committee of sponsoring organization of the treadway commission based on this evaluation management concluded that internal control over financial reporting wa effective of december because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate the effectiveness of the company internal control over financial reporting of december ha been audited by pricewaterhousecoopers llp an independent registered public accounting firm stated in their report which appears herein kenneth frazierrobert davischairman presidentand chief executive officerexecutive vice president global service and chief financial officeritem other information none of contentspart iii item director executive officer and corporate governance the required information on director and nominee is incorporated by reference from the discussion under proposal election of director of the company proxy statement for the annual meeting of shareholder to be held may information on executive officer is set forth in part of this document on page the required information on compliance with section of the security exchange act of if applicable is incorporated by reference from the discussion under the heading stock ownership information of the company proxy statement for the annual meeting of shareholder to be held may the company ha code of conduct our value and standard applicable to all employee including the principal executive officer principal financial officer principal accounting officer and controller the code of conduct is available on the company website at www merck com company overview culture and value code of conduct value and standard the company intends to disclose future amendment to certain provision of the code of conduct and waiver of the code of conduct granted to executive officer and director if any on the website within four business day following the date of any amendment or waiver every merck employee is responsible for adhering to business practice that are in accordance with the law and with ethical principle that reflect the highest standard of corporate and individual behavior the required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading board meeting and committee of the company proxy statement for the annual meeting of shareholder to be held may item executive compensation the information required on executive compensation is incorporated by reference from the discussion under the heading compensation discussion and analysis summary compensation table all other compensation table grant of plan based award table outstanding equity award table option exercise and stock vested table pension benefit table nonqualified deferred compensation table potential payment upon termination or change in control including the discussion under the subheading separation and change in control well all footnote information to the various table of the company proxy statement for the annual meeting of shareholder to be held may the required information on director compensation is incorporated by reference from the discussion under the heading director compensation and related schedule of director fee table and director compensation table of the company proxy statement for the annual meeting of shareholder to be held may the required information under the heading compensation and benefit committee interlock and insider participation and compensation and benefit committee report is incorporated by reference from the company proxy statement for the annual meeting of shareholder to be held may of contentsitem security ownership of certain beneficial owner and management and related stockholder matter information with respect to security ownership of certain beneficial owner and management is incorporated by reference from the discussion under the heading stock ownership information of the company proxy statement for the annual meeting of shareholder to be held may equity compensation plan informationthe following table summarizes information about the option warrant and right and other equity compensation under the company equity compensation plan of the close of business on december the table doe not include information about tax qualified plan such the merck saving plan plan categorynumber ofsecurities to beissued uponexercise ofoutstandingoptions warrantsand right weighted averageexercise price ofoutstandingoptions warrantsand right number ofsecurities remainingavailable for futureissuance under equitycompensation plan excludingsecuritiesreflected in column equity compensation plan approved by security holder equity compensation plan not approved by security holder includes option to purchase share of company common stock and other right under the following shareholder approved plan the merck co inc and incentive stock plan and the merck co inc non employee director stock option plan excludes approximately share of restricted stock unit and performance share unit assuming maximum payouts under the merck sharp dohme and incentive stock plan also excludes share of phantom stock deferred under the msd employee deferral program and share of phantom stock deferred under the merck co inc plan for deferred payment of director compensation item certain relationship and related transaction and director independence the required information on transaction with related person is incorporated by reference from the discussion under the heading related person transaction of the company proxy statement for the annual meeting of shareholder to be held may the required information on director independence is incorporated by reference from the discussion under the heading independence of director of the company proxy statement for the annual meeting of shareholder to be held may item principal accountant fee and service the information required for this item is incorporated by reference from the discussion under proposal ratification of appointment of independent registered public accounting firm for beginning with the caption pre approval policy for service of independent registered public accounting firm through fee for service provided by the independent registered public accounting firm of the company proxy statement for the annual meeting of shareholder to be held may of contentspart iv item exhibit and financial statement schedule the following document are filed part of this form financial statementsconsolidated statement of income for the year ended december and consolidated statement of comprehensive income for the year ended december and consolidated balance sheet of december and consolidated statement of equity for the year ended december and consolidated statement of cash flow for the year ended december and note to consolidated financial statementsreport of pricewaterhousecoopers llp independent registered public accounting financial statement schedulesschedules are omitted because they are either not required or not applicable financial statement of affiliate carried on the equity basis have been omitted because considered individually or in the aggregate such affiliate do not constitute significant subsidiary of exhibitsexhibitnumber restated certificate of incorporation of merck co inc november incorporated by reference to merck co inc current report on form filed november no by law of merck co inc effective july incorporated by reference to merck co inc current report on form filed july no indenture dated of april between merck sharp dohme corp schering corporation and bank trust national association successor to morgan guaranty trust company of new york trustee the indenture incorporated by reference to exhibit to msd registration statement on form no first supplemental indenture to the indenture dated of october incorporated by reference to exhibit to msd registration statement on form filed september no second supplemental indenture to the indenture dated november incorporated by reference to exhibit to merck co inc current report on form filed november no third supplemental indenture to the indenture dated may incorporated by reference to exhibit to merck co inc form quarterly report for the period ended march no indenture dated november between merck co inc schering plough corporation and the bank of new york trustee the indenture incorporated by reference to exhibit to schering plough current report on form filed november no second supplemental indenture to the indenture including form of note dated november incorporated by reference to exhibit to schering plough current report on form filed november no third supplemental indenture to the indenture including form of note dated september incorporated by reference to exhibit to schering plough current report on form filed september no of contentsexhibitnumber fifth supplemental indenture to the indenture dated november incorporated by reference to exhibit to merck co inc current report on form filed november no indenture dated of january between merck co inc and bank trust national association trustee incorporated by reference to exhibit to merck co inc current report on form filed december no description of the registrant common description of the registrant note due note due and note due description of the registrant note due and note due merck co inc executive incentive plan amended and restated effective june incorporated by reference to merck co inc schedule filed april no merck co inc deferral program including the base salary deferral plan amended and restated effective december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no merck co inc incentive stock plan amended and restated june incorporated by reference to merck co inc schedule filed april no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form quarterly report for the period ended march filed may no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by referent to exhibit to merck co inc form annual report for the fiscal year ended december filed february no of contentsexhibitnumber description form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of restricted stock unit term for quarterly and annual grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed on february no performance share unit award term under the merck co inc stock incentive plan incorporated by reference to exhibit to merck co inc current report on form quarterly report for the period ended march filed may no merck co inc incentive stock plan incorporated by reference to appendix to merck co inc schedule filed april no merck co inc change in control separation benefit plan effective amended and restated of january incorporated by reference to exhibit to merck co inc current report on form filed november no merck co inc separation benefit plan amended and restated of january incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no merck co inc non employee director stock option plan amended and restated of december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no retirement plan for the director of merck co inc amended and restated june incorporated by reference to exhibit to msd form quarterly report for the period ended june filed august no merck co inc plan for deferred payment of director compensation amended and restated effective of january incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no distribution agreement between schering plough and centocor inc dated april incorporated by reference to exhibit to schering plough amended for the year ended december filed may no amendment agreement to the distribution agreement between centocor inc can development llc and schering plough ireland company incorporated by reference to exhibit to schering plough current report on form filed december no severance agreement and general release between merck co inc and adam schechter dated december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no offer letter between merck co inc and jennifer zachary dated march incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for annual non qualified option grant under the merck co inc incentive stock plan form of restricted stock unit term for annual grant under the merck co inc incentive stock plan subsidiary of merck co inc consent of independent registered public accounting power of certified resolution of board of of rule certification of chief executive rule certification of chief financial section certification of chief executive section certification of chief financial in xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document sch xbrl taxonomy extension schema document cal xbrl taxonomy extension calculation linkbase document def xbrl taxonomy extension definition linkbase document lab xbrl taxonomy extension label linkbase document pre xbrl taxonomy extension presentation linkbase document cover page interactive data file formatted inline xbrl and contained in exhibit management contract or compensatory plan or arrangement certain portion of the exhibit have been omitted pursuant to request for confidential treatment the non public information ha been filed separately with the security and exchange commission pursuant to rule under the security exchange act of amended long term debt instrument under which the total amount of security authorized doe not exceed of merck co inc total consolidated asset are not filed exhibit to this report merck co inc will furnish copy of these agreement to the security and exchange commission on request item form summarynot applicable of contentssignaturespursuant to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized dated february merck co inc by kenneth frazier chairman president and chief executive officer by jennifer zacharyjennifer zachary attorney in fact pursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated signaturestitledatekenneth frazierchairman president and chief executive officer principal executive officer directorfebruary davisexecutive vice president global service and chief financial officer principal financial officerfebruary karachunsenior vice president finance global controller principal accounting officerfebruary brundirectorfebruary cechdirectorfebruary ellen coedirectorfebruary craigdirectorfebruary glocerdirectorfebruary lavizzo moureydirectorfebruary rothmandirectorfebruary russodirectorfebruary seidmandirectorfebruary thulindirectorfebruary wardendirectorfebruary wendelldirectorfebruary zachary by signing her name hereto doe hereby sign this document pursuant to power of attorney duly executed by the person named filed with the security and exchange commission an exhibit to this document on behalf of such person all in the capacity and on the date stated such person including majority of the director of the company by jennifer zacharyjennifer zachary attorney in fact